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Abstract 
Background: Campylobacter jejuni is an important foodborne pathogen and the 
leading cause of bacterial gastroenteritis. Despite the importance of C. jejuni infection 
and decades of research, the mechanisms for colonisation of the human intestinal tract 
by C. jejuni and how this causes diarrhoeal disease remain unclear, with a significant 
number of conflicting reports in the literature creating controversy in this area.  
Methods: The effect of different inhibitors of host cell pathways on the ability of the C. 
jejuni 81-176 wild-type strain to interact with and invade intestinal epithelial cells 
(IECs) was investigated. Defined isogenic C. jejuni 81-176 & 11168H ciaB, cadF and 
flpA mutants were constructed and characterised for the ability to interact with and 
invade host cells. 
Results: Disruption of microfilaments with Cytochalasin D increased C. jejuni invasion. 
Disruption of caveolae-mediated endocytosis with Methyl-beta-cyclodextrin, disruption 
of microtubules with Colchicine, disruption of clathrin-mediated endocytosis with 
Monodansylcadaverine, inhibition of phosphatidylinositol 3-kinase with Wortmannin 
all decreased C. jejuni invasion. Infection of the Galleria mellonella insect model with 
ciaB, cadF and flpA mutants resulted in a significantly reduced cytotoxic effect on the 
larvae. The ability of ciaB, cadF and flpA mutants to interact with and invade Caco-2 
and T84 IECs was significantly reduced. The ciaB, cadF and flpA mutants exhibited a 
more significant decrease in the number of invasive bacteria when co-cultured with 
IECs in the Vertical Diffusion Chamber model. Pre-treatment of Caco-2 IECs with 
OMVs isolated from the ciaB, cadF and flpA mutants reduced interactions and invasion 
of these IECs by live C. jejuni. 
Conclusion: C. jejuni invasion of IECs involves modulation of many host cell 
pathways. CiaB, CadF and FlpA all play an important role in C. jejuni interactions with 
IECs leading to bacterial invasion. Further studies are still required to elucidate the 
exact roles that these important C. jejuni virulence factors play during interactions with 
and invasion of host cells. 
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Chapter 1: Introduction 
1.1 Discovery of Campylobacter jejuni  
In 1906, two British veterinary surgeons Sir John McFadyean and Sir Stewart Stockman 
identified an unknown microorganism with spiral shaped morphology in the uterine 
mucous tissue of the aborted foetuses of sheep (McFadyean, 1913, Skirrow, 2006). 
McFadyean and Stockman isolated and designated the unknown microorganisms to the 
genus Vibrio. However, there is evidence that similar bacteria had been isolated even 
earlier. Theodor Escherich published a series of articles in 1882 in the Weekly Munich 
Medical Review after studying stool samples of 72 children suffering from intestinal 
diseases, from which he isolated bacteria with a spiral morphology from 35 of the 72 
samples (Butzler et al., 1973). Marian Taylor and Theobald Smith also observed similar 
microorganisms from aborting cattle in the USA, which they designated as Vibrio fetus 
due to the spiral shape and the ability to grow on a medium of agar supplemented with 
gelatine and serum (Smith 1919). In 1938, the first case of human Campylobacteriosis 
due to contaminated milk was reported in the USA, with bacteria observed from faecal 
smears. However, these bacteria could not be cultured (Levy 1946). Further reports 
occurred in 1947, where Vinzent et al. isolated Vibrio-like microorganisms from three 
pregnant women admitted to hospital due to sepsis (Vinzent, 1947). Elizabeth King was 
one of the first people to analyse human strains and she found that many were a classic 
type whilst other strains formed a distinct group which she termed “related vibrios”. 
King was the first to distinguish between these two groups based on serological 
differences and growth at 42°C, as Vibrio fetus does not grow at this temperature, 
highlighting the importance of using appropriate culturing procedures (King, 1957). The 
isolation of such bacteria from patients suffering from gastrointestinal disease was 
mainly from blood (Bokkenheuser, 1970). Attempts to culture the organisms from the 
faeces of patients always resulted in contamination and over growth of coliforms (Sellu, 
1986). In order to avoid contamination, two methods were introduced to isolate 
Campylobacter species. The first method for isolation was reported in 1969 by 
Dekeyser and colleagues in Brussels, using a 0.64 µm membrane to filter stool samples. 
This method removed other bacteria but allowed the smaller Campylobacter species to 
pass through (Dekeyser et al., 1972). The second method was reported by Cooper and 
Slee in the early 1970’s, who isolated a Campylobacter species from the blood of a 
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patient suffering from diarrhoea, which was found to be resistant to cephalothin. 
Antibiotic discs were placed on the agar plates that were inoculated with the faecal 
samples of the patients. The plates were also incubated under a reduced oxygen tension 
level. Campylobacter colonies were found in the zone of the cephalothin disc (Cooper 
and Slee, 1971, Slee, 1972). The method of isolation of Campylobacter species was 
further improved by Skirrow in 1977, whilst working as a microbiologist at the 
Worcester Royal Infirmary, who introduced a new method of isolating Campylobacter 
species from faecal samples that did not require filtration techniques. Skirrow 
inoculated faecal samples directly onto media supplemented with the antibiotics 
vancomycin, trimethoprim and polymyxin B followed by incubation at 43°C under 
atmospheric conditions of 5% oxygen, 10% carbon dioxide and 85% nitrogen (Skirrow, 
1977). Campylobacter species require microaerophilic conditions for growth, so the 
reduced oxygen tension allows optimum growth. Skirrow’s examination of faecal 
samples from over 800 patients revealed that Campylobacter species were the most 
common microorganism cultured, more so than Salmonella species, Shigella species or 
Escherichia coli (Skirrow, 1977). The delay in understanding the specific growth 
requirements of Campylobacter species was partly responsible for the delay in 
acknowledging the importance of this organism as a human pathogen (Sellu, 1986). 
Following extensive improvements in isolation of the bacteria and surveillance systems, 
there has been a significant increase in the number of cases reported (Hermans et al., 
2012). C. jejuni is now the predominant cause of bacterial diarrhoeal disease in England 
and Wales (PHE 2011) and one of the leading causes of foodborne bacterial 
gastroenteritis worldwide (Man, 2011).	  
1.1.1 Biology of Campylobacter jejuni 
The Campylobacter taxonomy has changed considerably since the microorganism’s 
classification in 1963 (Sebald and Veron, 1963). Initially the Campylobacter genus 
consisted of two species; Campylobacter fetus and Campylobacter bubulus, the latter 
now renamed Campylobacter sputorum (Sebald and Veron, 1963). Campylobacter 
jejuni and Campylobacter coli, which were misclassified previously as Vibrio species, 
were added to the new Campylobacter genus based on DNA similarities and serology 
tests (Hore et al., 1973). The genus of Campylobacter currently contains 25 species, 2 
provisional species (not yet denoted a scientific name) and 8 sub-species (Man, 2011). 
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C. jejuni is a member of the epsilon class of proteobacteria and belongs to the order of 
Campylobacteriales. C. jejuni are small (0.2–0.9 µm wide and 0.2–5.0 µm long), spiral 
shaped, Gram-negative rods with a single flagellum at one or both poles, which gives 
the bacteria a rapid, darting mobility (Alm et al., 1991, Butzler, 2004). C. jejuni is 
oxidase positive and hydrolyses both hippurate and indoxyl acetate (Kaur et al., 2011). 
C. jejuni grows optimally at 42°C and is a microaerophilic and capnophilic organism, 
requiring 85% N2, 10% CO2 and 5% O2 for optimal growth. Despite such specific 
growth requirements, C. jejuni is ubiquitous in the environment and can withstand many 
different environmental stresses (Fields and Thompson 2008). 
1.1.2 Transmission of Campylobacter jejuni 
C. jejuni is the major cause of foodborne bacterial diarrhoeal disease in humans 
(Friedman C. R., 2000). Most cases of Campylobacteriosis in humans are caused by C. 
jejuni, the remaining cases predominantly by C. coli (Janssen et al., 2008). C. jejuni is a 
commensal in avian species and colonises the intestines of chickens at a few days old 
(less frequently those of turkeys and ducks) in which overt disease is not observed 
(Welkos 1984). In humans, the consumption of contaminated chicken products or cross-
contamination with other food products seems to be responsible for more than 90% of 
all sporadic human cases. Transmission can occur from the consumption of infected 
poultry, and contaminated water or milk (Hopkins et al., 1984, Schmid et al., 1987, 
Schildt et al., 2006). In addition, the handling or cross contamination of raw poultry 
products (Newell et al., 2011), bird droppings, contact with pets, consumption of 
undercooked beef and pig meat have been reported as consistent sources of C. jejuni 
human infection (Dasti et al., 2010). Other sources of human infection include contact 
with wild birds (Kapperud et al., 1992, Wilson et al., 2008, Dasti et al., 2010).	  
1.1.3. Epidemiology of Campylobacter jejuni 
C. jejuni is found ubiquitously in the environment despite the microorganism’s strict 
microaerobic growth requirements. As such, C. jejuni poses a potential threat to public 
health (Dasti et al., 2010). 
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Figure 1.1 Important routes for human infection by Campylobacter jejuni (Dasti et al., 
2010) 
C. jejuni is the main cause of diarrhoeal disease in England and Wales causing a 
significant economic impact and is one of the leading causes of bacterial gastroenteritis 
in the world. In the United States, the Centre for Disease Control (CDC) report that C. 
jejuni is estimated to cause 1.3 million infections every year with the risk being highest 
in those that travel to Africa and South America. The CDC also reports that the 
microorganism is isolated more frequently in males than in females, predominantly in 
infants and young adults (CDC 2012).  
The Food Standards Agency (FSA) report 460,000 cases, 22,000 hospitalisations and 
110 deaths each year due to Campylobacter. Many C. jejuni infections go unreported 
and so the actual number of cases is presumed to be considerably higher (Butzler, 
2004). The FSA reported 72,571 laboratory confirmed cases of Campylobacter in 2012 
compared with 72,249 reported in 2011, costing the UK economy an estimated £580 
million (FSA). The incidence rate shows an increasing trend over the last 10 years (see 
Figure 1.2).  
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Figure 1.2 Annual incidence of Campylobacteriosis in England and Wales from 2000 to 
2012 (PHE 2012). 
Campylobacteriosis infections occur at all ages, although peaks are seen in children 
below the age of four and for patients aged between 15 and 55 years and increasing 
rates of Campylobacteriosis peak during the summer months, possibly due to an 
increase in barbeques and water sport activities, although this seasonality of C. jejuni 
infection is not fully understood (PHE 2012). Public Health England (PHE) data from 
1989 to 2008 shows that there has also been a decline in infection in young children and 
an increase in Campylobacteriosis cases in the elderly (see Figure 1.3) (Nichols et al., 
2012). Infections have been attributed to the cause of deaths, typically in elderly or 
immunocompromised patients. (Rodgers and Kagnoff, 1987, Pacanowski et al., 2008). 
Campylobacter associated disease is also a problem in developing countries, but data 
from these sources is scarce (Butzler, 2004). Shared space with animals, lack of 
sanitation and poor hygiene are thought to be the main cause of Campylobacteriosis in 
developing countries (Coker et al., 2002). In contrast to the disease presentation in 
developed countries, where a peak in prevalence is seen in young adults as bloody 
diarrhoea with mucus (Masanta et al., 2013), C. jejuni in developing countries primarily 
affects children under the age of 5 years old and presents as a watery diarrhoea leading 
to electrolyte loss (Cooke, 2010), with mortality occurring frequently (Mshana et al., 
2009, Senok and Botta, 2009). Frequent exposure to C. jejuni in developing countries 
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provides a protective immunity, demonstrated by the rise in Immunoglobulin A (IgA) 
with asymptomatic presentation in older children and adults (Mshana et al., 2009). 	  
 
Figure 1.3 Campylobacteriosis incidence reports by age group in England and Wales 
1989–2009 (PHE 2012) 
1.1.4 Pathogenesis and Symptoms of Campylobacter jejuni 
Human infection requires ingestion of as few as 100-500 colony forming units (cfu) of 
C. jejuni to cause gastroenteritis (Black et al., 1988, Alter et al., 2011), a low dose in 
comparison to the 103-108 cfu of Vibrio cholerae that are required to be ingested for 
successful human infection (Schmid-Hempel and Frank, 2007). Similarly, the infectious 
dose for both Salmonella and E. coli species is reported to be over 105 cfu (Kothary and 
Babu, 2001). Once the bacterium is ingested, there is a need to overcome host 
physiological and immunological barriers. A previous study hypothesised that the 
natural conditions in the human intestine may trigger C. jejuni to release virulence 
factors that could allow disease progression (Malik-Kale et al., 2008). C. jejuni 
colonises the lower sections of the intestinal tract (ileum, jejunum and colon and is 
thought to adhere to and invade the small intestinal and colonic mucosae (Konkel et al., 
2001, Dasti et al., 2010). In most symptomatic cases, Campylobacteriosis is a self-
limiting disease and presents with an incubation period of 1–10 days with 1-3 days of 
prodromal symptoms of fever, vomiting and headaches. By 3-7 days, most people 
exhibit clinical symptoms (Dasti et al., 2010). Infection with C. jejuni may result in a 
mild, watery, non-inflammatory diarrhoea and abdominal pain or severe bloody, 
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inflammatory diarrhoea with fever and vomiting (Blaser, 1997). Symptoms however are 
usually self-limiting and can be treated with antibiotics if required (Blaser, 1997). C. 
jejuni pathogenesis depends on both host- and pathogen-specific factors, including 
previous infection which provides specific humoral immunity to C. jejuni (Blaser, Sazie 
et al. 1987).  
1.1.5 The human gastrointestinal tract 
The human gastrointestinal tract (GIT) is a complex microbial ecosystem with over 400 
bacterial species present at any given time (Hooper et al., 1998). As well as providing a 
protective natural defence barrier (O'Hara and Shanahan, 2006), the interplay between 
the organisms encountered at the epithelium surface and the innate immune response 
protects the host from intestinal bacteria by distinguishing the resident flora from 
enteric pathogens that may penetrate the host intestinal epithelium and spread into the 
surrounding tissues (Cebra, 1999).  
The human gut epithelium is protected from microbial pathogens by several 
mechanisms. These include, rapid cell turnover which removes colonised pathogens 
(Radtke and Clevers, 2005, Chichlowski and Hale, 2008), rapid cell exfoliation, 
presence of tight junctions, providing strong structural integrity of the epithelial cell 
barrier. The competitive colonisation of the epithelium by the commensal microbiota 
provides protection against potential bacterial pathogens and the innate defence 
mechanisms which maintain the host immune tolerance as well as the production of a 
mucus layer (Hoffmann, 2003, Leser and Molbak, 2009, Neish, 2009, Sansonetti and 
Medzhitov, 2009, Kim et al., 2010). The importance of intact epithelial surfaces is as a 
highly effective barrier against invasion by pathogens (Webb and Kahler, 2008). The 
ability to breach these structures is an important characteristic for numerous bacterial 
pathogens (Hornef et al., 2002).  
The main aims of pathogenic bacteria is to gain access to the host, avoid or subvert the 
host innate defences, evade acquired specific immune responses, multiply and persist to 
cause tissue damage or disease and finally to transmit to new hosts (Falkow, 1996). 
Numerous bacterial pathogens have evolved highly specialised strategies to enable them 
to subvert the host cell, hijack the cellular machinery in order to gain access and possess 
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adaptive intracellular survival systems to avoid the host defence mechanisms (Kim et 
al., 2010).  
1.1.6 Post-infectious sequelae of Campylobacter jejuni 
In most cases of Campylobacteriosis, the disease manifestations are self-limiting, 
however C. jejuni-mediated enteritis has been linked to bacteraemia which is rare in 
healthy individuals and mainly observed in patients that present with 
immunocompromised conditions such as liver cirrhosis or AIDS (Pigrau et al., 1997). 
Campylobacter enteritis has also been associated with the development of inflammatory 
bowel disease (Garcia Rodriguez et al., 2006). The bacterium has been linked to a 
number of more serious post-infectious sequelae that are rare but include polyarthalgia 
and a serious neurodegenerative disease Guillain-Barré Syndrome (GBS), which can 
cause axonal degeneration leading to paralysis (Nachamkin, Allos et al. 1998). It is 
hypothesised that molecular mimicry of human gangliosides in the peripheral nervous 
system by C. jejuni lipo-oligosaccharide (LOS) induces cross-reactive antibodies that 
lead to GBS in approximately 1-2 cases per 1000 infections (Prendergast et al., 1998, 
Godschalk et al., 2004, Heikema et al., 2010). GBS and Miller Fisher Syndrome (which 
presents as a paralysis more localised in the nerves of the head and neck) are recognised 
post-infectious sequelae of C. jejuni infection (Rees et al., 1995, Jacobs et al., 1998, 
Nachamkin et al., 2007, Islam et al., 2010).  
1.2 Models Used to Study Campylobacter jejuni Pathogenesis 
Despite the prevalence of C. jejuni as a major cause of gastroenteritis, our knowledge of 
how this bacterium causes disease, interaction with intestinal epithelial cells (IECs), 
how the bacterium causes diarrhoea and survival in the environment is still limited and 
lagging far behind our knowledge of other enteropathogens. (Young et al., 2007). One 
of the biggest hurdles in understanding the disease process is the lack of a convenient 
small animal model, if available, would allow us to accurately observe the interactions 
between C. jejuni and the host and efficiently reproduce human-like disease (Dorrell 
and Wren, 2007). Ethical considerations prevent human studies due to the risk of 
volunteers developing GBS and standard in vitro infection models are of limited use 
(Friis, Pin et al. 2005, Dorrell and Wren 2007). Current models used to study C. jejuni 
are described in the following sections. 
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1.2.1 in vivo models used to study C. jejuni 
To gain a better understanding of C. jejuni interactions with the human host, numerous 
animal models have been employed with minimal success and often with major 
limitations (Chang and Miller, 2006). Chicks (Beery et al., 1988), non-human primates 
(Russell et al., 1989), canine pups (Macartney et al., 1988), mice, ferrets (Bell and 
Manning, 1991, Yao et al., 1997) and newborn piglets (Babakhani et al., 1993) have all 
been challenged experimentally with C. jejuni in an attempt to replicate human disease 
(Newell, 2001). However the lack of reproducible data, as well as the high cost and 
maintenance of animals for such studies has hampered progress in this area (Chang and 
Miller, 2006). There has been some successful representation of disease using ferret and 
rhesus monkey experimental models, reproducing a human-like Campylobacteriosis 
disease (Russell et al., 1989, Bell and Manning, 1991). Using these models, researchers 
observed penetration of the intestinal mucosa by intracellular invasion, with 
inflammation, bacteraemia and infiltration of the lamina propria by neutrophils, 
suggesting C. jejuni invasion to be an important pathogenic mechanism during infection 
(Harvey, Battle et al. 1999). However these models are not widely available, require 
special facilities and the unavailability of genetic manipulation procedures often makes 
these models unsuitable for C. jejuni pathogenesis studies (Newell, 2001, Mansfield et 
al., 2008, Mills et al., 2012).  
The chick model is a relatively inexpensive model and has been used extensively in C. 
jejuni studies (Hendrixson and DiRita, 2004, Flanagan et al., 2009). However 
experimental colonisation of the chick model with C. jejuni does not reproduce typical 
disease patterns as seen in humans, despite the fact that C. jejuni can colonise chicken 
caeca in numbers exceeding 1010 cfu per gram of caecal contents (Clench, 1995). 
Chicken intestinal mucus has been proposed to play a role in inhibition of the bacteria, 
indicating that the molecular makeup of the mucus may allow the high levels of 
colonisation but without infection in chickens (Nachamkin et al., 1993). However these 
models do not inform us about the course of human disease. The most favourable model 
that mimics some aspects of human disease is the mouse model, where the small size, 
wide availability, relatively low costs and ease of maintenance has led to the use of this 
model in C. jejuni experimentation studies for well over 30 years (Blaser et al., 1983a), 
providing some useful immunological data (Wassenaar and Blaser, 1999). Studies using 
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Nuclear Factor-κappa B (NF-κB) knockout mouse models reported that when the C. 
jejuni 81-176 wild-type strain and a Cytolethal Distending Toxin (CDT) mutant were 
inoculated into NF-κB deficient and C57BL/129 (wild-type) mice, the wild-type strain 
produced severe gastritis and proximal duodenitis in C57BL/129 mice and with 
significantly more severe gastrointestinal lesions than those caused by the CDT mutant, 
whilst persistent colonisation of NF-κB deficient mice with both the wild-type strain 
and the CDT mutant was associated with significantly impaired Immunoglobulin G 
(IgG) and the subclass Immunoglobulin G2a (IgG2a) humoral responses. This data 
correlates with defects in the innate or adaptive immune system, suggesting that the 
mechanism of clearance of C. jejuni is NF-κB dependent and that CDT exhibits 
proinflammatory activity in vivo (Fox et al., 2004). Subsequent studies found that C. 
jejuni was unable to colonise adult immunocompetent mice, but was able to colonise 
mice deficient in myeloid differentiation factor 88 (MyD88), an adaptor protein 
necessary for cell signalling through the Toll-like receptors (TLR). Virulence gene 
mutants were unable to colonise MyD88 mice and the researchers also reported that 
mouse models deficient in a key integral membrane protein termed Natural resistance-
associated macrophage protein 1 (N-ramp1) exhibited increased susceptibility to C. 
jejuni (Watson et al., 2007). N-ramp1 is expressed by professional phagocytes and is 
reported to play an important role in the capacity of the host cells ability to control 
intracellular invasion and survival of pathogens by limiting access to divalent cations in 
the host cell such as magnesium and calcium (Marshall and Piddock, 1994, Gruenheid 
and Gros, 2000).  
Both mammalian and bacterial transporters may compete for these cations in the 
phagosomal space, so N-ramp1 is thought to function by interfering with intracellular 
microbial replication, therefore affecting the survival of intracellular pathogens 
(Gruenheid and Gros, 2000). Champion et al. reported a significant reduction in C. 
jejuni colonisation in N-ramp1 positive mice, whilst N-ramp1 negative mice showed no 
significant reduction in C. jejuni colonisation, however the mice exhibited chronic 
inflammatory responses and some histopathological lesions (Champion et al., 2008). 
Collectively, MyD88 and N-ramp1 mouse models have been shown to be a useful tool 
in C. jejuni pathogenesis studies (Watson et al., 2007, Champion et al., 2008). Another 
mouse model is the interleukin-10 (IL-10) knock out mouse model (Mansfield et al., 
2007). IL-10 is secreted by Th2 cells (a sub-set of T cells) (Fiorentino et al., 1989) and 
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is essential in the activation of B-cells for successful antibody-mediated responses 
against pathogens and acts as regulatory cytokine with important functions in 
macrophages or mononuclear cells (Moore et al., 1993). Expression of IL-10 in both 
human and mouse cells is thought to be critical in the inflammatory response as IL-10 
inhibits pro-inflammatory chemokines and is also thought to be of importance in the 
immune response to normal enteric flora antigens (Kuhn et al., 1993, Moore et al., 
2001). Studies by Mansfield et al. reported that, the C. jejuni 11168 wild-type strain 
colonised the GIT tract of IL-10-deficient (IL-10-negative) mice at a higher level than 
the wild-type mouse (C57BL), with the IL-10-negative mice developing clinical signs 
and pathology such as a severe typhlocolitis. There was also a significant increase in 
circulating anti-C. jejuni plasma immunoglobulin levels in both wild-type and IL-10-
negative mice. This increased C. jejuni wild-type colonisation of IL-10-negative mice, 
due to altered IL-10 immunity, indicates the use of C57BL/6 IL-10-positive and IL-10-
negative mice as potential disease study models for C. jejuni pathogenesis in humans 
(Mansfield et al., 2007).  
However the results obtained using these models have been known to exhibit variability 
in experimental findings, due to the differences in the species of mice used, inoculation 
methods and variation in bacterial cfu loads have produced disease severity levels, 
ranging from asymptomatic to severe diarrhoea (Yrios and Balish, 1985, Stanfield et al., 
1987, Baqar et al., 1996). Despite these issues, there has been significant progress with 
this model, however there are still many questions concerning C. jejuni pathogenesis yet 
to be answered and so the availability of a consistent, reliable, reproducible small 
animal model is still to be achieved. 
1.2.2 Galleria mellonella model of C. jejuni infection 
Due to the lack of a convenient small animal model to study C. jejuni pathogenesis and 
the potential virulence determinants involved in disease progression, researchers have 
used alternative models involving invertebrate hosts for infection (Champion et al., 
2010). Caenorhabditis elegans has been used as model for a variety of bacterial 
pathogens, including Staphylococcus aureus, Burkholderia species, Salmonella enterica 
Typhimurium, Acinetobacter baumannii, Pseudomonas aeruginosa and Yersinia pestis 
(Darby, 2005, Peleg et al., 2009). However, one disadvantage of models such as C. 
elegans is that they are unable to survive at 37°C and also lack specific components of 
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the mammalian immune response such as phagocytic cells (Mylonakis et al., 2007). 
One advantage of insect models such as Galleria mellonella larvae is that they can 
survive at 37°C. This insect model also possesses specialised structures called 
haemocytes that behave in a similar way to mammalian phagocyes (Mylonakis et al., 
2007, Champion et al., 2010). These haemocytes have the ability to phagocytose 
microbial pathogens, are capable of releasing antimicrobial peptides and produce 
reactive oxygen species (Lavine and Strand, 2002, Bergin et al., 2005). Studies by 
Champion et al. found that the G. mellonella insect larvae model could be successfully 
infected with C. jejuni to study potential virulence factors (Champion et al., 2010). C. 
jejuni can survive within G. mellonella and cause damage to the gut of these larvae 
(Senior et al., 2011). There are other advantages of using G. mellonella larvae as an 
infection model. The larvae are commercially available and bred as live food for 
domestic reptiles. The larvae are small, around 1–2 cm long, allowing ease of handling 
and if kept under the right conditions, can survive for up to 3 weeks before pupating. 
Upkeep is minimal, no feeding is required and the larvae require minimal maintenance. 
In contrast to other invertebrate models of infection, G. mellonella larvae can be 
injected with precise amounts of bacteria (Champion et al., 2010). The G. mellonella 
response to infection produces a melanisation, changing the colour of the larvae from 
cream to dark brown or black. The exact cause of this discoloration is not fully 
understood but seems to be in response to the injection of the bacteria (Nappi and 
Christensen, 2005). The ease of use of G. mellonella larvae as a model of infection for 
C. jejuni virulence, with the ability to survive at 37°C, indicate that this is an ideal 
model for screening C. jejuni wild-type strains and mutants.  
1.2.3 in vitro Models Used to Study Campylobacter jejuni 
The lack of availability of a convenient small animal model has led researchers to use 
alternative means to study C. jejuni pathogenesis, particularly tissue culture cells which 
have provided most of the data with regards to C. jejuni interactions with host cells in 
vitro (Friis et al., 2005). Tissue culture studies investigating host pathogen interactions 
often utilise cells that are not polarised, these cell lines have been used to study the 
interactions of bacteria, the triggering of host cell signalling pathways and the methods 
bacteria utilise to internalise into the host cell (Everest et al., 1992). The mucosal 
epithelium in contrast is polarised with distinct apical and basolateral membranes. Both 
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membranes also display distinct transport roles (Mostov et al., 2000, Snoeck et al., 
2005) and in addition, the presence of particular surface structures such as Toll-like 
receptors (Backhed and Hornef, 2003). Therefore, polarised cell lines are more suitable 
for studying bacterial interactions with host cells, cell invasion and host cell 
permeability (McCormick, 2003).  
1.2.4 Cell Line Models 
C. jejuni has been reported to attach to and invade a number of cell lines in vitro, both 
polarised and non-polarised intestinal epithelial cells (IECs) such as Caco-2 IECs 
(Everest et al., 1992), T84 IECs (Monteville and Konkel, 2002) and INT407 IECs 
(Konkel et al., 1992b). However, variation in the levels of C. jejuni adhesion and 
invasion reported for each individual cell line is high and the levels of invasion of C. 
jejuni strains are lower than those observed for other enteropathogenic bacteria (Friis et 
al., 2005). A possible reason for the low numbers of interacting and invading C. jejuni 
is that in vitro tissue culture studies are usually performed in a CO2 incubator under 
atmospheric O2 conditions, due to the oxygen requirements of the IECs (Mills et al., 
2012). Despite a number of oxidative stress responses in C. jejuni including superoxide-
dismutase B (SodB) and catalase A (KatA) (Purdy et al., 1999, Day et al., 2000) which 
enable C. jejuni survival under higher oxygen conditions, these experimental conditions 
probably alter the behaviour of the bacteria during interactions with tissue culture cells. 
Microscopic observations have demonstrated translocation of C. jejuni both through and 
between cultured epithelial cells (Harvey, Battle et al. 1999) and in some cases 
identified C. jejuni localised in between junctional spaces (Konkel, Mead et al. 1992). 
C. jejuni invasion thus seems to employ transcellular (translocation through enterocytes 
/ M cells) and paracellular routes (in between adjacent epithelial cells), however the 
relative importance of these different routes has yet to be elucidated (Kopecko, 2008). 
Numerous cell culture systems, such as HEp-2 and INT407, have been employed 
widely to study disease mechanisms of Campylobacter species (De Melo, Gabbiani et 
al. 1989). In an effort to understand host-pathogen interactions, these different cell types 
are useful research tools, but as these cells of epithelial origin are non-polarised, the 
infection pattern may not be truly representative of enteric bacterial infection. However, 
important information has been obtained on bacterial virulence, cell signalling pathways 
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and ultimately internalisation of the pathogen into the host cell by the experimental use 
of non-polarised cell lines (Everest, Goossens et al. 1992, Elsinghorst 1994). The 
enterocyte-like Caco-2 (human colon adenocarcinoma) and T84 (human colonic 
carcinoma) cell lines are more appropriate to use in interaction (adhesion and invasion) 
and invasion assays with C. jejuni as these cell lines are more representative of the in 
vivo situation, in both makeup and function (Grant, Konkel et al. 1993). Polarised IECs 
produce distinct apical and basolateral surfaces through the process of differentiation; 
these cells possess microvilli, tight junctions, brush borders, organised actin 
cytoskeletons and distinct membrane domains which are involved in cell movement, 
division and transport of molecules in and out of the cell and are important 
characteristics of IECs (Grant et al., 1993, Schuck and Simons, 2004, Snoeck et al., 
2005, Laukoetter et al., 2008).	  
Polarised cell models are extremely useful for analysing the effects of microbes on the 
permeability of host cells, trancytosis and invasion of the host cell (McCormick 2003). 
These cells form polarised monolayers when grown in vitro in tissue culture flasks, 
thereby mimicking the epithelium and layout of the human intestine that is encountered 
by the enteric pathogens. Previous bacterial invasion studies including those on 
Campylobacter species have used Caco-2 cells grown on non-permeable tissue wells 
(Conte, Longhi et al. 1996). Despite previous studies demonstrating the ability of C. 
jejuni to translocate across Caco-2 cell monolayers (Ketley 1995), the mechanism C. 
jejuni employs to invade these cells, or the relevance of C. jejuni translocation 
paracellularly into host cells and the eventual epithelial penetration and invasion of host 
cells is not fully understood (O. Croinin and Backert, 2012). Previous studies have 
found that for C. jejuni to cause enteritis, the organism has to enter and invade host 
epithelial mucosa (Russell and Blake 1994, Allos 1997).  
The numbers of invading C. jejuni into IECs can be quantified by using the 
aminoglycoside antibiotic gentamicin (Elsinghorst, 1994). IECs are co-cultured with 
bacteria for the desired time period, followed by washing of the cells to remove any 
unattached bacteria. The intestinal epithelial cells are then incubated with gentamicin. 
The gentamicin protection assay works on the premise that gentamicin has minimal 
ability to enter eukaryotic cells, but kills extracellular bacteria whilst the internalised 
bacteria are protected by the host cell (Backert and Hofreuter, 2013). Using this method, 
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the number of adhered and invading bacteria can be quantified and the same procedure 
can be used for studying the behaviour of the bacteria following extended incubation as 
with intracellular survival studies (Friis et al., 2005). The gentamicin protection assay 
however has resulted in varying results for C. jejuni adherence and invasion studies, 
depending on the strain (Harvey et al., 1999, Biswas et al., 2000), the type and age of 
IECs and the length of incubation time (Fauchere et al., 1986, De Melo et al., 1989).  
1.2.5 The Vertical Diffusion Chamber Model 
The levels of interaction with and invasion of IECs for C. jejuni are considerably lower 
than those observed for other enteric pathogens (Friis et al., 2005). With invasion levels 
of only around 1% of the co-cultured bacteria recovered following gentamicin treatment 
(Friis et al., 2005). This low level is not a true reflection of C. jejuni invasion and fails 
to correlate with the clinical presentation of C. jejuni infection observed in humans 
(Friis et al., 2005). A major limitation of in vitro models used to study gastrointestinal 
infections is that the culture conditions including high oxygen levels generally favour 
eukaryotic cell survival. However conditions in the intestinal lumen are almost 
anaerobic (Blaut and Clavel, 2007). Pathogens under very low oxygen conditions 
express virulence genes whose expression changes under aerobic conditions (Marteyn et 
al., 2010). As such, data obtained using standard cell culture models may give an 
inaccurate indication of bacterial interactions with host cells. The use of a Vertical 
Diffusion Chamber (VDC) system (see Figure 1.4) has been developed which permits 
the co-culture of bacteria and host cells under different medium and gas conditions 
(Cottet et al., 2002a, Schuller and Phillips, 2010, Mills et al., 2012). The VDC system is 
advantageous as it closely mimics the conditions present in the human intestine, where 
bacteria will be under conditions of considerably low oxygen tension whilst the tissue 
will be supplied with oxygen from the blood. 
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Figure 1.4 The Vertical Diffusion Chamber Model. Polarised IEC monolayers grown in 
Snapwell™ inserts were placed into a VDC creating an apical and basolateral compartment, 
which were individually filled with bacterial broth and cell culture medium respectively (Naz et 
al., 2013). 
The VDC has been successfully used previously with Helicobacter pylori and resulted 
in both increased bacterial adhesion and an increased expression of the virulence factor 
cytotoxin-associated gene-A antigen (CagA) (Covacci et al., 1993, Cottet et al., 2002b). 
Similar studies reported that co-culturing of enterohaemorrhagic E. coli (EHEC) with 
IECs displayed increased bacterial adhesion with IECs using the VDC system (Schuller 
and Phillips, 2010), indicating that the behaviour of non-microaerobic bacteria was also 
variable when co-cultured with IECs under either microaerobic or anaerobic conditions. 
Thus, the VDC model is an improved and very useful model for analysis of the host-
pathogen interaction. Data obtained by Mills et al. using the VDC showed significantly 
increased interactions with and invasion of IECs by C. jejuni 11168H and 81-176 wild-
type strains and this was mirrored with an equally significant increase in the induction 
of the pro-inflammatory cytokine Interleukin-8 (IL-8), indicating the importance of low 
oxygen conditions in the apical compartment of the VDC for C. jejuni interactions with 
host cells (Mills et al., 2012). 	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1.3 Molecular basis of Campylobacter jejuni pathogenesis 
Once ingested, C. jejuni utilises numerous bacterial virulence determinants which are 
thought to contribute to the pathogenesis of this microorganism. Numerous virulence 
determinants including, flagella and motility, have been shown to be required for the 
attachment to and colonisation of the host intestinal epithelium (Guerry, 2007, O. 
Croinin and Backert, 2012). Adherence mechanisms utilised by microorganisms 
typically consist of adhesins, often appendages such as the pili and/or flagella that are 
found on the surface of many Gram-negative and Gram-positive species (see Figure 1.5) 
(Pizarro-Cerda and Cossart, 2006). These will be discussed below.  
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Figure 1.5 Current list of potential C. jejuni virulence factors. C. jejuni bacterial virulence 
factors with arrows indicating possible roles of CadF, FlpA, CiaB, CiaC and CiaI in 
pathogenesis (O. Croinin and Backert, 2012).  
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1.3.1 C. jejuni Flagellum 
C. jejuni contains one or two polar flagella which endow the bacterium with efficient 
motility and enable the bacterium to colonise a host by penetrating the mucous layer 
(Morooka et al., 1985, Guerry, 2007, Young et al., 2007). Furthermore, flagella play a 
role in secretion and in host-cell invasion where the bacteria require close contact to 
enter cells (Newell et al., 1985, Black et al., 1988, Wassenaar et al., 1991) as has been 
demonstrated in the chick model (Barrero-Tobon and Hendrixson, 2012). Early studies 
on C. jejuni motility revealed not only that motility was required for attachment to and 
invasion of IECs (Malik-Kale et al., 2008, Dasti et al., 2010) but that the adhesion and 
invasive ability of C. jejuni was increased when mucosal viscosity was increased 
(Morooka et al., 1985, Grant et al., 1993, Szymanski et al., 1995). 
C. jejuni motility is regulated by chemotaxis, which allows the bacterium to swim 
towards favourable conditions and away from unfavourable ones (Lertsethtakarn et al., 
2011). A C. jejuni flagellum contains three distinct sections: the basal body, the hook 
and the filament. The basal body anchors the flagella to the bacterial cell envelope, the 
filament protrudes from the bacterial surface and the hook transfers energy between the 
two (Konkel et al., 2004, Guerry, 2007). The filament section is made up of two 
proteins, a major flagellin FlaA and a minor flagellin FlaB, with an estimated size of 
~59 kDa (Guerry et al., 1991). The genes which encode the proteins responsible for the 
structural assembly of the flagella are transcribed in the order required for flagella 
assembly (Chevance and Hughes, 2008). This order is conserved in numerous species of 
bacteria including P. aeruginosa, H. pylori and V. cholera (Totten et al., 1990, Klose 
and Mekalanos, 1998, Spohn and Scarlato, 1999). The two flagellin genes flaA and flaB 
present in C. jejuni are almost identical (Nuijten et al., 1990). The regulation of 
transcription of flaA and flaB genes requires 28 (FliA) and 54 (RpoN) respectively. In 
C. jejuni, these two alternative σ factors control the expression of the flagellar genes 
that encode components of the flagellar organelle (Hendrixson et al., 2001). σ54 is 
required for the expression of FlaB as well as the flagellar rod and hook genes, while 
σ28 is required for the expression of flaA, which encodes the major flagellin and other 
filament genes (Hendrixson and DiRita, 2003, Carrillo et al., 2004, Wosten et al., 
2004). The Type III secretion (T3SS) components of the flagellar include FlhA, FlhB, 
FliP and FliR. FlgRS, is a two-component regulatory system (a sensor protein and a 
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response regulator protein) (Hendrixson and DiRita, 2003). The FlhF GTPase is another 
regulator that initiates transcription by σ54 RNA polymerase holo-enzyme (Hendrixson 
and DiRita, 2003, Balaban et al., 2009, Boll and Hendrixson, 2011). Two component 
regulatory systems are essential for the detection and transduction of the signals that 
facilitate linking of external and internal stimuli to correct certain behavioural responses 
such as gene expression (Gao and Stock, 2009). Current models suggests that the 
cytoplasmic FlgS histidine kinase autophosphorylates due to a stimulatory signal from 
the flagellar T3SS which then leads to activation of the FlgR response regulator for σ54-
dependent expression of flagellar rod and hook genes (Joslin and Hendrixson, 2009). As 
with other motile bacteria, the activity of σ28 in C. jejuni is suppressed by FlgM (an anti-
σ factor) until the flagellar rod and hook biosynthesis is complete (Wösten et al., 2010). 
Following rod and hook formation, FlgM is secreted from the cytoplasm to release σ28 
from transcriptional suppression, thereby resulting in flaA expression which is required 
for filament synthesis (Balaban et al., 2009, Barrero-Tobon and Hendrixson, 2012). The 
FlgSR and σ54 are also required for expression of the Fed proteins, which are co-
expressed with flagellar proteins but are not required for motility. Five Fed proteins 
have been identified as necessary for avian colonisation: FedA, FedB, FedC, FedD, and 
CiaI. Recently one of these proteins, CiaI, was shown to be required for invasion of 
human intestinal epithelial cells (Buelow et al., 2011a, Barrero-Tobon and Hendrixson, 
2012) 
1.3.2 C. jejuni Glycan structures  
Genome sequence analysis of the first C. jejuni strain NCTC11168 revealed the 
surprising ability of the pathogen to produce a diverse array of carbohydrates (Parkhill 
et al., 2000). These carbohydrate structures include a capsule, LOS, O-linked 
glycosylation of the flagella and a N-linked general glycosylation system (Karlyshev et 
al., 2005b). These glycan structures are found on all bacterial cells and are thought to 
play an important role in the interaction of bacteria with the host and the environment 
(Parker et al., 2008, Nizet V, 2009).  
1.3.3 Capsule 
The capsular polysaccharide (CPS) is on the outer most part of the bacterial cell and 
CPS has been suggested to play a role in interaction with host cells and in pathogenesis, 
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avoiding phagocytosis and enhancing bacterial survival. (Szymanski et al., 2003b, 
Guerry and Szymanski, 2008). CPS was first observed in 1996, but it was not until 
several years later that the biosynthetic mechanism of CPS was identified (Chart et al., 
1996, Karlyshev et al., 2000). CPS is assembled by an ATP binding cassette (ABC) 
pathway, these comprise a large class of proteins with roles in nutrient uptake, cellular 
functions and polysaccharides (George and Jones, 2012). C. jejuni capsule biosynthesis 
genes are split into three regions (see Figure 1.6), the first and third regions encode the 
KpS proteins that are involved in capsular assembly, transport and are highly conserved 
whilst the second central region is involved in polysaccharide synthesis is variable. This 
variation forms the basis of the different C. jejuni Penner serotypes. This genetic 
ordering of C. jejuni capsular genes is similar to those found in E. coli K1, K5, 
Haemophilus influenza and Neisseria meningtidis (Guerry et al., 2012). 
 
Figure 1.6 Comparison of bacterial capsule organisation genes of E. coli groups 2 and 3 
and C. jejuni (Guerry et al., 2012). 
The presence of C. jejuni CPS is dependent on a functional kps gene cluster and 
determines the Penner serotype (Karlyshev et al., 2000, Parkhill et al., 2000). KpsE and 
KpsM are both involved in C. jejuni capsule synthesis and mutation of kpsE resulted in 
a complete absence of capsular polysaccharide and although this mutant was able to 
colonise the chick model, the number of bacteria isolated from the caecum was 
significantly lower than those observed with the wild-type strain (Bachtiar et al., 2007). 
Similarly, mutation of kpsM also resulted in a loss of the capsule. Bacon et al. showed 
that a 81-176 kpsM mutant displayed a significant reduction in the ability to interact 
with and invade INT407 cells and displayed reduced virulence in the ferret model 
(Bacon et al., 2001), similar data was obtained with other non-capsular mutants 
(Corcionivoschi et al., 2009). CPS rather than LOS is the sero-determinant of the 
Penner serotyping system (Penner and Hennessy, 1980, Karlyshev et al., 2005a). CPS 
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displays a high level of variation between strains and this variation has been attributed 
to the presence of different biosynthetic genes and also phase variation of some 
biosynthetic genes due to slip-strand mispairing (Parkhill et al., 2000, Guerry et al., 
2002, Szymanski et al., 2003b).  
1.3.4 Lipooligosaccharide 
C. jejuni also expresses a LOS core, with the genes encoding proteins involved in the 
biosynthesis of LOS, this is highly variable and current genotyping has identified 19 
different classes (Parker et al., 2005, Parker et al., 2008). The genes involved in the 
synthesis of lipid A and the inner core are conserved and are the same in all strains 
(Houliston et al., 2011). Hence, C. jejuni LOS displays high levels of variation in the 
outer core and is important for virulence, epithelial cell adherence and invasion, endows 
protection from antimicrobials and plays a role in serum resistance (Linton et al., 2000, 
Parkhill et al., 2000, Naito et al., 2010). 
 LOS is made up of two distinct structural sections, a hydrophobic lipid A portion that is 
anchored in the bacterial outer membrane possessing endotoxic activity (Moran, 1997) 
and a non-repeating oligosaccharide which also has a conserved inner core and a 
variable outer core region (Parker et al., 2008). C. jejuni is capable of endogenously 
synthesising sialic acid residues for attachment onto the ganglioside-like LOS cores 
(Haddad et al., 2010). LOS displays a high level of variation due to phase variation of 
some LOS biosynthetic genes, in particular cgtA which encodes an N-
acetylgalactosaminyltransferase and wlaN which encodes a β-1,3 galactosyltransferase 
(Linton et al., 2000, Guerry et al., 2002). The cluster of genes responsible for the 
biosynthesis of LOS show a great range of genetic diversity (Gilbert et al., 2004). The 
LOS separates C. jejuni from other enteric Gram-negative bacterial pathogens due to the 
ability of the bacterium to mimic the structures of human gangliosides present on 
peripheral nerves. Due to this molecular mimicry, antibodies produced against C. jejuni 
LOS structures cross react with the host gangliosides (Yuki, 1997, Prendergast et al., 
1998) this is consistent with a role in immune avoidance and can give rise to 
autoimmune disorders such as GBS (see Section 1.1.6).  
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1.3.5 Glycosylation pathways 
C. jejuni possesses both N- and O- linked glycosylation systems (Szymanski et al., 
2003a) and these pathways have been attributed to play a role in C. jejuni pathogenesis 
(Karlyshev et al., 2005b, Mahdavi et al., 2014).  
1.3.5.1 O-linked protein glycosylation 
Glycosylation of the C. jejuni flagella was first identified in 1989 (Logan et al., 1989) 
(see Figure 1.7) and reported to be a prerequisite for filament assembly as mutants 
defective in flagellar glycan synthesis were unable to assemble a fully functional 
filament (Guerry and Szymanski, 2008). The O-linked glycosylation locus of 
NCTC11168 consists of around 50 genes, with variation in the genetic organisation of 
the O-linked locus between both species and strains. This is evident in a large cluster of 
genes Cj1318–Cj1332 which are present in NCTC11168 but are absent in 81-176 
(Parkhill et al., 2000, Logan, 2006). Campylobacter flagellins are decorated with O-
linked glycans which modify serine or threonine residues within flagellin and are 
essential for the production of a functional filament and flagella (Goon et al., 2003, 
Logan, 2006). Studies have identified up to 19 sites for O-linked glycosylation which 
contributes ~10% of flagellin mass (Guerry and Szymanski, 2008). The 81-176 wild-
type strain was found to be heavily glycosylated with pseudaminic acid (Thibault et al., 
2001).  
The importance of the flagella in the role of motility and functioning as a possible 
flagellar export apparatus for the secretion of the Cia proteins indicates that the O-
linked glycosylation pathway is directly related to the organism’s motility, 
autoaggregation, interaction with and invasion of host cells (Guerry et al., 2006). Early 
studies found that the flagella is the dominant immune antigen on the bacterial surface 
and mutations in Cj1331 and Cj1332 in C. coli VC167 (involved in post-translational 
modification of flagellin) resulted in reduced immunogenicity (Guerry et al., 1996, 
Logan, 2006). Mutations introduced in the O-linked glycosylation locus genes which 
led to a loss of 5,7-diacetamido-3,5,7,9-tetradeoxy-L-glycero-L-manno nonulosonic 
acid (or pseudaminic acid, Pse5Ac7Ac), a nine-carbon sugar that is structurally similar 
to sialic acid (Neu5Ac) or the acetamidino form of Pse5Ac7Ac (Pse5Am7Ac), led to a 
reduction in interaction, invasion and reduced virulence in the ferret model (Guerry et 
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al., 2006). This was further confirmed by an inability of non-flagellated mutants to 
colonise experimental animals (Guerry et al., 1991, Yao et al., 1994). Numerous genes 
in the flagellar glycosylation locus contain homopolymeric tracts, making these genes 
susceptible to slipped strand mispairing with subsequent phase variation, resulting in 
variation of the flagellin glycan structures. This variation in surface exposed flagellar 
glycan structures has been proposed to enable evasion of the host immune system 
response (Alm et al., 1992, Karlyshev et al., 2005a). However, the human immune 
system is unlikely to provide an influential evolutionary selective pressure in the life 
cycle of C. jejuni and more immediate environmental factors within the avian species 
such as the presence of bacteriophages are likely to the evolutionary forces for 
instigating changes in the surface of the C. jejuni cell (Scott et al., 2007). The exact role 
of the O-linked modifications on the flagella filament biosynthesis is unclear and 
requires further investigation (Gilbreath et al., 2011).  
 
Figure 1.7 O-linked protein glycosylation system. The O-linked protein glycosylation systems 
of Campylobacter and Helicobacter species. The pseB gene encodes the enzyme which converts 
the starting compound UDP-α-d-GlcNac to the first intermediate of the PseAc biosynthesis 
pathway resulting in the production of varying types of glycans linked to flagellin proteins 
(Gilbreath et al., 2011). 
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1.3.5.2 N-linked protein glycosylation 
Prior to the discovery of N-linked glycosylation in C. jejuni, this type of post–
translational modification of proteins had only been previously observed in eukaryotes 
and archaea (Szymanski et al., 1999). In contrast to C. jejuni surface structures such as 
the capsule, LOS and O-linked glycan, the N-linked glycan encoded by a 16 kb gene 
cluster termed the protein glycosylation locus (pgl) is highly conserved in all C. jejuni 
strains studied to date (Dorrell et al., 2001, Szymanski et al., 2003b). N-linked 
glycosylation involves an oligosaccharyltransferase (PglB) which enables coupling of a 
glycan to an asparagine residue forming a N-linked glycoprotein (Szymanski et al., 
2003a), this type of N-linked glycosylation is rare in most bacteria with the exception of 
C. jejuni, H. influenza and H. pullorum (Szymanski et al., 1999, Linton et al., 2002, 
Grass et al., 2010, Jervis et al., 2010). The conserved sequence for N-linked 
glycosylation in C. jejuni consists of D/E-X-N-X-S/T (see Figure 1.8) (where N is the 
modified asparagine and X can be any amino acid except for proline) (Nita-Lazar et al., 
2005, Kowarik et al., 2006).	  
 
Figure 1.8 N-linked protein glycosylation. N-linked protein glycosylation pathway in C. jejuni 
begins with UDP-GlcNAc resulting in a heptasaccharide that is attached to a lipid carrier on the 
cytoplasmic side of the inner membrane (IM). The heptasaccharide is then flipped to the 
periplasm by PglK, removed from the carrier by PglB and attached to a protein (Gilbreath et al., 
2011).  
The role of the N-linked glycosylation system is the modification of over 100 
periplasmic proteins with diverse roles in colonisation, adhesion and invasion 
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(Szymanski et al., 1999, Dasti et al., 2010, Scott et al., 2012, Alemka et al., 2013). 
Disruption of N-linked glycosylation genes pglB, pglD pglE, pglF, pglH or pglK has 
resulted in changes in levels of immune reactivity of specific glycosylated proteins, a 
reduced capacity of interaction with and invasion of IECs and a reduction in 
colonisation in the chick and mouse model (Szymanski et al., 1999, Szymanski et al., 
2002, Hendrixson and DiRita, 2004, Jones et al., 2004, Karlyshev et al., 2004). In 
addition, in vitro studies by Karlyshev et al. and Szymanski et al. reported that for the 
successful adherence and invasion of IECs, the complete PgL system was essential, 
indicating that N-linked glycosylation is required for C. jejuni interactions with and 
invasion of human IEC and avian hosts, however the exact roles have yet to be revealed 
(Szymanski et al., 2002, Karlyshev et al., 2004). 
1.3.6 Cytolethal distending toxin  
CDT is a type of bacterial toxin, that specifically interferes with the eukaryotic cell 
cycle, due to the presence of nuclease activity that damages the chromosomal DNA 
(Heywood et al., 2005). CDT causes arrest at the growth period/synthesis (G1/S) or pre-
mitotic phase (G2/M) transition of the cell cycle, depending on the cell type 
(Whitehouse, Balbo et al. 1998, Lara-Tejero and Galan 2000, Lara-Tejero and Galan 
2001). The presence of CDT in Campylobacter species was first reported in 1988 where 
cell distension and cytotoxicity of mammalian cells was observed (Johnson and Lior, 
1988). CDTs are produced by a number of Gram-negative bacteria such as E. coli, 
Helicobacter species, Haemophilus ducreyi, Shigella dysenteriae, Aggregatibacter 
actinomycetemcomitans and Salmonella enterica serotype Typhimurium (Guerra et al., 
2011). CDT is formed from three proteins CdtA, CdtB and CdtC, all required for toxin 
activity (Jinadasa et al., 2011). The toxic component is CdtB as studies have shown this 
protein leads to similar cell damage as observed with the holotoxin (Lara-Tejero and 
Galan, 2000). The action of CdtB is that of a DNAse and this subunit shares homology 
with DNAse I-like proteins (Lara-Tejero and Galan, 2001). CdtB is thought to be 
delivered by the binding proteins CdtA and CdtC into the host cell where CdtB localises 
with the nucleus, resulting in DNA damage (Lara-Tejero and Galan, 2000). C. jejuni 
CDT has been found to trigger the release of IL-8, but IL-8 can also been triggered in 
the absence of CDT (Hickey et al., 2000). CDT may possibly play a role in immune 
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modulation and invasiveness (Purdy et al., 2000). The exact role of CDT in C. jejuni 
pathogenesis is not fully understood and further studies need to be undertaken. 
1.4 Host response to C. jejuni infection 
Despite many in vitro studies to investigate the interaction of C. jejuni with human 
immune cells, it is still unclear as to the exact mechanism by which the infection is 
cleared (Young et al., 2007). Human infection with C. jejuni occurs via the oral route 
following ingestion of contaminated foods (Schildt et al., 2006, Newell et al., 2011). 
The acidic environment of the stomach kills a significant number of the bacteria, 
however those that remain able to attack the mechanical and immunological barriers of 
the GI tract. The mucus layer of the GI tract serves as a first line of defence against the 
bacteria. C. jejuni has specific traits such as motility and a cork screw like morphology 
that enable the bacterium to over-come this barrier (Young et al., 2007). C. jejuni is able 
to then attach to IECs, colonising the lower intestinal tract (ileum, jejunum, and colon) 
and begin replication (Janssen et al., 2008). However, the exact mechanisms of how C. 
jejuni causes disease are still poorly understood.  
Studies have shown that C. jejuni is able to invade cell monolayers (Everest et al., 1992, 
Fernandez and Trabulsi, 1995). Invasion leads to disruption of the epithelium and 
allows C. jejuni access to the host cell (Walker et al., 1986, Wooldridge and Ketley, 
1997). in vitro experiments with human IECs have shown that C. jejuni can induce the 
secretion of a range of cytokines and chemokines such as Interleukin-1β, IL-8 and nitric 
oxide (NO) (Hickey et al., 1999, Hickey et al., 2000, Al-Salloom et al., 2003, Jin et al., 
2003, Enocksson et al., 2004). Following infection with C. jejuni, human monocytes 
produce a number of cytokines and chemokines, including IL-6, IL-8, IL-1β and tumour 
necrosis factor alpha (TNFα) and it has been suggested that the activation and 
production of these host cytokines and chemokines could be responsible for the disease 
pathology observed (Jones et al., 2003, Siegesmund et al., 2004).  
IECs are capable of microbial sensing and producing specific immune responses 
(Kagnoff and Eckmann, 1997, Eckmann, 2005). The innate immune system is activated 
when pathogen associated molecular pattern molecules (PAMPS) engage with the 
pattern recognition receptors (PRRs) found on IECs, dendritic cells (DCs) and 
macrophages (Lavelle et al., 2009). Of the PRRs, the most widely studied are a group of 
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integral membrane proteins termed toll-like receptors (TLRs), which are central in 
recognising specific pathogen ligands such as flagella, LOS and DNA and initiating the 
immune defence against foreign invaders (Philpott and Girardin, 2004, Janssen et al., 
2008, Zilbauer et al., 2008). The activation of TLRs leads to the production of pro-
inflammatory cytokines (O'Hara and Shanahan, 2006). Watson and Galan reported that 
Campylobacter flagellin was not recognized by IEC TLR5 and did not play a role in the 
bacterial-mediated immune response, therefore the role of other TLRs in interaction 
with C. jejuni warranted further study (Watson and Galan, 2005). C. jejuni is capable of 
evading the immune stimulation of TLR5 due to the high level of differences in the 
amino acid sequences present in the flagellar structure compared to other bacteria 
(Andersen-Nissen et al., 2005, Watson and Galan, 2008b). Studies on the involvement 
of C. jejuni with a second intracellular member of the PRR family termed nucleotide 
binding oligomerisation domain (NOD) proteins, showed that NOD1 was triggered and 
initiated an immune response including the induction of IL-8 and human-β defensin 
(HβD2). NOD1 knockouts in Caco-2 IECs produced a significant reduction in innate 
immune activity, with increased intracellular C. jejuni observed during this reduced 
innate immune response. In contrast, studies with NOD2 reported a minimal 
involvement of this PRR in intestinal epithelial innate immunity (Inohara et al., 2005, 
Zilbauer et al., 2007). 
An important C. jejuni virulence factor is the diversity found in the LOS structure. A 
subdivision of C. jejuni strains that express an LOS class A, B, or C gene locus have 
been found to harbour genes involved in sialic acid biosynthesis and are therefore able 
to synthesise sialylated LOS (Guerry et al., 2000, Gilbert et al., 2000, Godschalk et al., 
2004). The presence of a cst-II gene in C. jejuni class A and B strains encodes a 
sialyltransferase which transfers sialic acid onto the LOS core and LOS sialylation of C. 
jejuni class C strains depends on the presence of the cst-III gene (Chiu et al., 2004). 
Thus these C. jejuni possess genes encoding proteins involved in sialic acid biosynthesis 
and are capable of LOS sialylation (Louwen et al., 2008).  
LOS sialylation has been found to play an important role in microbial recognition and 
activation of the immune response (Angata and Varki, 2002, Varki and Gagneux, 2012) 
and LOS sialylated C. jejuni strains have been found to invade IEC at higher levels, 
produce a more aggressive form of gastroenteritis. In addition these strains were also 
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reduced in susceptibility to human serum and are an important risk factor in the 
development of GBS (Guerry et al., 2000, van Belkum et al., 2001, Louwen et al., 
2008, Mortensen et al., 2009). 
LOS sialylation has been reported to activate DCs and mouse myeloid cells (Hu et al., 
2006a, Kuijf et al., 2010, Huizinga et al., 2012). DCs are widely distributed in tissues 
including the intestinal mucosa and are involved in not only innate but also the adaptive 
immune responses to microbial pathogens due to the ability to present antigens to T-
cells (Medzhitov and Janeway, 1997). DCs are antigen presenting cells and are 
important in both innate and adaptive immune defence activation (Balazs et al., 2002, 
Craxton et al., 2003). C. jejuni is susceptible to serum, which highlights the importance 
of complement mediated killing (Blaser et al., 1985). The primary method by which 
bacteria are cleared by the body is via cell mediated immunity and includes the action of 
DCs and macrophages (Al-Salloom et al., 2003, Fox et al., 2004, Hu et al., 2006a). C. 
jejuni infection of T84 IECs has been found to increase the expression of IL-8, which 
has been reported to be involved in the recruitment of DCs (Johanesen and Dwinell, 
2006).  
in vitro studies have found that C. jejuni is rapidly internalised by DCs (Hu et al., 
2006a), resulting in the activation of NF-κb and the subsequent induction of numerous 
cytokines and TNF-α, a signature of DC activation (Jones et al., 2003). Kuijf et al. 
reported that LOS stimulation of human DCs triggered the release of soluble immune 
factors which enhanced the proliferation of B cells (Kuijf et al., 2010). Subsequent 
work by Stephenson et al. reported a direct correlation between the variations in TLR4 
stimulation in cytokine induction and the degree of LOS sialylation (Stephenson et al., 
2013). Other components of the innate immune response found to play a key role in 
defence against C. jejuni are the antimicrobial human β-defensins, these molecules 
belong to a family of epithelial antimicrobial peptides and are a major component of the 
host innate defence at the gastrointestinal mucosal surface (Hamanaka et al., 2001, 
Dhaliwal et al., 2003, Dommett et al., 2005). Members of the human β Defensin (hβD) 
family have been found to be secreted during gastrointestinal infection (Bevins et al., 
1999, Wehkamp et al., 2003, Zaalouk et al., 2004, Zilbauer et al., 2005), previous 
studies have reported that the constitutive expression of hβD-1 was necessary for 
immune surveillance whilst hβD-2 and hβD-3 are up-regulated during gastrointestinal 
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infection (O'Neil et al., 1999, Dhaliwal et al., 2003, Lehrer, 2004, Zilbauer et al., 2005). 
These hβDs have been found to be secreted during C. jejuni infection of IEC, with an 
equal increase in the levels of peptide expression and bactericidal effects were also 
observed in the presence of recombinant-β-defensins, providing further evidence that 
these antimicrobial peptides produce a potent response against C. jejuni (Bevins et al., 
1999, Wehkamp et al., 2003, Zaalouk et al., 2004, Zilbauer et al., 2005).  
1.4.1 Humoral Immune Response to C. jejuni 
Following natural or experimental infection with C. jejuni, most people develop 
antibodies to C. jejuni surface proteins and LOS (Wenman et al., 1985, Nachamkin and 
Hart, 1985, Dunn et al., 1987). Previous studies have reported that experimental 
infection of human volunteers and macaques causes antibodies to appear around 6 to 7 
days after infection (Mills and Bradbury, 1984, Russell et al., 1989). The suggestion 
that humoral immunity plays a key role in clearance of the bacteria is supported by the 
reduction in clinical symptoms of gastroenteritis observed along with the production of 
circulating anti-C. jejuni antibodies (Mills and Bradbury, 1984). in vitro studies showed 
that anti-C. jejuni antibodies were effective at killing the homologous strain used for 
infection (Black, 1992). However, when sera from volunteers infected with 
heterologous strains was used to kill C. jejuni, the bactericidal activity was significantly 
reduced indicating strain-specific antibody protection (Pennie et al., 1986). The ability 
of C. jejuni to induce inflammatory cytokines and the interaction of C. jejuni with the 
host or the regulation of host cell responses may be crucial to the course of infection 
(Johanesen and Dwinell, 2006, Dasti et al., 2010). 
1.5 Adhesion to and invasion of host epithelial cells 
Bacterial attachment to host cells is a key process in initiating the early stages required 
for successful colonisation (Finlay and Falkow, 1997). Binding to host cells enables cell 
invasion and thus protection from humoral immunity (Roberts, 1990, Isberg and Van 
Nhieu, 1994, Alrutz and Isberg, 1998). A major theme is the ability of pathogenic 
microorganisms to hijack host cell molecules which enable binding and ultimately entry 
of the pathogen into the host cell (Watarai et al., 1996). The bacterial factors involved in 
adhesion and invasion of host cells range from single monomeric proteins to complex 
multimeric macromolecules that are involved in highly developed functions (Pizarro-
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Cerda and Cossart, 2006). Tissue culture studies have identified C. jejuni virulence 
determinants including CadF (Campylobacter Adhesion to Fibronectin) (Konkel, Garvis 
et al. 1997), a second fibronectin- like binding protein FlpA (Flanagan et al., 2009), a 
periplasmic binding protein PEB1 (Pei and Blaser 1993) and the surface lipoprotein 
JlpA (Jin, Joe et al. 2001) as key molecules that facilitate bacterial adhesion and 
invasion. Also, secretion of Campylobacter invasion antigens (Cia) proteins into host 
IECs have been identified (Hu and Kopecko 1999, Konkel, Kim et al. 1999) and CiaB 
has been reported to be required for C. jejuni internalisation (Konkel, Kim et al. 1999).  
1.5.1 C. jejuni Invasion	  
C. jejuni invasion is an essential process in the internalisation and translocation of the 
bacteria across the epithelial cell barrier of the intestine and is important for causing 
enteritis (van Spreeuwel, Duursma et al. 1985). However the understanding C. jejuni 
invasion of IECs is still incomplete (O. Croinin and Backert, 2012). Several in vitro 
models have shown that C. jejuni can cross cell monolayers but with only a small 
number of bacteria actually invading cells (Friis et al., 2005). Translocation of C. jejuni 
by disruption of the tight cell junctions was observed in Caco-2 IECs (MacCallum, 
Hardy et al. 2005). There is also a particular inflammatory signature of invasion, as the 
production of IL-8 and the prostaglandin E2 by polarised human colonic HCA-7 cells 
was only induced upon infection with invasive C. jejuni strains and not with non-
invasive strains (Beltinger, del Buono et al. 2008).  
Pathogens interacting with the intestinal epithelium can modify the function of the 
epithelium and enable penetration across the epithelial barrier and to target mucosal host 
defences for survival (Lu and Walker 2001). Similar to other enteric pathogens, C. 
jejuni interacts with the host cytoskeleton, producing changes in the architecture of the 
host cell, leading to eventual uptake of the bacteria by the cell (Clerc and Sansonetti, 
1987, Cossart and Sansonetti, 2004). The eukaryotic host cytoskeleton composition is 
made up of microtubules (MTs) and microfilaments (MFs), the latter of which provides 
rigidity to the cell (Granger et al., 2014). This network of filaments provides the cell 
with shape, function and movement (Mundy et al., 2002, Chang and Goldman, 2004). 
Extracellular stimuli can produce changes in the cytoskeleton (Rosenshine 1998) and 
many enteric pathogens can subvert the host cell cytoskeleton into uptake of the 
bacterium by the secretion of proteins into the host cell using a specialised T3SS. These 
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are complex macromolecular structures that allow pathogenic bacteria to secrete 
proteins across the inner and outer membranes (Pizarro-Cerda and Cossart, 2006). 
Through this mechanism, extracellular bacteria that are in close contact with eukaryotic 
cells can deliver bacterial proteins into the cytosol (Gauthier and Finlay, 1998, Cornelis, 
2006). Many T3SS effector proteins have been identified in Salmonella species, 
Shigella species, enteropathogenic E. coli (EPEC), enterohaemorrhagic E. coli (EHEC) 
and Yersinia species which appear to act directly on intracellular host effector proteins 
(Finlay and Cossart, 1997, Kubori et al., 1998, Goosney et al., 1999). Upon secretion 
into host cells, bacterial effector proteins cause activation of the host cell tyrosine kinase 
phosphorylation and calcium movement from within intracellular stores or activation of 
small guanine-nucleotide binding proteins (GTPases) belonging to the Ras superfamily, 
such as Rac and Rho proteins, these small GTPases play highly organised roles in cell 
processes (Finlay and Cossart, 1997, Vetter and Wittinghofer, 2001). This process 
eventually leads to actin cytoskeleton rearrangements and internalisation of the bacteria 
into the cell (Neutra 1999).  
Early studies showed that C. jejuni motility was essential for IEC invasion in vitro and 
that an increase in mucus viscosity increased the levels of motility, adherence and 
invasion (Szymanski et al., 1995). This association between motility and invasion 
combined with the lack of an identifiable classical T3SS or type IV secretion system 
(T4SS) led researchers to conclude that the flagellum could be used as a secretory 
apparatus for injection of invasion-associated effector molecules (Desvaux et al., 2006). 
The C. jejuni flagellum components are homologous to the classical T3SS and play an 
essential role in C. jejuni pathogenesis (Neal-McKinney and Konkel, 2012).  
The flagellum of C. jejuni is composed of a basal body, hook and filament. The basal 
body spans both the inner and outer membranes. The hook is composed of the protein 
FlgE, and capped by the hook-filament proteins FlgK and FlgL. Mutation of flgK, flgL 
or flgE results in an inability to form a functional flagellar filament (Konkel et al., 2004, 
Fernando et al., 2007b). The flagellar filament is composed of FlaA and FlaB and is 
capped by FliD, which allows the flagellin subunits to polymerise into the extending 
flagellum (Yokoseki et al., 1995). Previously, the flagellum transport machinery was 
thought only to be essential in organelle biogenesis. Studies performed with Yersinia 
enterocolitica found that this bacteria secreted flagellar outer proteins (FopS) via the 
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flagellum which are involved in host cell interactions, thus suggesting that the flagellum 
may be a general method for the secretion of bacterial proteins and therefore acts as a 
T3SS, additionally a C. jejuni flhB export mutant was found to be deficient in secretion 
of the Cia proteins (Young et al., 1999, Christensen et al., 2009, Neal-McKinney et al., 
2010).  
The first non-flagellar C. jejuni secreted factor identified was CiaB, secretion of this 
protein seemed to require at least one of the flagellar subunits and mutations of ciaB 
resulted in a significant reduction in intracellular bacteria (Konkel et al., 1999b, Konkel 
et al., 2004). Other secreted proteins identified so far are CiaC (Christensen et al., 
2009), CiaI (Buelow et al., 2011b) and CiaD (Samuelson et al., 2013). Numerous 
studies have reported that C. jejuni proteins secreted via the flagellum have been found 
to play a role in chick colonisation and in the invasion of IECs (Konkel et al., 1999b, 
Ziprin et al., 2001, Fernando et al., 2007b). However, the only potential T3SS in C. 
jejuni is the flagella (Parkhill et al., 2000). The role of the flagella as a T3SS in C. jejuni 
is controversial, as another study reported no significant	  reduction in invasion by a 81-
176 ciaB mutant suggesting that further work is required on CiaB (Novik et al., 2010). 
In the absence of a “classical T3SS” in C. jejuni, other potential virulence factors have 
been investigated. The ability of C. jejuni to harbour plasmids and the involvement of 
plasmids in Campylobacter pathogenesis and antimicrobial resistance has been studied 
since the 1980s (Taylor et al., 1983). The pVir plasmid found in some C. jejuni isolates 
is a ~37.5 kb plasmid conferring tetracycline resistance and has been implicated in 
virulence (Bacon et al., 2000). Sequencing of pVir found that the plasmid harboured 
four genes which encoded homologs of a bacterial (T4SS), utilised by a number of 
pathogenic bacteria (Bacon et al., 2002). Studies with C. jejuni isolates containing this 
plasmid have demonstrated pVir plays roles in cell invasion and pathogenicity in the 
ferret model (Hu and Kopecko, 1999, Bacon et al., 2000, Desvaux et al., 2006, Goni, 
2014). Further to this, the presence of pVir was significantly associated with bloody 
diarrhoea indicating a role for pVir in the pathogenesis of more invasive strains and 
severe forms of Campylobacter infection (Louwen et al., 2006). However, 
electroporation of the pVir plasmid into NCTC11168 did not produce an increase in 
invasion of IEC (Bacon et al., 2000), indicating that other virulence determinants are 
also probably involved in severe forms of C. jejuni infections (Skirrow MB, 2000). The 
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possible mechanisms of C. jejuni secretion have been investigated but remain poorly 
understood in comparison to other bacterial pathogens (see Section 1.5.4). 	  
Enteric pathogens have been shown to hijack the host cell by inducing changes in the 
host cytoskeleton by rearranging the vast actin network of MFs that leads to uptake of 
the invading pathogen (Sansonetti 2001). Enteric organisms such as Salmonella and 
Shigella (Finlay and Falkow 1988, Elsinghorst, Baron et al. 1989, Finlay and Falkow 
1989, Sansonetti 2001) have been found to induce cytoskeletal changes leading to 
bacterial internalisation. Bacterial interactions with both MFs and MTs have been 
identified as key to invasion and intracellular survival (Yoshida and Sasakawa 2003, 
Abrahams and Hensel 2006). However the details on C. jejuni entry and invasion are 
unclear, for instance C. jejuni has been reported to gain entry using either MF 
interactions (De Melo, Gabbiani et al. 1989, Konkel and Joens 1989), occurring mainly 
at the basolateral surface of the host cell (Kopecko 2008), or using MT interactions, 
which is the most predominantly observed pathway occurring at the apical surface 
(Oelschlaeger, Guerry et al. 1993, Hu and Kopecko 1999). C. jejuni has also been 
reported to exploit both MF- and MT-dependent pathways simultaneously for invasion 
(Oelschlaeger et al., 1993, Kopecko et al., 2001b, Biswas et al., 2003, Monteville et al., 
2003b) or neither (Russell and Blake 1994) (See Figure 1.9) 
 
 
Figure 1.9 Hypothetical model of C. jejuni, interacting with and invasion of intracellular 
survival and transmigration mechanisms. (Backert and Hofreuter, 2013). 
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Studies have reported a reduction in the invasion levels of certain C. jejuni strains with 
the use of MT and MF inhibitors (Fauchere et al., 1986, Konkel and Joens, 1989, 
Biswas et al., 2003). However, C. jejuni 81-176 invasion was significantly enhanced 
using MF inhibitors (Oelschlaeger, Guerry et al. 1993). Previous studies have shown 
that some inhibitors can increase or decrease the invasiveness of bacteria depending on 
bacterial species and tissue type (Wells et al., 1998). Also the passage number of tissue 
culture cells, the multiplicity of infection (MOI) and time-length of assay may all 
influence such data (Delie and Rubas, 1997). 	  
In summary, there is conflicting data in the literature with regards to C. jejuni invasion. 
This can in part be attributed to differences with the bacterial strain used in experiments 
(Harvey, Battle et al. 1999, Biswas, Itoh et al. 2000), cell line and culturing methods 
and the assay methodology used which can all lead to variation in the results obtained 
(Friis et al 2005). The ability of C. jejuni to adhere to and invade human IECs has been 
studied extensively using tissue culture methods (Konkel and Joens 1989). However, 
such studies suggest relatively low levels of invasion (~1%) and until recently there was 
little evidence to suggest that C. jejuni survives in IECs (Friis et al., 2005, Watson and 
Galan, 2008b)	  
When engulfed by macrophages, C. jejuni is unable to avoid delivery to the lysosomes 
and is rapidly destroyed (Watson and Galan 2008). However, C. jejuni can survive 
within IECs by entering vacuoles and avoiding delivery to lysosomes, the bacteria 
appear to survive within a Campylobacter Containing Vacuole (CCV) in IECs which 
moves to a close proximity to the Golgi apparatus (Watson and Galan, 2008b). It is 
therefore clear that uptake via active invasion, rather than passively by phagocytosis, is 
crucial for virulence in C. jejuni infection (Watson and Galan, 2008b).  
It is still unclear which route of invasion “zipper” or “trigger” is utilised by this bacteria 
(O. Croinin and Backert, 2012). However, recent studies using high resolution electron 
microscopy imaging of infected INT407 IECs showed that interestingly, C. jejuni may 
share certain features of both “trigger” and “zipper” entry (Krause-Gruszczynska et al., 
2011, Boehm et al., 2012). The C. jejuni flagellum is able to transport bacterial effectors 
into the host cell and/ or the flagella can act as an adhesin by binding to host cell 
receptors, leading to signalling and invasion of C. jejuni. C. jejuni triggers membrane 
ruffling via direct contact with the host cell followed by entry with first the flagella tip, 
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then the opposite flagella end (Krause-Gruszczynska et al., 2007a, Krause-
Gruszczynska et al., 2011, O. Croinin and Backert, 2012). Further studies are needed to 
more precisely understand this process. 
1.5.2 The putative role of C. jejuni outer membrane vesicles in invasion of IEC 
Both pathogenic and non-pathogenic Gram-negative bacteria release outer membrane 
vesicles (OMVs) from growing cells, spherical in shape with varying sizes of ∼10 to 
500 nm diameter (Mayrand and Grenier, 1989, Beveridge, 1999, Kuehn and Kesty, 
2005, McBroom and Kuehn, 2007). OMVs are formed from sections of the bacterial 
membrane which bleb off to form vesicles (see Figure 1.10) (Chatterjee and Das, 1967, 
Ellis and Kuehn, 2010, Kulp and Kuehn, 2010). OMVs in non-pathogenic bacteria play 
a protective role by reducing the presence of toxic components, aiding bacterial survival 
(Loeb and Kilner, 1978, Kobayashi et al., 2000). The secretion of OMVs has been 
found to be increased when the bacteria are under environmental stress (McBroom and 
Kuehn, 2007).  
OMVs play a role in pathogenesis, mediating intercellular exchange events and by 
acting as vehicles for delivery of virulence factors, include toxins, adhesins, 
lipopolysaccharide (LPS) and immune-modulatory compounds (Beveridge, 1999, 
Horstman and Kuehn, 2000, Kesty et al., 2004, Kuehn and Kesty, 2005). OMVs are 
also involved in bacterial quorum sensing, aggregation of bacteria thereby enabling 
biofilm formation (Mayrand and Grenier, 1989, Whitchurch et al., 2002, Nakamura et 
al., 2008, Ellis and Kuehn, 2010). In addition, OMVs have been reported to modulate 
the host immune response, as previous studies have found that OMVs secreted by 
Moraxella catarrhalis contain a super-antigen molecule which is able to induce a non-
specific immune response that diverts from targeting the actual Moraxella catarrhalis 
bacterial cells, therefore playing an important role in the pathogenesis of this 
microorganism (Bomberger et al., 2009, Vidakovics et al., 2010). Numerous Gram-
negative bacteria including E. coli, P. aeruginosa, C. jejuni and H. pylori have been 
shown to produce OMVs (Bomberger et al., 2009, Lindmark et al., 2009, Kulp and 
Kuehn, 2010, Vidakovics et al., 2010, Elmi et al., 2012). OMV production has also 
been reported to be important in the life cycle of intracellular pathogens as Francisella 
species, Salmonella species and Legionella pneumophila have been shown to release 
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OMVs directly into the phagosomal compartments the bacteria reside in (Anthony et 
al., 1991, Garcia-del Portillo et al., 1997, Fernandez-Moreira et al., 2006). 
Delivery or injection of bacterial virulence factors directly into the target cell is an 
important mechanism and requires intimate contact with the host cell via a T3SS or 
T4SS, utilised by both pathogenic and non-pathogenic bacteria, allowing the delivery of 
adhesins, toxins and immunomodulatory compounds, which can directly mediate 
bacterial binding and invasion, causing cell death and modulation of the host immune 
response (Mota and Cornelis, 2005, Cornelis, 2006, Grant et al., 2006). C. jejuni lacks 
classical virulence factors identified in other Gram-negative pathogenic bacteria 
(Parkhill et al., 2000). The C. jejuni flagella apparatus has been reported to function as a 
possible T3SS (Parkhill et al., 2000) and also to be involved in the secretion of Cia 
proteins into the host cell (Konkel et al., 2004). However the flagellar serving as a 
secretory apparatus for the delivery of C. jejuni Cia proteins is controversial (Novik et 
al., 2010). The identification of C. jejuni OMVs was noted over 30 years ago, but has 
only recently become an active area of research due to the discovery that 81-176 OMVs 
contain CDT (Logan and Trust, 1982, Blaser et al., 1983b, Lindmark et al., 2009). 
Lindmark’s study was the first evidence to show that C. jejuni was capable of delivering 
virulence factors into IECs and the surrounding environment using OMVs (Lindmark et 
al., 2009). A recent study reported that C. jejuni OMVs alone were capable of inducing 
the production of significant levels of IL-8, IL-6, TNF-α, and hBD-3 from T84 IECs 
(Elmi et al., 2012). Therefore, in the absence of classical virulence associated secretion 
systems in the C. jejuni cell, the hypothesis that C. jejuni may be utilising OMVs in 
order to deliver bacterial effector proteins which promotes the interactions with, 
invasion of IECs and immune modulation of the host response (Elmi et al., 2012).  
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Figure 1.10 Outer membrane vesicle model. Bacterial outer membrane vesicle formation 
model. The OMVs contain periplasmic material and outer membrane proteins, lipids and other 
virulence factors (Ellis and Kuehn, 2010) This model shows the budding of the Gram-negative 
bacterial envelope.  
1.5.3 Inhibition of C. jejuni adhesion to and invasion of intestinal epithelial cells 
In order to gain access to the host, evade the host immune system and cause disease. 
Many enteropathogenic bacteria enter the host cell via the interaction of microbial 
surface determinants with host receptors that once engaged are capable of transmitting 
signals which disrupt the cytoskeleton and enable entry of the pathogen (Fasano, 1998). 
The cytoskeleton is made up of three components; microfilaments, intermediate 
filaments and microtubules which are the largest protein filaments (Cooper, 2000) . 
These cytoskeletal structures are required for normal cell function by playing a role in 
cell division, movement of organelles, as well as being involved in cell signalling and 
maintaining the cytoskeletal dynamics of the cell (Desai and Mitchison, 1997). By 
utilising the host cell actin and microtubules which are involved in the transportation of 
endosomes and lysosomes within the cells, the bacteria can use the host cells 
polymerised filamentous actin as a method of uptake, where the bacteria is the key 
initiator of internalisation. (Stahl and Schwartz, 1986, Swanson and Watts, 1995). These 
protein filaments allow movement of bacteria into the host cell (Finlay and Cossart, 
1997). Many enteric invasive microorganisms have been found to enter the host cell via 
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the MF pathway such as Salmonella, Shigella, Listeria and Yersinia species (Clerc and 
Sansonetti, 1987, Finlay and Falkow, 1989, Falkow et al., 1992, Isberg and Van Nhieu, 
1994).  
Different types of endocytosis have been described and are dependent on the size of the 
endocytic vesicle, the type of cargo and the mechanism of vesicle formation. These are; 
phagocytosis, caveolin-mediated endocytosis, macropinocytosis, clathrin-mediated 
endocytosis and clathrin- and caveolin-independent endocytosis (Conner and Schmid, 
2003). These endocytic pathways have been targeted by microbial pathogens, enabling 
internalization into non-professional phagocytes via caveolae and clathrin-mediated 
endocytosis, macropinocytosis or by avoiding delivery to the lysosomes (Gruenberg and 
van der Goot, 2006). In order to understand the mechanisms of C. jejuni invasion, the 
actin filament polymerisation inhibitor Cytochalasin D has been used previously. This is 
a fungal metabolite and acts by binding to the fast growing ends of microfilaments and 
blocking the action of the actin monomers (MacLean-Fletcher and Pollard, 1980, Brown 
and Spudich, 1979, Pollard and Mooseker, 1981). Cytochalasin D has previously been 
found to both decrease and increase C. jejuni invasion of IECs (Hu and Kopecko, 1999, 
Hu et al., 2008, Bouwman et al., 2013).  
The cholesterol depleting agent methyl-beta-cyclodextrin (MβCD) has been used to 
ascertain whether lipid rafts present in the host plasma membrane are involved in 
bacterial invasion. Membrane lipid rafts were first proposed in 1997 by Simons and 
Ikonen and are rich in sphingolipids and cholesterol, these areas of high lipid 
concentrations play a role in intracellular trafficking and possible cell signalling events 
(Simons and Ikonen, 1997). Lipid rafts have been found to be involved in membrane 
trafficking, construction of immunological synapses, involvement in cellular processes 
such as cell adhesion mechanisms and endocytic activity (Simons and Ikonen, 1997, 
Brown and London, 1998). Lipid rafts have also been found to provide a gateway for a 
number of pathogens including several species of E. coli (EPEC), S. flexneri, S. 
Typhimurium, Mycobacterium species, Chlamydia species, Ehrlichia chaffeensis, 
Anaplasma phagocytophilum, C. jejuni, L. monocytogenes and Mycoplasma fermantas 
(Manes et al., 2003, Pelkmans and Helenius, 2003, Lafont et al., 2004, Seveau et al., 
2004, Yavlovich et al., 2004). Endocytosis of the organism through lipid rafts allows 
translocation of the organism into the cell (Zaas et al., 2005). Clathrin-mediated 
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endocytosis of C. jejuni has been observed (Oelschlaeger et al., 1993, Biswas et al., 
2000) and recently Watson and Galan showed that C. jejuni was translocated into IECs 
via lipid rafts (Watson and Galan, 2008b). 
Many studies have found that bacterial attachment to and invasion of the host cell leads 
to activation of host cell signalling cascades (Finlay and Falkow, 1997). Host cell 
effector proteins, such as phosphatidylinositol 3-kinase (PI3-kinase), are signal 
transducer enzymes and are involved in cell growth, motility differentiation, 
proliferation, survival and intracellular trafficking and once induced can lead to 
dramatic changes in the host cell, whereby triggering Rac1 downstream leads to 
massive cytoskeletal deformation, actin rearrangements and membrane ruffling 
(Hawkins et al., 1995), with eventual internalisation of the bacteria into the cell (Finlay 
and Cossart, 1997). Wortmannin, a potent specific inhibitor of the PI3-Kinase pathway, 
this pathway has been found to be involved in the endocytosis of C. jejuni as previous 
studies have found inhibition of PI3-Kinase led to decreased invasion levels of C. jejuni 
(Arcaro and Wymann, 1993, Ninomiya et al., 1994, Wooldridge et al., 1996b, Krause-
Gruszczynska et al., 2011, Sun et al., 2013). 
Clathrin-mediated endocytosis involves the uptake of material from outside of the cell 
to the inside of the cell using clathrin coated vesicles which are pre-formed on the 
plasma membrane (Pearse, 1976). This cellular machinery has been found to be 
harnessed by many pathogenic organisms including, S. aureus, Salmonella species, 
Shigella species, uropathogenic E. coli, Candida albicans and Yersinia pestis as well as 
viruses and toxins (Oelschlaeger et al., 1994, Almeida et al., 1996, Pizarro-Cerda et al., 
1997, Cossart, 1997, Duncan et al., 2002, Green and Brown, 2006, Nazli et al., 2006, 
Veiga et al., 2007). Previous work by Oelschlaeger et al. showed that C. jejuni 81-176 
entry via clathrin-mediated endocytosis was inhibited by the use of specific inhibitors of 
coated pit formation g-Strophantin and Monodansylcadaverine (Oelschlaeger et al., 
1993). These inhibitors of clathrin-mediated endocytosis have been used since the early 
1980s in many different cell lines (Schlegel et al., 1982, Mato et al., 1983). Russell and 
Blake found that C. jejuni 81-176 bacterial entry into Caco-2 IECs was not inhibited by 
monodanyslcadaverine, however Biswas et al. reported a decrease in C. jejuni 81-176 
invasion into INT407 IECS in the presence of monodansycladaverine (Russell and 
Blake, 1994, Biswas et al., 2000), suggesting the importance of multiple cellular 
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pathways utilised by different strains of C. jejuni in different eukaryotic cell lines (Hu 
and Kopecko, 1999, Friis et al., 2005, Young et al., 2007, van Putten et al., 2009, 
Bouwman LI 2012).  
Some pathogenic organisms have been found to utilise the microtubule pathway to gain 
entry into host cells (Finlay and Falkow, 1989, Finlay and Falkow, 1997, Yoshida and 
Sasakawa, 2003). Previous work by Oelschlaeger et al. found that C. jejuni required 
intact microtubules for gaining entry into the INT407 IECs, as use of the microtubule 
inhibitor colchicine, a potent mitotic inhibitor and therefore results in microtubule 
formation arrest, reduced the number of intracellular bacteria (Dustin, 1978, Kang et al., 
1990, Oelschlaeger et al., 1993). How C. jejuni uses the host cell cytoskeleton is still 
under investigation. 
1.5.4 Role of CiaB 
Previous studies on intestinal biopsies from infected patients showed that C. jejuni is an 
invasive organism due to the presence of internalised bacteria observed in the gut tissue 
(van Spreeuwel et al., 1985). This same level of invasion has also been observed during 
in vitro studies where C. jejuni isolated from individuals suffering from diarrhoea and 
fever were able to attach and invade IECs at a higher level than the strains isolated from 
patients with no reported symptoms (Fauchere et al., 1986). C. jejuni secretes a set of 
proteins, termed Campylobacter invasion antigens (Cia) that are required for the 
invasion of cultured IECs (Konkel et al., 1999b, Rivera-Amill et al., 2001). The first 
Cia protein identified was termed Campylobacter invasion antigen B (CiaB), a 73 KDa 
protein with weak homology to other bacterial T3SS effector proteins. CiaB was 
thought to be translocated into the cytoplasm of host cells and was thus proposed to be a 
T3SS effector protein (Konkel et al., 1999b). The presence of CiaB was also reported to 
be directly involved in the secretion of 18 other Cia proteins which were found to be 
secreted upon contact with host cells, calf serum or bile salts (Rivera-Amill and Konkel, 
1999, Malik-Kale et al., 2008). Mutants that lack a functional ciaB gene did not display 
any differences in binding to INT407 IECs but were significantly affected in invasion 
ability and also exhibited reduced chick colonisation levels (Konkel et al., 1999b, Ziprin 
et al., 2001). Currently, the characterised Cia proteins are designated CiaB, CiaC, CiaD, 
CiaI, FlaC and FspA (Konkel et al., 1999a, Song et al., 2004, Poly et al., 2007, 
Christensen et al., 2009, Buelow et al., 2011b, Samuelson et al., 2013). The most 
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widely studied is CiaB which has also been found to be secreted in the presence of 
mucus (Biswas et al., 2007). However, the secretion of these Cia proteins does not 
occur via a classical T3SS but reported to be released via the flagellum which in the 
case of C. jejuni produces a mechanistic action similar to that of a T3SS (Konkel et al., 
2004). 
in vitro studies with C. jejuni infection of IECs, showed an increase in the expression of 
the genes that are responsible for encoding the Cia proteins (Konkel and Cieplak, 1992, 
Konkel et al., 1993). Once inside the host cell, in particular the action of one Cia protein 
(CiaC) has been proposed to interact and interfere with host cell signalling proteins such 
as Rac-1, leading to changes in the host cell structure and allowing the entry of C. jejuni 
(Krause-Gruszczynska et al., 2007a, Eucker and Konkel, 2012a) although the exact role 
of CiaC in Rac-1 activation is not yet fully known (O. Croinin and Backert, 2012). 
These Cia proteins have been shown to play an important role in C. jejuni 
pathogenesis.(Konkel et al., 1999b, Rivera-Amill et al., 2001). The importance of CiaB 
was demonstrated using a piglet infection model, when inoculated with a C. jejuni wild-
type strain, gastrointestinal and histological disturbances were observed including 
diarrhoea within 24 h of infection, in contrast when the piglets were inoculated with a 
ciaB mutant, no symptoms were observed until 3-4 days post inoculation, where only 
mild histological changes and some diarrhoea was observed. The ciaB mutant strain 
therefore demonstrated an attenuation in virulence (Konkel et al., 2001, Raphael et al., 
2005).  
Mutations in flagellar subunit genes such as flgB, flgC and flgE2 that encode proteins 
that are involved in flagellar filament assembly resulted in the inability to secrete CiaB, 
indicating a possible function in flagellar assembly and export (Konkel et al., 2004). For 
the secretion of CiaB, either FlaA or FlaB are required and in vitro studies with INT407 
IECs found that invasion was dependent on the secretion of these Cia antigens (see 
Section 1.5.1) and motility (Konkel et al., 2004). in vitro studies found that FlaC was 
secreted via the flagellar apparatus and displayed maximal adherence in binding to Hep-
2 cells and flaC mutants were found to be significantly reduced in invasion of Hep-2 
cells indicating that FlaC plays an important role in cell invasion (Song et al., 2004). 
FspA was also found to be secreted via the flagellar and in vitro studies using INT407 
IECs resulted in cell death, further to this a high level of heterogeneity was observed in 
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the fspA alleles, suggesting a varying virulence potential mechanism in C. jejuni strains 
(Poly et al., 2007).  
More recently further Cia proteins have been found to be involved in C. jejuni 
virulence. CiaC was reported to be required for the interaction with and invasion of 
INT407 IECs by modulating host cell proteins and inducing cytoskeletal 
rearrangements of the IECs leading to internalised C. jejuni and studies by Konkel et al. 
found that CiaC was delivered into the host cell cytosol by the presence of bound 
bacteria (Christensen et al., 2009, Neal-McKinney and Konkel, 2012). CiaI was also 
found to be secreted through the flagella apparatus and was reported to play a role in C. 
jejuni intracellular survival (Buelow et al., 2011b). CCVs enable C. jejuni intracellular 
survival (Watson and Galan, 2008a). The CCV was found to deviate from the typical 
endocytic pathway as increased numbers of CCVs surrounding the cell nucleus were 
observed (Watson and Galan, 2008a, Buelow et al., 2011a). The mechanism of how the 
bacterium manipulates the vacuole to ensure survival and avoidance in delivery of the 
CCV to the lysosomes is not fully understood. However, the discovery of CiaI led to 
studies showing the importance of CiaI in the formation of the CCV, by avoidance of 
the delivery of the CCV to lysosomes and the in the intracellular survival of C. jejuni 
(Buelow et al., 2011a). Both CiaC and CiaI were found to modulate the host cell 
signalling activities and further studies found that the expression of CiaC and CiaI was 
directly related to virulence (Konkel et al., 2004, Christensen et al., 2009). In 2013, 
CiaD was identified, this Cia protein was also reported to be delivered into host cell 
cytosol, altering the behaviour of the host cell and was involved in both the maximal 
invasion of INT407 IECs and triggering the secretion of IL-8 from IECs (Samuelson et 
al., 2013). Studies by Samuelson et al. found that CiaD contained a possible 
nucleotidyltransferase domain and these domains have been found to also be present in 
other bacterial effector proteins and function by remodelling the host cell actin 
cytoskeleton via adenylation of RhoGTPase and inducing the release of IL-8, indicating 
that CiaD may also be involved in cell signalling events (Samuelson et al., 2013). The 
same group also reported a significant reduction in invasion of INT407 IECs with both 
ciaD and ciaC mutants in comparison to the wild-type strain, a similar observation was 
made in in vivo mouse infection studies with a ciaD mutant which resulted in no 
gastrointestinal disease. Infection with the wild-type strain resulted in overt 
gastrointestinal disturbances including enlarged lymph nodes and blood present in the 
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caecum and colon. The wild-type phenotype was restored with complementation, 
indicating a role for the CiaD protein in development of disease in the mouse model 
(Samuelson et al., 2013, Itzen et al., 2011). CiaB and other secreted Cia proteins 
(CiaA–H) have been reported to require a functional flagellar export apparatus for their 
secretion (Konkel, Klena et al. 2004).  
However C. jejuni does not possess a classical T3SS and evidence for the injection of 
bacterial virulence proteins into the host cell is not totally convincing as Novik et al. 
found that CiaB did not play a role in IEC invasion (Novik, Hofreuter et al. 2010). 
Therefore the role of flagellar in secretion of C. jejuni virulence proteins during IEC 
invasion is still controversial.  
1.5.5 Role of CadF  
In order for a microorganism to cause infection, for persistence and dissemination in the 
host and to avoid removal by the fluids that bathe the cells, attachment to host cells is 
vital (Boland et al., 2000). Bacteria have evolved to possess an array of adhesion 
proteins (Wilson, 2002). Fibronectin is a large essential glycoprotein found in the 
extracellular matrix (ECM), body fluids and on the surface of eukaryotic cells, 
consisting of two 250 kDa monomers (Hynes 1973, Hynes 2004). Fibronectin is an 
essential component of the extracellular matrix (ECM), regulating cellular processes 
and acting as a scaffolding protein by maintaining tissue organisation (Ali et al., 1977, 
Hynes, 1990, Midwood et al., 2006). Fibronectin is a large dimeric glycoprotein and is 
composed of 12 Fibronectin type I repeats, two Fibronectin type II repeats and 15–17 
fibronectin type III repeats (Xu et al., 2009). Binding of pathogens to fibronectin has 
been reported to trigger the formation of integrin clusters and recruitment of host cell 
effector molecules (Talay et al., 2000, Schwarz-Linek et al., 2004, Marjenberg et al., 
2011). The focal complexes formed from the assembly of multiproteins act as a 
signalling platform and enables the linkage of fibronectin in the ECM to the 
cytoskeleton and the cell’s signalling machinery, this cell signalling via the focal 
complexes enables cytoskeletal and membrane rearrangements by fibronectin and these 
cytoskeletal movements are involved in mitosis, motility and phagocytosis (Pankov and 
Yamada, 2002, Mao and Schwarzbauer, 2005, Broussard et al., 2008, Sandig et al., 
2009). Proteins that are present at these focal complex sites include cytoskeletal 
elements such as α-actinin, vinculin, talin, scaffolding proteins such as paxillin and 
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signalling molecules such as focal adhesion kinase (FAK). These focal complexes serve 
several important functions by not only linking integrins to the cytoskeleton but with 
roles in the transmission of signalling inside the cell (Zamir and Geiger, 2001).  
The presence of fibronectin not only plays a major role as a bacterial adhesion target 
enabling bacterial attachment but also in the stimulation of host cell pathways leading to 
signalling events that promote internalisation of the pathogen (Sandig et al., 2009, 
Henderson et al., 2011, Marjenberg et al., 2011). For this purpose the presence of 
fibronectin allows attachment of the bacteria to the host cell surface. Fibronectin is an 
important target in initial bacterial attachment (Pankov and Yamada 2002). Fibronectin 
is also a common target for many pathogens such as Mycobacterium avium, E. coli, 
Streptococcus pyogenes and S. aureus (Kuusela, 1978, Myhre and Kuusela, 1983, 
Ryden et al., 1983, Froman et al., 1984, Visai et al., 1991, Schorey et al., 1996, Jaffe et 
al., 1996). Bacterial proteins that bind to components of the ECM have been termed 
microbial surface components recognising adhesive matrix molecules (MSCRAMMs) 
(Schwarz-Linek, Hook et al. 2006). Over a hundred bacterial fibronectin binding 
proteins have been identified (Henderson, Nair et al. 2011). Despite the lack of a 
complete understanding of C. jejuni virulence, several proteins are known to contribute 
to adherence to eukaryotic cells and binding of C. jejuni to specific ligands on the host 
cell surface is suggested to play a pivotal role in colonisation of the host, thereby 
avoiding the removal of the organism from the intestines by the normal function of 
peristalsis and cell washing (Fauchere, Rosenau et al. 1986).  
One of the most widely studied C. jejuni adhesins is a 37 kDa major outer membrane 
protein (MOMP) termed CadF (Campylobacter adhesion to Fibronectin), the action of 
this protein was confirmed by binding of recombinant CadF to fibronectin (Kuusela et 
al., 1989, Konkel et al., 1997, Moser et al., 1997). Due to the localisation of fibronectin 
on the basolateral side of confluent IEC monolayers (Kowalczyk et al., 1990), previous 
studies have found that C. jejuni invasion occurs preferentially at the basolateral layer 
(Konkel, Garvis et al. 1997). CadF is conserved among C. jejuni strains (Konkel, Gray 
et al. 1999) and mutations in cadF prevent binding to fibronectin and a reduction in the 
level of invasion of IECs (Krause-Gruszczynska, van Alphen et al. 2007). C. jejuni 
cadF mutants were also found to exhibit reduced adhesion to INT407 IECs compared to 
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the wild-type strain (Monteville, Yoon et al. 2003) and reduced colonisation in chick 
IECs (Ziprin et al., 1999, Monteville et al., 2003b).  
Further studies by Konkel’s group identified the surface exposed amino acid binding 
sites of CadF and specific mutations in the respective amino acid residues led to a 
significant reduction in C. jejuni binding to INT407 IECs (Monteville et al., 2003b). 
Gruszczynska et al. reported that C. coli possessed an extra 39 bp insertion in cadF, 
thereby increasing the size of CadF in C. coli, in vitro studies with these strains resulted 
in significantly reduced interaction and invasion of INT407 IECs (Krause-Gruszczynska 
et al., 2007b), suggesting the importance of the presence of a conserved gene. Recent 
studies report that C. jejuni binds to fibronectin, triggering β-1 integrin and focal 
adhesion kinase (FAK) complexes, leading to phosphorylation of epidermal growth 
factor receptor (EGFR) / platelet derived growth factor receptor (PDGFR). Followed by 
Vav2 activation (guanine nucleotide exchange factor), Vav proteins then activate the 
Rho family GTPases. These GTPases control the organisation of the host cell 
cytoskeleton and cause PI3-K stimulation, finally leading to activation of cell division 
control protein (Cdc42). Cdc42 is involved in regulation of the cell cycle and leads to 
manipulation and rearrangements of actin or microtubules allowing the eventual entry 
of C. jejuni (see Figure 1.11) (Krause-Gruszczynska et al., 2007a, Krause-Gruszczynska 
et al., 2011, Eucker and Konkel, 2012b). However, other studies have reported that the 
fibronectin and integrin β1 receptors are positioned basolaterally and it is unclear as to 
how C. jejuni is able to access these receptors (O. Croinin and Backert, 2012, Backert et 
al., 2013) 
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Figure 1.11 Activation of the host cell signalling pathway by CadF leading to C. jejuni 
invasion Hypothetical model for CadF-induced signalling and activation of Cdc42 leading to 
bacterial invasion. C. jejuni adheres to host cells via the fibronectin-binding protein CadF by 
engaging the integrin-β1 receptor. Integrin occupancy and clustering in lipid rafts leads to 
activation of FAK. Phosphorylation of FAK and Src triggers a cascade of signalling leading to 
the formation of protein complexes which activate other signalling factors. Assembly of 
integrin- complexes leads to phosphorylation of PDGFR and EGFR, followed by activation of 
PI3-K and Vav2. Vav2 then induces the activation of Cdc42. This signalling leads to actin and 
microtubule rearrangements at the site of C. jejuni entry, resulting in C. jejuni uptake. 
1.5.6 Role of FlpA  
In addition to CadF, C. jejuni possesses a lipoprotein that also harbours fibronectin 
binding amino-acid domains termed fibronectin-like protein A (FlpA) and flpA is 
conserved in C. jejuni strains, indicating a possible role in pathogenesis (Larson et al., 
2013). Initially, FlpA was found to play a significant role in the colonisation of 
chickens, as mutation of flpA completely prevented the colonisation of chicks 
(Flanagan, Neal-McKinney et al. 2009). Further studies by Konkel’s group reported 
FlpA to exhibit binding to fibronectin and a C. jejuni flpA mutant also displayed a 
reduction in interaction to INT407 IECs (Konkel, Larson et al. 2010). Recent studies 
have suggested that CadF and FlpA may act co-operatively to target fibronectin and 
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allow binding of C. jejuni and invasion of IECs by triggering integrin receptors α5 and 
β1. Leading to the activation of host cellular proteins and the epidermal growth factor 
(EGF). In addition, inhibition of EGF receptor resulted in a significant drop in invading 
C. jejuni and the importance of integrin mediated cell adhesion and triggering of the 
EGF receptor has been confirmed previously (Moro et al., 2002). Konkel’s group also 
reported that for efficient C. jejuni host cell invasion, PI3-Kinase, tyrosine kinase 
protein (c-Src) (involved in cell growth) and FAK are required. As inhibition of these 
host cell proteins led to a significant reduction in C. jejuni invasion, indicating a role for 
these proteins in cytoskeletal rearrangements (Eucker and Konkel, 2012b).  
A subsequent study showed that invasion of IECs with C. jejuni cadF or flpA mutants 
was significantly reduced and a cadF flpA double mutant did not activate the EGF 
receptor and RhoGTPases (Larson et al., 2013). Further to this, the role of another host 
cell signalling molecule which is located downstream of EGF, the extracellular signal-
regulated kinase (ERK) was investigated. ERKs are involved in the regulation of a 
number of cellular processes including differentiation, proliferation and survival 
(Deschenes-Simard et al., 2014). INT407 IECs infected with a C. jejuni flpA mutant 
produced reduced levels of ERK phosphorylation whereas infection with a C. jejuni 
capA mutant (Campylobacter adhesion protein) actually produced an increase in the 
levels of ERK phosphorylation. This indicated that ERK was activated by FlpA-
mediated binding to the IEC and that FlpA triggers downstream signalling events from 
the outside of the host cell (Larson et al., 2013).  
In addition, infection of INT407 IECs with a flpA mutant resulted in both reduced cell 
membrane ruffling and activation of Rac1, suggesting that the loss of FlpA disrupted 
activation of host cell signalling pathways (Krause-Gruszczynska et al., 2011, Larson et 
al., 2013). In vivo studies performed by Larson et al. also investigated the role of FlpA 
in disease development using an IL-10 negative mouse model. Mice infected with a C. 
jejuni wild-type strain and a flpA complement resulted in the presence of overt disease 
and mice showed signs of oedema and softening of stools in comparison to no disease 
observed with infection of mice with a flpA mutant. In addition, lower numbers of 
bacteria were found in the spleen of mice infected with a flpA mutant in comparison to 
those infected with C. jejuni wild-type and a flpA complement, further demonstrating 
the importance of this adhesin in disease development (Larson et al., 2013).  
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Another pathway that may be utilised by C. jejuni is the activation of paxillin, a focal 
adhesion signalling molecule and component of the focal complex which produced an 
increase in tyrosine phosphorylation in response to C. jejuni infection (Monteville et al., 
2003b). The hypothetical pathway utilising paxillin involves a signalling cascade of; 
CadF/FlpA binding to fibronectin which activates integrin-β1 receptor and stimulates 
focal adhesion kinase, this in turn activates paxillin (Monteville et al., 2003a). 
Phosphorylation of paxillin occurred at the same time as intracellular bacterial numbers 
increased, indicating the importance of fibronectin binding by C. jejuni for mediating 
host cell internalisation (Monteville et al., 2003b, Eucker and Konkel, 2012b). Further 
studies with a C. jejuni flpA mutant indicated that signalling from the outside of the host 
cell is triggered by binding of FlpA to fibronectin through integrin β1 receptors (Larson 
et al., 2013). This could be providing a platform for C. jejuni invasion of IECs by 
activation of ERK signalling which ultimately leads to actin rearrangements and uptake 
of C. jejuni (Larson et al., 2013). The exact mechanism and role of ERK activation by 
FlpA in Campylobacter pathogenesis requires further investigation. 
1.5.7 Intracellular survival of C. jejuni  
A number of microbial pathogens are capable of intracellular survival and replication 
within the harsh and constantly changing internal environment of mammalian cells 
(Mekalanos, 1992). Following phagocytosis by macrophages, bacteria are contained 
within a membrane bound vacuole and the trafficking of the vacuole containing the 
bacteria normally fuses with the lysosomes where it is rapidly destroyed due to the 
presence of reactive oxygen species released by the macrophages, however the survival, 
replication and escape of the pathogen varies greatly for those pathogens with 
intracellular adaptations (Hassett and Cohen, 1989, Garcia-del Portillo and Finlay, 
1995, Mosser and Edwards, 2008). Some pathogens such as Shigella flexneri (Cossart 
and Sansonetti, 2004, Ogawa and Sasakawa, 2006), Trypanasoma cruzi (Brener, 1973), 
Listeria monocytogenes (Goebel and Kuhn, 2000) are able to break out of the 
phagocytic vacuole and replicate inside the infected cell. A pathogen with specific 
adaptations is Leishmania species, which is also able to survive in the very hostile, low 
oxygen, low (Alexander et al., 1999). Another highly studied intracellular pathogen is 
Salmonella typhimurium, an organism which is also capable of surviving within a 
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vesicular compartment and avoiding delivery to lysosomes (Knodler and Steele-
Mortimer, 2003).  
Previous studies by Watson and Galan found that C. jejuni co-localises in a 
compartment within the host cytoplasm which is distinctly separate from the lysosomes 
and termed the CCV. The CCV has been reported to interact transiently with early 
endosomal marker proteins and RhoGTPase members Rab4 and Rab5, however the 
CCV did not progress via the normal endocytic pathway as CCVs were rarely observed 
associating with the lysosomal marker Cathepsin B and clustering of CCVs occurred 
around the nucleus (Konkel et al., 1992b, Watson and Galan, 2008b). However, the 
exact mechanism of the formation of the CCV and how C. jejuni manipulates the 
internal environment of the CCV enabling deviation from the endocytic pathway is still 
unclear as the genes involved in C. jejuni intracellular survival and trafficking are 
unknown. A C. jejuni ciaI mutant is significantly reduced in intracellular survival 
ability within INT407 IECs compared to the wild-type strain (Buelow et al., 2011a). 
Also, when INT407 IECs were infected with a ciaI mutant, the CCVs were found to 
more readily localise with the endosomal marker Cathepsin D (which is a endoprotease 
and is involved in proteolysis) in comparison to the CCVs in INT407 IECs infected 
with the wild-type strain, suggesting that the secretion of CiaI may in some way be 
involved in modifying the internal environment of the CCV (Boya et al., 2003, Buelow 
et al., 2011b, Bewley et al., 2011). Novik et al. investigated a number of C. jejuni genes 
that were potentially required for intracellular survival and identified three genes aspA 
which encodes aspartate ammonia-lyase, aspB which encodes aspartate 
aminotransferase, these enzymes produce fumarate which acts both as a carbon source 
and electron acceptor in anaerobic respiration and sodB which encodes (superoxide 
dismutase) which is an important virulence factor in C. jejuni and C. coli (Pesci et al., 
1994, Purdy et al., 1999). SodB detoxifies reactive oxygen intermediaries generated 
during oxidative stress by catalysing the conversion of superoxide (O2−) to less harmful 
substances, oxygen and hydrogen peroxide (H2O2) (Hassan, 1989, Miller and Britigan, 
1997). Mutations in the above genes produced a significant reduction in intracellular 
survival in T84 IECs as well as reduction in colonisation levels in the mouse model but 
the results observed could not be solely attributed to the mutation as the phenotype of 
aspA and aspB mutants was reversed when the bacteria was supplied with fumarate 
(Novik et al., 2010). Further studies on aspA, aspB and sodB mutants found that the 
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reduction in the amount of bacteria recovered was not due solely to the respective 
mutation but due to a combination of defects in both adhesion and intracellular survival 
(Novik et al., 2010). Further studies are still required to dissect the molecular basis of C. 
jejuni intracellular survival. 
1.5.8 Imaging of C. jejuni adhesion to and invasion of Caco-2 intestinal epithelial 
cells  
In order to study the interactions of bacteria within the host cell, cell staining procedures 
have allowed investigators to study host-pathogen interactions using fluorescence 
microscopy, confocal microscopy, flow cytometry and flourochrome labelling (Falk et 
al., 1994). Laser and confocal fluorescence microscopy are powerful tools to observe 
and study molecular events occurring in cells (Takata et al., 1997). The advantage of 
fluorescence microscopy is the detailed study of molecules in cells and tissues by 
multiple fluorescent staining and allows researchers to visualise the location of 
particular molecules of interest in the cell. Cellular structures such as the cell 
cytoskeleton, plasma membrane and nucleus can be observed with various 
fluorochromes that bind to these structures (Suzuki et al., 2007). Staining particular 
cellular structures such as actin with Phalloidin, a toxic compound produced by the 
deathcap mushroom Amanita phalloides, specifically binds to F-actin in the cell (Suzuki 
et al., 2007). Following labelling with the appropriate fluorochrome, the cellular 
structures of interest can be visualised by fluorescence microscopy.  
Fluorescent labelling of cellular structures can provide high levels of sensitivity that are 
useful for a wide range of analytical applications. Conjugating antibodies with 
fluorescent labels is usually achieved by in vitro chemical conjugation of specific 
organic fluorophores (Hermanson, 1996). This requires large amounts of purified 
protein and leads to issues in optimisation of the level of conjugation and loss of 
activity. These techniques have proved to be time consuming and sometimes inefficient 
(Casey et al., 2000). The Green fluorescent protein (GFP) which was originally isolated 
from the jellyfish Aequorea victoria, has been genetically conjugated to numerous 
proteins in a number of different species to produce stable chimeras capable of retaining 
both biological activity and fluorescent properties of the native GFP for visualising in 
vivo host-pathogen interactions. These GFPs are particular useful in the study of 
bacteria within a host cell, using microscopy (Chalfie et al., 1994, Stearns, 1995, 
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Valdivia and Falkow, 1997, Yrlid et al., 2001, Mixter et al., 2003). As a result, GFP is 
now widely used as a reporter for gene expression and as a fusion tag to monitor protein 
localisation within living cells (Misteli and Spector, 1997). GFP displays high levels of 
stability making GFP an important tool in in vitro studies. Previously, bacterial 
pathogens have been studied indirectly using fluorescent antibodies (Valdivia et al., 
1996). The problems encountered with fluorescent antibodies arise from the coupling 
reaction as there is a limit to the amount of fluorescence molecules that can be 
conjugated to an antibody. This has been reported to result in a population of antibodies 
where the number of fluorescence molecules per antibody is variable and so the 
fluorescence detected may result in large variations (The and Feltkamp, 1970). Multiple 
fluorophores being used in the same procedure can actually lead to a decrease in 
fluorescence via quenching mechanisms (Gruber et al., 2000). 
Optimisation studies performed previously have identified problems in under and over 
antibody labelling, leading to decreases in fluorescence due to either a lack of 
fluorphores or too many fluorophores. This has resulted in non-specific staining and 
loss of antibody-antigen specificity (Holmes and Lantz, 2001). In order to study the 
interactions of bacteria inside the host cell, fluorescent antibodies do not always provide 
efficient results due to time consuming procedures, bleaching and dilution of the 
fluorescence signal over time (Ellenberg, 1997). Whilst more recently, the utilisation of 
fluorescent marker proteins has enabled the visualisation of host-pathogen interaction 
on a whole new level. The increased use of techniques involving fluorescent protein 
(FP) labelling and computer-controlled systems for fluorescence and laser-confocal 
microscopes has enabled direct visualisation of the intricate structure of living cells 
(Miyawaki, 2003). Conventional fluorescent staining involves immunostaining using 
the fluorochrome-labelled specific antibodies and chemical staining that specifically 
react with the target molecules in the cell with fluorochrome-labelled chemical reagents 
(Suzuki et al., 2007). Fluorescent labelling of molecules by genetic engineering do not 
require the time-consuming staining procedures necessary for microscopy, allowing the 
easy observation of molecules of interest in living cells.  
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1.6 Aims and Objectives 
Given the uncertainty of the mechanisms of C. jejuni pathogenesis and the development 
of new methods such the VDC, the aim of my thesis was to reinvestigate the 
mechanisms of C. jejuni adhesion to, invasion of and survival within human intestinal 
epithelial cells (IECs). 
The specific objectives were:- 
1. Reinvestigation of C. jejuni invasion of intestinal epithelial cells by studying the 
effects of inhibition of microfilaments, microtubules, caveolae-mediated 
endocytosis, clathrin-mediated endocytosis and host protein tyrosine 
phosphorylation. 
2. Reinvestigation of the role of CiaB in C. jejuni invasion of intestinal epithelial 
cells.  
3. Reinvestigation of the roles of CadF and FlpA in C. jejuni adhesion to and 
invasion of intestinal epithelial cells. 
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Chapter 2: Materials and Methods  
2.1 Bacterial strains and plasmids  
In this study, two C. jejuni wild-type strains were used to investigate bacterial 
interactions with IECs. The 11168H wild-type strain is a hypermotile variant of 
NCTC11168 and readily colonises the GI tract of chicks and as such is considered a 
better strain to use to investigate host-pathogen interactions. (Parkhill et al., 2000, 
Karlyshev et al., 2002, Jones et al., 2004). The 81-176 wild-type strain was isolated 
from a milk-borne outbreak in the USA and is probably the most widely studied 
laboratory strain. 81-176 harbours a putative virulence plasmid (pVir), which encodes a 
potential T4SS which has been reported to be involved in C. jejuni invasion of IECs 
(Korlath et al., 1985b, Black et al., 1988, Bacon et al., 2000). All C. jejuni strains and 
mutants used in this study are listed in Table 2.1. All E. coli strains used in cloning 
studies are listed in Table 2.2 and all the plasmids used are listed in Table 2.3. 
2.1.1 Chemicals and reagents 
Chemicals used in this study were purchased from Invitrogen/Gibco (Paisley, UK), 
Sigma-Aldrich (Poole, UK), Fisher Scientific (Loughborough, UK) or 
VWR/BDH/Merck (Poole, UK), unless stated otherwise. 
2.1.1.1 Sterilisation 
All reagents, media and solutions were sterilised by autoclaving at 121°C for 20 
minutes in a wet autoclave (LTE Scientific, Oldham, UK) or dry steam sterilisation was 
performed at 134°C for 15 minutes in an AAJ autoclave (Astell Scientific, Sidcup, UK). 
Filter sterilisation was performed using a 10 ml syringe (BD Plastipak, Oxford, UK) and 
a 0.2 µm (32 mm) Acrodisc® syringe filter with Stupor® membrane (Pall Life Sciences, 
Portsmouth, UK).  
2.1.1.2 Reagent preparation 
Unless otherwise stated, all reagents, solutions and media were prepared using either 
Ultra-pure Milli-Q water or Ultra-pure Milli-RO water (Millipore, Billerica, USA).  
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Table 2.1 C. jejuni strains used in this study 
  
 
C. jejuni strains 
/mutants 
Description 
 
References 
 
81-176  A strain isolated from a multi-state milk 
borne outbreak in the USA. Wild-type 
laboratory passaged strain. 
(Blaser et al., 
1979, Korlath 
et al., 1985b) 
11168H  Hypermotile derivative of original 
sequenced strain NCTC11168, which 
produces higher levels of colonisation in 
chick model 
(Karlyshev et 
al., 2002, Jones 
et al., 2004) 
81-176+bs1 C. jejuni strain expressing Evoglow® 
fluorescent protein 
This study 
11168H+pp1 C. jejuni strain expressing Evoglow® 
fluorescent protein 
This study 
81-176+eGFP C. jejuni expressing enhanced green 
fluorescent protein 
This study  
11168H+eGFP C. jejuni expressing enhanced green 
fluorescent protein 
This study  
81-176 
ciaB mutant 
Isogenic mutant, Cj0194 81-176 
(ciaB) gene function disrupted with 
insertion of 1.4 kb Km r cassette. 
This study 
11168H 
ciaB mutant 
Isogenic mutant, Cj0921 11168H 
(ciaB) gene function disrupted with 
insertion of 1.4 kb Km r cassette. 
This study 
81-176 
ciaB complement 
Complemented mutant containing Cj0194 
81-176 gene and chlr inserted into one of 
three ribosomal genes pRRC vector 
This study 
11168H 
ciaB complement 
Complemented mutant containing Cj0921 
11168H gene and chlr inserted into one of 
three ribosomal genes in pRRC vector 
This study 
81-176 
cadF mutant 
Isogenic mutant, Cjj1471 81-176 (cadF) 
gene function disrupted with insertion of 
1.4kb Km r cassette. 
This study 
11168H  
cadF mutant 
Isogenic mutant, Cj1478 11168H (cadF) 
gene function disrupted with insertion of 
1.4kb Km r cassette. 
This study 
81-176 
flpA mutant 
Isogenic mutant, Cjj1295 81-176 
(flpA) gene function disrupted with insertion 
of 1.4 kb Km r cassette. 
This study 
11168H  
flpA mutant 
Isogenic mutant, Cj1279c 11168H 
(flpA) gene function disrupted with insertion 
of 1.4 kb Km r cassette. 
This study 
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  Table 2.2 E. coli strains used in this study 
 
E. coli strains 
 
 
Description 
 
 
References 
 
 
DH5α 
competent cells 
 
 
F-,φ80deoR lacZ∆M15 endA1 
recA1 hsdR17(rK-mk+) supE44 
thi-1 gyrA96 relAl ∆(lacZYA-
argF) U169 
 
 
Invitrogen, Paisley 
UK 
 
 
XL2- BLUE MRF  
high efficiency 
competent cells 
 
endA1 gyrA96(nalR) thi-1 
recA1 relA1 lac glnV44 F’[:: 
Tn10 proAB+ lacIq 
∆(lacZ)M15 Amy CmR] 
hsdR17(Rk-mK+) 
 
 
Stratagene, Agilent 
Technologies, Santa 
Clara, CA, USA 
 
SCS110 competent cells rpsL(Strr) thr leu endA thi-1 
lacY galK galT ara tonA tsx 
dam dcm supE44 Δ 
(lac-proAB) [FtraD36 proAB 
lacIq ZΔM15] 
 
Stratagene, Agilent 
Technologies, Santa 
Clara, CA, USA 
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Table 2.3 Plasmids used in this study 
 
 
 
 
Plasmid 
 
 
Information 
 
 
References 
 
 
pGEMT®-T easy 
 
Commercial TA cloning vector with ampicillin 
resistance cassette 
Promega 
 
 
pGEMT+Cj1478 
11168H 
pGEMT-easy vector with inserted 0.96 kb 
11168H cadF gene disrupted by insertion of Kmr 
cassette 
This study 
pGEMT+Cjj1471 
81-176 
pGEMT-easy vector with inserted 0.96 kb 81-176 
cadF gene disrupted by insertion of Kmr cassette 
This study  
pGEMT+Cj1279c 
11168H 
pGEMT-easy vector with inserted 1.2 kb 11168H 
flpA gene disrupted by insertion Kmr cassette 
This study 
pGEMT+Cjj1275 
81-176 
pGEMT-easy vector with inserted 1.2 kb 81-176 
flpA gene disrupted by insertion Kmr cassette 
This study 
pGEMT+Cj0921 
11168H 
pGEMT-easy vector with inserted 1.86 kb 
11168H ciaB gene disrupted by insertion of Kmr 
cassette 
This study 
pGEMT+Cjj0194 
81-176 
pGEMT-easy vector with inserted 1.86 kb 81-176 
ciaB gene disrupted by insertion of Kmr cassette 
This study 
pRRC  C. jejuni complementation vector pRRC for 
studies 
(Karlyshev 
and Wren, 
2005) 
eGFP E. coli expressing enhanced green fluorescent 
protein (Received from Dr Dominic Mills, 
LSHTM) 
(Karlyshev 
and Wren, 
2005) 
pGLOW-bs1/pp1 pGLOW plasmid containing genes encoding a 
fluorescent reporter protein (Evocatel, 
Dusseldorf) 
Evoglow® 
pRRC+bs1  
 
pRRC vector containing Evoglow® bs1 gene 
encoding a fluorescent reporter protein  
This study 
pRRC+pp1 
 
pRRC vector containing Evoglow® pp1 gene 
encoding a fluorescent reporter protein 
This study 
pJMK30 Plasmid containing a gene encoding for 
Kanamycin resistance (aphA3) (1.4 kb) 
(Trieu-Cuot 
et al., 1985) 
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2.1.2 Microbiological procedures 
2.1.2.1 Bacterial strains, media and growth conditions 
C. jejuni strains were routinely cultured on blood agar (BA) plates containing Columbia 
agar (Oxoid, Basingstoke, UK) supplemented with Campylobacter selective supplement 
(Oxoid) and 7% (v/v) horse blood (TCS Biosciences, Botolph Claydon,UK). C. jejuni 
strains were incubated in a Variable Atmosphere INcubator (VAIN) (Don Whitley 
Scientific, Sheffield, UK) filled with a mixture of 85% N2, 10% CO2 and 5% O2 at 
37°C. C. jejuni mutants and complements were grown on BA plates supplemented with 
kanamycin (50 µg/ml) or chloramphenicol (10 µg/ml) as required. All antibiotics were 
obtained from Sigma-Aldrich. Strains were routinely sub-cultured every 3-4 days up to 
a maximum of 10 passages. C. jejuni cultures were grown in pre-equilibrated Brucella 
broth (Oxoid) in 25 cm2 tissue culture flasks (Corning NY, USA) with shaking at 75 
revolutions per minute (rpm) on a SSM-1 platform orbital shaker (Stuart/Bibby 
Scientific, Stone, UK) in the VAIN. 
2.1.2.2 Culturing conditions for E. coli 
E. coli strains were routinely grown on Luria Bertani (LB) agar plates (Oxoid) and 
incubated at 37°C under aerobic conditions in a MIR-262 incubator (Sanyo, 
Loughborough, UK). E. coli cultures were grown in LB broth (Oxoid) at 37°C in a 
shaking incubator (Gallenkamp/Sanyo, Loughborough, UK) at 150 rpm. When required, 
antibiotics were added in the following concentrations; ampicillin (100 µg/ml), 
kanamycin (50 µg/ml) or chloramphenicol (50 µg/ml).  
2.1.3 Examination of C. jejuni morphology 
2.1.3.1 Gram staining 
A single colony was taken from a 24 hour BA plate and resuspended in filter sterilised 
Milli-Q water. A drop of this suspension was placed onto a microscope slide (Fisher 
Scientific) and the slide briefly passed through a flame to heat fix. The slide was then 
flooded with 2 ml of crystal violet stain (0.02% w/v) for 1 minute, then 2 ml of Iodine 
solution (0.01% w/v) for 3 minutes, followed by decolourisation with alcohol for 20 
seconds. The slide was then counterstained with 2 ml of safranin (0.025% w/v) for 2 
minutes. Slides were examined using a Nikon Eclipse E600 microscope (Fisher 
Scientific). 
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2.1.4 Preparation of specific OD600 suspension of C. jejuni 
C. jejuni were grown on a BA plate for 24 h, bacteria were collected using a sterile 10 
µl loop and re-suspended in 1 ml Brucella broth. The suspension was mixed either by 
pipetting or vortexing. The optical density at a wavelength of 600 nm (OD600) was 
determined by diluting the bacterial suspension 1:10 with 900 µl of Brucella broth in a 
cuvette (10 mm path length, Kartell, Noviglio, Italy). 1 ml of Brucella broth was used as 
a blank. The OD600 was recorded using a spectrophotometer (WPA Lightware®, 
Cambridge, UK).  
The OD600 inoculum required was modified depending on the experiment. The inoculum 
required to produce an OD600 0.1 was calculated as follows; Volume required = 
Inoculum required at OD600 0.1  x Final volume x 1000  
   (10x OD600 reading)   
 
2.1.5 Glycerol stock preparation of C. jeuni and E. coli strains 
For preparation of glycerol stocks for C. jejuni, 900 µl of a log phase culture in Brucella 
broth supplemented with 10% (v/v) foetal calf serum (FCS) (Sigma-Aldrich) was mixed 
with 100 µl sterile glycerol (Sigma-Aldrich). 100 µl aliquots were transferred into 0.6 
ml microcentrifuge tubes (Eppendorf, Histon, UK) and snap-frozen by immersion into 
an ethanol and dry ice filled container for 5 minutes. Frozen stocks were then stored in a 
-80°C freezer (New Brunswick Scientific, St Albans, UK). Frozen stocks of E. coli were 
prepared by mixing 800 µl of a 16 hour broth culture with 150 µl of sterile glycerol in a 
Nunc Cryovial (Fisher Scientific) and transferred directly into a -80°C freezer.  
2.1.6 Preparation of electrocompetent C. jejuni cells 
C. jejuni electrocompetent cells were prepared as described previously (Karlyshev and 
Wren, 2005). Briefly, C. jejuni was grown on a BA plate for 24 h, bacteria harvested 
with a sterile loop and resuspended in 10 ml of ice-cold sterile EBF buffer (272 mM 
sucrose, 15% (v/v) glycerol) (see Appendix). The suspension was centrifuged at 4,000 
rpm for 15 min at 4°C and the supernatant discarded. The pellet was resuspended in 1 
ml of ice-cold EBF wash buffer and transferred to a sterile 1.6 ml eppendorf. The 
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suspension was centrifuged at 13,000 rpm for 5 minutes at 4°C. The supernatant was 
removed and the pellet resuspended in another 1 ml of ice-cold EBF buffer, mixed by 
gently pipetting and the process repeated a further two times. After the final spin, the 
supernatant was discarded and the pellet was resuspended in 1 ml ice-cold EBF buffer. 
Aliquots of 100 µl were transferred into pre-labelled 0.6 ml eppendorf tubes and stored 
at -80°C until required. 
2.1.7 Resuscitation of C. jeuni and E. coli frozen stocks. 
C. jejuni frozen stocks were removed from the -80°C freezer and placed on ice and 
allowed to thaw. Once thawed, 100 µl was restreaked onto a BA plate and incubated for 
48 h. Individual colonies were picked and sub-cultured onto a fresh BA plate. E. coli 
strains were resuscitated from glycerol stocks by plating onto LB agar plates and 
incubated at 37°C overnight. LB plates streaked with E. coli were parafilm sealed 
(Neenah, WI, USA) and maintained at 4°C for three weeks.  
2.1.8 Motility assays 
Motility assays were performed as described previously (Malik-Kale et al., 2007). 
Briefly, a 24 h culture of C. jejuni was adjusted to OD600 1.0. 5 µl of this suspension 
was pipetted into the centre of a motility agar plate consisting of Brucella broth 
supplemented with 0.4% (w/v) bacteriological agar (Oxoid). Plates were incubated 
(without inverting) at 37°C under microaerobic conditions. Plates were checked at 
intervals of 24, 48 and 72 h and images were recorded on a gel doc system (GeneGenius 
Gel imager (UVP), Cambridge, UK). Motility was recorded by measuring the diameter 
of the halo around the centre of the plate. 
2.1.9 C. jejuni in vitro growth kinetics assay 
10 ml of Brucella broth was transferred into a 25 cm3 tissue culture flask and pre-
incubated in the VAIN on a platform orbital shaker at 75 rpm for 18 h. A C. jejuni 
suspension was prepared and used to inoculate the 10 ml of pre-incubated Brucella 
broth to a starting OD600 of 0.1. The culture was then incubated in the VAIN with 
shaking at 75 rpm. Samples were taken every 2 h from time 0 h to 32 h and OD600 
readings were recorded as an indication of bacterial growth. 
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2.1.10 Quantifying bacterial numbers by counting colony forming units  
To quantify bacterial numbers in a culture at selected time points, 100 µl of culture was 
serially diluted 1:10 in Brucella broth up to a dilution factor of 10-7. 200 µl of each 
dilution was plated on BA plates in triplicate, spread out with L-shaped spreaders 
(VWR) and incubated for 3 days. Dilutions with counts between 100-300 cfus were 
selected for counting to calculate bacterial numbers in the initial culture.  
2.1.11 C. jejuni autoaggregation studies 
Autoaggregation (AAG) assays were performed as described previously (Howard et al., 
2009). C. jejuni was grown on a 24 h BA plate. Bacteria were harvested using a sterile 
cotton swab and resuspended in 10 mM PBS (pH 7.2) and the OD600 adjusted to 
approximately 2.0. The suspension was transferred into 13 x 100 mm diameter sterilised 
glass test tubes (Fisher Scientific) and incubated for 24 h at 37°C under microaerobic 
conditions. After the 24 h incubation period, the top 1.0 ml was gently aspirated and the 
OD600 reading recorded. The reduction in the OD600 reading from the initial reading of 
2.0 reflected the degree of autoagglutination. 
 
% AAG =             Pre-incubation value (OD600) – Sample value (OD600)     x 100 
Pre-incubation value (OD600) 
 
2.1.12 Galleria mellonella model of C. jejuni infection 
G. mellonella larvae were purchased from Livefoods UK Ltd (Rooks Bridge, Somerset, 
UK) and stored on wood chips at 16°C. Experiments were performed similar to the 
original published method (Champion et al., 2009). Briefly, for each experiment, 10 G. 
mellonella larvae of similar weight were selected. C. jejuni grown on BA plates for 24 h 
was harvested, resuspended in PBS and the OD600 adjusted to OD600 of 0.1. The larvae 
were infected with ~106 cfu in 10 µl inocula by micro-injection (Hamilton, Nevada, 
USA) into the right foremost leg. Controls of PBS only and no injection were also 
performed with each set of experiments. The larvae were incubated at 37°C and survival 
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was recorded at 24 h intervals for 72 h. Larvae were recorded as dead when the 
colouration changed from normal pale cream to dark brown and larvae were non-
responsive to touch.  
2.2 Mammalian cell culture 
2.2.1 Tissue culture 
The cell lines used in this study were human enterocyte-like Caco-2 IEC line 
(HTB37™), human T84 colonic IEC line (CCL-248™) IECs and the murine 
macrophage-like cell line (J774A.1), obtained from American type culture collection 
(ATCC) (LGC Standards, Teddington, England). Caco-2 IECs possess the ability to 
produce high trans-epithelial electrical resistance due to the formation of tight junctions 
(Pinto et al., 1983, Everest et al., 1992). Caco-2 IECs possess distinctive polarity due to 
the presence of apical microvilli and a basolaterally positioned nucleus (Hidalgo et al., 
1989). T84 IECs were derived from a lung metastasis of a colon carcinoma in a 72 year 
old male. These cells also express polarised characteristics such as tight junctions 
between cells (MacCallum et al., 2006). 
2.2.2 Maintenance and passaging of tissue culture cell lines 
The Caco-2 human IECs and J774A.1 mouse macrophage cell lines were maintained 
using the following media:-  
Dulbeccos Modified Eagles Medium (DMEM) (Sigma-Aldrich)      500 ml 
FCS 10% (v/v) heat-inactivated           50  ml 
Non-essential amino acids 1% (v/v) (Sigma-Aldrich)          5  ml 
Penicillin 100 Units/ml) and Streptomycin (100 µg/ml) (Sigma-Aldrich)        5  ml 
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The T84 IECs were maintained using the following media:- 
1:1 mixture of DMEM and Ham’s F12 medium and GlutaMAX™ 2.5 mM, L-
glutamine, 15 mM Hepes and 0.5 mM sodium Pyruvate (Gibco) ……………   500 ml 
FCS 10% (v/v) heat-inactivated………………………………………………     50 ml 
Penicillin (100 U/ml) Streptomycin (100 µg/ml) solution .............................         5 ml 
These two media will henceforth be referred to as cell culture media in this study. Both 
cell lines were incubated in the appropriate cell culture medium at 37°C and 5% CO2 
incubator (Sanyo, Loughborough, UK). Cell culture medium was replaced every 2 days. 
2.2.3 Passaging of tissue culture cells 
Caco-2 or T84 IECs were passaged every 5-7 days and J774A.1 cells were passaged 
every 2 days when the cells reached a confluency level of around 90%. Cell culture 
media was removed and discarded. Then the monolayer was gently washed three times 
with 10 ml of pre-warmed PBS and gently tilting the flask to ensure even coverage. The 
PBS was removed and discarded followed by the addition of 5 ml of 0.05% (w/v) 
Trypsin / 0.02% (w/v) EDTA in Hanks’ Balanced Salt Solution (Invitrogen). The flasks 
were placed back in the incubator for 10 minutes. Flasks were visually checked for 
detachment of cells. After the 10 minute incubation time, 8 ml of cell culture medium 
was added to the flasks to inhibit any further trypsin activity. The suspension was gently 
pipetted up and down to mix the cells. The suspension was transferred into a sterile 50 
ml Falcon tube and centrifuged at 1300 rpm for 10 minutes. The supernatant was 
decanted and the pellet gently resuspended in fresh cell culture medium at a ratio of 1:4.  
2.2.4 Enumerating the number of cells using a haemocytometer 
Calculating the number of cells required for interaction, invasion, intracellular survival 
and macrophage survival assays, was performed by taking 100 µl of the cell suspension 
and adding this to a 5 ml sterile bijoux, followed by the addition of 800 µl of cell culture 
medium and 100 µl of Trypan Blue dye (Sigma-Aldrich). The suspension was mixed by 
pipetting and 10 µl of this suspension was loaded onto the haemocytometer (Weber 
Scientific, Teddington, UK) and covered with a slide (VWR). The average number of 
cells present in the suspension was determined by counting the number of cells per 
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square using an inverted microscope (Leica Microsystems, Milton Keynes, UK) and 
applying the following formula:- 
Total number of viable cells/ml = N x dilution factor (1000) x dilution (10) 
(Where N is the mean number of cells counted in 5 large squares). 
Appropriate dilutions were performed to obtain the required concentration of cells for 
the relevant assay and 1 ml volumes were then seeded into 24 well plates (Corning) and 
incubated at 37°C in a CO2 incubator.  
2.2.5 Storage of tissue culture cells 
Cells were grown for 5-7 days until confluent, followed by washing and detaching as 
described above. Cells were pelleted and resuspended in DMEM without antibiotics but 
supplemented with 5% (v/v) Dimethy sulfoxide (DMSO) to act as a cryoprotectant. The 
suspension was aliquotted in 1 ml volumes into cryovials (Nunc) and allowed to cool 
slowly down to -80°C overnight using a Mr Frosty™ freezing box (Nunc). Cryovials 
containing IECs were placed in a liquid nitrogen storage tank (Statebourne, Washington 
Tyne & Wear, UK).  
2.2.6 Resuscitation of tissue culture cells from frozen stocks 
A cryovial of frozen cells was removed from liquid nitrogen storage and placed in a 
37˚C incubator. The vial was gently mixed to ensure quick and even thawing. Once the 
vial was thawed fully, the vial was wiped with 70% (v/v) ethanol before placing in the 
hood (Envair, Haslingden, U.K). The thawed cells from the vial were transferred to an 
Easy Flask® containing fresh pre-warmed culture medium and placed in the incubator. 
The cell medium was replaced with fresh cell medium 24 h later to prevent dead cells 
inhibiting the growth of the cells. 
2.2.7 Bacterial interaction assay 
1 x 105 Caco-2 IECs or 5 x 105 ml T84 IECs were seeded into each well of a 24 well 
tray. Cells were grown for 5-7 days until 80-90% confluency was reached. Once cells 
were confluent, the wells were washed three times with 1 ml of pre-warmed PBS. 
Interaction (adhesion and invasion) assays were performed using C. jejuni grown from a 
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24 h plate. Bacteria was collected with a sterile swab and resuspended in a 1.6 ml 
microcentrifuge tube containing 1 ml DMEM. The suspension was adjusted to an OD600 
of 0.1 (~1 x108 cfu/ml) in a final volume of 24 ml and 1 ml of this suspension was 
added to each well, equating to a multiplicity of infection (MOI) of approximately 100 
bacteria to one eukaryotic cell. The infected monolayers were incubated for 3 h, 6 h or 
24 h. After the desired incubation time, the supernatant was gently removed from the 
wells and the cells were washed three times with 1 ml of pre-warmed PBS, which 
removed the unadhered C. jejuni bacteria. The cells were then lysed in 1 ml of 0.2% 
(v/v) Triton X-100 (Sigma-Aldrich) in PBS at 37°C in a CO2 incubator for 20 minutes. 
This step allowed the enumeration of adhered and invaded bacteria. 100 µl of the lysed 
suspension was serially diluted 10-fold up to 10-4 and 200 µl of the final suspension was 
spread plated out in triplicate onto BA plates. Plates were incubated for 72 h in the 
VAIN and cfu numbers counted. 
2.2.8 Bacterial invasion assays 
To enumerate the number of intracellular C. jejuni bacteria within the IECs, invasion 
assays were performed as described above, however before lysing the IECs with Triton 
X-100, the extracellular bacteria were killed using gentamicin. 1 ml of fresh DMEM 
supplemented with 1% (v/v) FCS and 150 µg/ml of gentamicin was added to each well 
and incubated at 37°C in a CO2 incubator for 2 h. Monolayers were then washed three 
times with PBS and lysed as described previously. 
2.2.9 Triton and gentamicin sensitivity assays 
C. jejuni was grown on BA plates for 24 h at 37°C. Bacterial cells were harvested in 1 
ml PBS and adjusted to an OD600 of 0.1. Bacterial cells were exposed to 0.2% (v/v) 
Triton X-100 for 20 minutes or gentamicin (150 µg/ml) for 2 h. Sensitivity assays were 
performed on all the mutants and respective wild-type strains. Serial dilutions were 
prepared (10−1 to 10−7) and 200 µl of the final dilution was plated onto BA plates in 
triplicate, incubated for 48 h and then colonies counted. 
2.2.10 Immunofluorescence staining of Caco-2 IECs 
Caco-2 IECs were seeded (~ 1 x 105 cells) onto 17 mm cover slips in 24 well plates and 
grown to confluency. On the day of the experiment, cell culture media was removed and 
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the cells washed three times with PBS. The Caco-2 IECs were then fixed with 500 µl of 
4% (v/v) paraformaldehyde (PFA) (Sigma-Aldrich) for 15 min at room temperature. 
IECs were washed three times with PBS, followed by permeabilisation with 0.1% (v/v) 
Triton X-100 (Sigma-Aldrich) for 5 min at room temperature and then blocked with 1% 
(w/v) FCS in PBS for 1 h at room temperature. For actin staining, IECs were incubated 
with Alexa Fluor 555-conjugated phalloidin (Invitrogen) (stock diluted 1:1,000 in PBS) 
for 1 h in the dark, coverslips were washed and mounted in Vectashield mounting 
medium containing 4′6-diamidino-2-phenylindole (DAPI; final concentration 1.5 µg/ml) 
(Vector Laboratories, Peterborough, United Kingdom) on a coverslip (Fisher Scientific) 
and examined with a Zeiss LSM510 confocal microscope (Carl Zeiss AG, Jena, 
Germany). 
2.2.11 Anti- C. jejuni antibody staining of C. jejuni for confocal microscopy 
Caco-2 cells were seeded (~ 1 x 105 cells) onto 17 mm cover slips in 24 well plates and 
grown to confluency. For infection, C. jejuni culture was added to the wells at an MOI 
100:1 and incubated for 2 h and 6 h. Coverslips were washed three times with PBS and 
fixed in 4% (v/v) PFA for 15 minutes at room temperature. Cover slips were washed 
with PBS and stained with rabbit polyclonal IgG anti-C. jejuni antibody (10 µg/ml) in 
PBS and 5 % (v/v) FCS for 45 min at room temperature (Abcam, Cambridge, UK). 
After three washes with PBS for 10 minutes each, coverslips were stained with a 
secondary antibody (Alexa Fluor 488- conjugated goat anti-rabbit antibody) in the dark 
for 30 min at room temperature. To perform intracellular staining of internalised C. 
jejuni, cells were stained with anti-C. jejuni antibody in PBS with 5% (v/v) FCS and 
0.05% (w/v) saponin (Sigma-Aldrich) (to permeabilise cells) for 45 min at room 
temperature, followed by Alexa Fluor 546-conjugated goat anti-rabbit antibody in the 
same buffer for 30 min at room temperature. Coverslips were washed three times in 
PBS. The coverslips were washed and mounted in Vectashield mounting medium 
containing (DAPI; final concentration 1.5 µg/ml) on to a clean glass slide and sealed 
with nail varnish. Slides were stored at 4°C in dark until imaging on a Zeiss LSM510 
confocal microscope. 
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2.2.12 Quantification of mean fluorescence intensity (MFI) 
A Zeiss LSM510 confocal microscope was used to capture images of eGFP or 
Evoglow®-expressing bacteria. Volocity software (PerkinElmer) was used to quantify 
confocal images following the manufacturer’s instructions. The eGFP or Evoglow®-
expressing bacteria were identified by volocity measurements (standard 'find' protocol) 
and the fluorescence intensities were quantified. 
2.2.13 Pre-treatment of Caco-2 IECs with biochemical inhibitors 
Stock inhibitors used in this study were prepared as follows:- 
Inhibitor Stock  Final concentration used in 
experiments per/ml 
Cytochalasin D (CytD) 10 mM (in DMSO) 2 µM 
Methy-β-cyclodextrin 
(MβCD) 
10 mM (in MQ-H20) 5 µM 
Colchicine 1 M (in DMSO) 10 µM 
Wortmannin 10 mM (in DMSO) 1 µM 
Monodansylcadaverine 
(MDC) 
100 mM (in DMSO) 250 µM 
 
Inhibition of invasion studies were performed basically as described previously 
(Oelschlaeger et al., 1993, Yao et al., 1997, Hu and Kopecko, 1999). Inhibitors of 
eukaryotic cell processes were added to the cell monolayer 1 h prior to the addition of 
bacteria. Monolayers were then washed three times with PBS. C. jejuni cells from a 24 
h plate were collected using a sterile cotton swab and re-suspended in a 1.6 ml 
microcentrifuge tube containing 1 ml DMEM and adjusted to produce a final OD600 of 
0.1 (~ 1 x 108 cfu/ml). 100 µl of this suspension was added to each well of a 24 well 
plate and incubated for 3 h, 6 h or 24 h. Following the incubation period, the infected 
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monolayer was washed three times with PBS and the numbers of interacting and 
invading bacteria were enumerated as described previously.  
2.2.14 Cytotoxicity assays 
To ascertain whether the use of chemical inhibitors had any detrimental effect on the 
integrity of the IECs, cytotoxicity assays were performed. Caco-2 IECs were seeded 
onto 24 well plates (~ 1 x 105 cells per well). IECs were grown for 5-7 days until 
confluent, the IECs were then washed three times with PBS followed by the addition of 
the appropriate concentration of each inhibitor as well as a control without inhibitor. 
The IECs were incubated for 1 h with the inhibitor, then the supernatants were removed 
and the IECs washed three times with pre-warmed PBS. This was followed by the 
addition of 1 ml fresh culture medium and the Caco-2 IECs were incubated for a further 
24 h. After 24 h, the supernatants were collected and analysed for the release of lactate 
dehydrogenase (LDH) enzyme using the CytoTox 96® non-Radioactive Cytotoxicity 
Assay kit (Promega, Southampton, UK). Total lysis of IECs following treatment with 
1% (v/v) Triton X-100 represented the 100% cytotoxicity positive control. 
2.2.15 Intracellular survival assays 
Intracellular survival assays were performed using the same protocol as that for the 
invasion assays, except that after incubating the cells with 150 µg/ml gentamicin for 2 
h, the monolayers were washed with 1 ml of PBS and then incubated in DMEM 
containing a reduced concentration of gentamicin (10 µg/ml) for 19 h (Naito et al., 
2010). The low concentration of gentamicin does not affect the internalised bacteria 
over the extended incubation period, but allows the killing of any extracellular bacteria. 
Following the incubation period, the monolayers were then washed three times with 
PBS and lysed and described previously. 
2.2.16 Macrophage survival assays 
Macrophage survival assays were performed using J774A.1 mouse macrophages. A 
bacterial suspension with an OD600 of 0.1 was prepared in DMEM. C. jejuni cells (~ 1 x 
108 cfu) were added to a culture of ~ 5 x 105 J774A.1 mouse macrophage cells (MOI 
200:1) and incubated for 3 h. IECs were washed three times in PBS followed by 
incubation in DMEM containing gentamicin (150 µg/ml) for 2 h to allow killing of 
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extracellular bacteria. The macrophages were then incubated in DMEM containing a 
reduced concentration of gentamicin (10 µg/ml) and bacterial survival determined at 0 
h, 4 h and 16 h. At each time point, the macrophages were washed three times with PBS 
and lysed by adding 0.2% (v/v) Triton X-100. Serial dilutions, plating and enumeration 
of bacterial numbers were performed as described previously. 
2.2.17 Maintenance of IECs for Vertical Diffusion Chamber experiments 
Caco-2 cells or T84 IECs were seeded (~ 1 x 107) into the upper compartment of a 
Snapwell filter (Corning Life sciences, Amsterdam, Netherlands). IECs were grown for 
a minimum of 21 days for Caco-2 IECs or 14 days for T84 IECs to allow for the 
formation of a polarised monolayer (Mills et al., 2012). The growth medium was 
changed every 2 to 3 days. 
2.2.18 Measurement of transepithelial electrical resistance of IEC monolayer for 
Vertical Diffusion Chamber experiments 
The transepithelial electrical resistance (TEER) of a Caco-2 monolayer in a Vertical 
Diffusion Chamber (VDC) was measured by placing two voltage-sensing AgCl 
electrodes close to the cell monolayer on each side of the insert, passing a current 
through two further electrodes placed at the two distal ends of the insert and reading the 
voltage necessary to keep the current flowing. Resistance was calculated according to 
Ohm's law (R = V/I, where R = resistance, V = voltage, and I = current) and multiplied 
by the surface area of the monolayers (1.12 cm2). 
2.2.19 Assembly of the Vertical Diffusion Chamber model system for C. jejuni 
Caco-2 and T84 IECs invasion studies. 
Before each experiment, the two compartments of the VDC (Harvard Apparatus, 
Holliston, MA) were sterilised by immersion in Haz-Tabs (Guest Medical, Ltd., 
Aylesford, United Kingdom) solution for 2 h, followed by three washes with Milli-Q 
water. A Snapwell filter carrying a polarised monolayer of Caco-2 or T84 IECs was 
removed from the culture plate, washed three times with pre-warmed PBS and placed in 
between the two compartments of the VDC. For C. jejuni invasion studies, bacteria 
were harvested from a 24 h BA plate, resuspended in 1 ml brucella broth, adjusted to an 
OD600 of 0.1 and added to the apical compartment. The basolateral compartment was 
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filled with tissue culture medium supplemented with 1% (v/v) FCS and 1% (v/v) non-
essential amino acids. The VDC was maintained under microaerobic conditions in a 
VAIN to ensure the survival of C. jejuni. Whilst a gas mixture of 95% O2 and 5% CO2 
was perfused through the basolateral compartment to maintain the IECs. 
2.2.20 Disassembly of the VDC for enumeration of intracellular C. jejuni 
At the desired time point of co-culturing, the basolateral supernatants were removed 
from the VDC and stored at −80°C for subsequent analysis. The Snapwell filter was 
removed from the VDC placed into a 6-well tissue culture dish. The Snapwells were 
washed three times with 400 µl PBS. The IECs were then incubated in DMEM 
containing 150 µg/ml gentamicin for 2 h at 37°C, followed by lysis with Triton X-100. 
All VDC experiments were performed with at least two technical replicates and at least 
three biological replicates per experimental data set. 
2.2.21 Cytokine analysis of IEC supernatants following co-culture with C. jejuni 
T84 IECs were infected with C. jejuni for 24 h as described previously The IEC 
supernatants were probed for the presence of IL-8 or TNFα using a human IL-8 or 
human TNFα enzyme-linked immunosorbent assay (ELISA) development kit 
(eBioscience, Hatfield, UK), according to the manufacturers' instructions.  
2.3 Molecular biology techniques 
2.3.1. Isolation of C. jejuni genomic DNA 
C. jejuni genomic DNA (gDNA) was isolated from a 24 hour BA plate using the 5 
PRIME DNA extraction kit (5prime, GmbH, Germany) following the manufacturer’s 
instructions. 
2.3.2 Bacterial gDNA extraction for PCR screening 
A single colony was transferred into a microcentrifuge tube containing 200 µl filter 
sterilised water and vortexed. The suspension was incubated at 95°C for 10 min, 
centrifuged at 13,000 rpm for 10 min then the resulting supernatant collected and used 
as a template for PCR. This supernatant was referred to as a boilate. 
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2.3.3 Isolation of plasmid DNA from E. coli 
Plasmid DNA was isolated from overnight cultures of E. coli using the QIAprep® 
Miniprep Kit (Qiagen, Crawley, UK) following the manufacturer’s instructions.  
2.3.4 Oligonucleotide design 
Primers used in this study are listed in Table 2.4. Primers were designed manually and 
checked (http://www.oligoevaluator.com) for the formation of secondary structures, 
such as hair-pins, dimers and melting temperature (Tm). The primers listed in Table 2.4 
were synthesised by Invitrogen. Primers were reconstituted with sterilised Milli-Q H2O 
to 100 µM, aliquotted and stored at -20°C. 
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Table 2.4 Primers used in this study 
Primers Sequence 5’ to 3’ Restriction sites 
pGLOW-pp1-
Forward TAATTCTAGAAAGCTTGCATGCCTGCAGTC XbaI 
pGLOW-pp1-
Reverse TAATTCTAGAGCATGCCTGCAGTCAGTG XbaI 
pGLOW-bs1-
Forward TAATTCTAGAGAATTCGAGCTCCATATG XbaI 
pGLOW-bs1-
Reverse GCAGGTCGACTCTAGAGGATC XbaI 
eGFP-Forward GGACTAGTAGGAGATTTAAATGGTGAGCAAGGGCGAGGAGCTGTTCAC XbaI  
eGFP-Reverse CTCTAGAAGGCCTTTACTTGTACAGCTCGTCCATGCCGAGAGTG XbaI 
pRRC-Forward GGATGAATTACAAGACTTGC Vector specific 
ciaB-Forward AGAAATAGCTAAATTGGTTA BclI 
ciaB-Reverse CTTATATCTTTCAAATTCTCC BclI 
ciaBcomp-
Forward 
CCC TCTAGA 
GAGAATAAAAGTATGAATAATTTTAAAG XbaI 
ciaBcomp-
Reverse 
CCCTCTAGATTAATGATGATGATGATGATGTTTT
TTCTTATATCTTTCAAATTC XbaI 
cadF- Forward ATGAAAAAAATATTCTTATGTTTAGGTTTG BclI 
cadF-Reverse TTATCTTAAAATAAATTTAGCATCCACTCT BclI 
cadFcomp-
Forward 
CCCTCTAGGTTTTTTCTATGAAAAAAATATTATT
ATG XbaI 
cadFcomp-
Reverse 
CCCTCTAGATTAATGATGATGATGATGATGTCTT
AAAATAAATTTAGCATCC XbaI 
flpA-Forward ATGATGAAAAGATTTCGC  
flpA-Reverse CTACTGAGCCGCCTTAAC  
flpA–IPCRM- 
Forward ATCAGATCTGCAAGGCTTTACCTCCTCAAG BglII 
flpA–IPCRM-
Reverse ATCAGATCTACCCACTCTTTATCCCATT BglII 
pGEMT-SP6 GATTTAGGTGACACTATAG Vector specific 
pGEMT-T7 TAATACGACTCACTATAGGG. Vector specific 
Kanr- Forward GTGGTATGACATTGCCTTCTGCG  
Kanr- Reverse TGGGTTTCAAGCATTAGTCCATGCAAG  
flpAcomp- 
Forward AAATCTAGAGTTAAAGCACCTTTGATGGAAG XbaI 
flpAcomp- 
Reverse 
TCTTCTAGACTAATGATGATGATGATGATGCTGA
GCCGCCTTAACTTTG XbaI 
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2.3.5 Amplification of C. jejuni genes for cloning 
Defined isogenic mutants were constructed by designing the appropriate primers (see 
Table 2.4) to amplify the gene of interest. The presence of a unique restriction site 
(BglII, BamHI or BclI sites) removed the need for IPCRM (see Section 2.3.17).  
2.3.6 Polymerase chain reaction PCR 
All PCR reactions were prepared in thin-walled 0.6 ml microcentrifuge tubes 
(Eppendorf) in a final volume of 25 µl, containing 0.5 µl of each forward and reverse 
primers (100 µM), 1 µl of gDNA (~1 µg), 23 µl of PCR pre-mix (2 µl dNTP mix 
(dNTPS at 10 mM), 5 µl 10X PCR buffer and 1 µl GoTaq DNA polymerase (10 U/µl)) 
(Promega). PCR reactions performed for complementation studies used a proof reading 
DNA polymerase Pfx (Invitrogen) according to the manufacturer’s instructions. PCR 
reactions were performed using a Tetrad-2 thermal cycler (Biorad, Hemel Hempstead, 
UK). PCR conditions were modified depending on the Tms of the primers and the 
length of the size of the product to be amplified. 
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dNTPs mix was prepared:- 
dNTP stock solution (1.25 mM of dATP, dTTP, dCTP and dGTP) prepared:- 
dATP (100 mM)         12.5 µl 
dTTP (100 mM)         12.5 µl 
dGTP (100 mM)        12.5 µl 
dCTP (100 mM)          12.5 µl 
Sterilised Milli-Q water                           to 1000 µl 
PCR premix was prepared:- 
10 X buffer          100 µl 
dNTPs (1.25 mM)         168 µl 
MgCl2 (25 mM)            60 µl 
Taq polymerase (5 U/µl)            6 µl 
Sterilised Milli-Q water              to 1000 µl 
Premix was mixed and stored at -20°C until required. 
PCR reactions were set up as follows:- 
Forward primer (100 µM)          0.5 µl 
Reverse primer (100 µM.)          0.5 µl 
Genomic DNA (~ 1 µg)            1 µl 
PCR Pre-mix             23 µl 
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PCR program:- 
Step 1: Denature at 94°C for 15 seconds 
Step 2: Anneal at 55°C for 1 min 
Step 3: Extension at 72°C for 1 min 
Repeat Steps 1-3 34 times 
Step 4: End cycle with 72°C for 4 min 
Steps 2 and 3 were varied to optimise PCR amplification conditions / amplification of 
larger products (usually 1 minute per Kb). Modifications to PCR reaction conditions 
were also dependent on the Tm of the primers used. 
2.3.7 Analysing PCR products by gel electrophoresis  
Prior to cloning, the amplified PCR products were analysed on a 0.7% (w/v) agarose gel 
in 1X TAE electrophoresis buffer (see Appendix) supplemented with 0.5 µg ml-1 
ethidium bromide (Fisher Scientific). 5 µl of each PCR reaction was mixed with 1.5 µl 
of 5 X DNA loading buffer (Bioline, London, UK) and loaded into a well of the agarose 
gel. 5µl of hyperladder I marker (Bioline) was also added to a separate well. The gel 
was placed into an electrophoresis tank (AGE electrophoresis tank, Biorad, Hemel 
Hempstead, UK). The gel was run at 120 mV for 30-45 min. PCR products were 
visualised using a transilluminator (UVP, Cambridge, UK) and gel images recorded 
using a GeneGenius Gel imager (UVP). 
2.3.8 Purification of PCR products 
PCR products intended for further cloning studies were purified using the QIAquick® 
PCR purification kit (Qiagen). Briefly, 20 µl of the PCR product was transferred to a 1.6 
ml eppendorf and 100 µl of binding buffer BP1 was added, mixed by gently pipetting, 
and then transferred to a QIAquick spin column in a 2 ml collection tube. The tube was 
centrifuged at 13,000 rpm for 1 minute and the flow-through discarded. The tube was 
placed back into the 2 ml collection tube, 750 µl of RPE buffer added to the tube, then 
centrifuged again at 13,000 rpm for 1 minute. The QIAquick column was placed into a 
fresh 1.6 ml eppendorf, 20 µl of pre-heated sterile Milli-Q water was added to the centre 
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of the QIAquick spin column and left to stand for 1 minute at room temperature, 
followed by centrifuging at 13,000 rpm for 1 minute to elute the DNA. The sample was 
incubated on ice and the purity of DNA was quantified using the Nano-drop. The 
purified PCR products were stored at -20°C. 
2.3.9 Restriction enzyme digestion 
Restriction enzyme digest reactions of PCR products or plasmid DNA were set up as 
follows. Briefly, 5 µl of 10 X reaction buffer and 2 µg of the PCR product or plasmid 
DNA were mixed in a 1.6 ml eppendorf and the volume adjusted to 48 µl with Milli-Q 
water and 1 µl (10 U/µl) of BglII, BamHI, XbaI (New England Biolabs, Hitchin, 
England) added. The reaction tubes were placed in a 37°C water bath for 60-90 min, 
followed by purification using the QIAquick® PCR purification kit The purified 
products were quantified using the Nano-Drop. Purified products were stored at -20°C. 
2.3.10 Dephosphorylation of plasmid DNA 
Prior to use in subsequent cloning procedures, digested plasmid DNA was 
dephosphorylated using Antarctic phosphatase (New England Biolabs) to avoid the 
vector self-ligating. Briefly, 8 µl of plasmid DNA (~1 µg) was added to a 0.6 ml tube, 
followed by 1 µl of 10 X dephosphorylation buffer and finally 1 µl of Antarctic 
phosphatase enzyme (10 U/µl) was added. The reaction mixture was incubated at 37°C 
for 15 minutes, followed by a further incubation of the reaction mixture at 65°C in a 
heat block to inactivate the enzyme. The sample was then ready to use in further 
reactions. 
2.3.11 Cloning of purified PCR products into a plasmid vector 
0.6 ml eppendorf tubes were labelled as background control, test sample and positive 
control. Into each tube, 5 µl of 10 X ligation buffer, 1 µl of pGEMT®- easy vector (50 
ng/µl), 0.4 µl of T4 DNA ligase (10 U/µl) (New England Biolabs) and 1 µl H2O were 
added. Finally 2 µl of the PCR product (~ 1µg/ml) was added to the test sample tube 
and 2 µl of the control insert was added to the positive control tube. To the background 
control, a further 2 µl of H2O was added. The reactions were mixed by pipetting and 
incubated overnight at 4°C. Ligation reactions were prepared with ratio of insert to 
vector of either 1:1 or 3:1:- 
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Amount of plasmid to insert was calculated using the following equation: 
( (insert size (kb) /vector size (kb) ) x nanogram vector = nanogram insert. 
2.3.12 Transformation of E. coli  
Tubes containing the ligation reaction mix were centrifuged to collect contents. 2 µl of 
the ligation reaction was placed into a 1.6 ml eppendorf, pre-cooled on ice. 50 µl of 
electrocompetent E. coli cells (see Table 2.2) were thawed on ice, gently tapped to mix 
the contents, 2 µl β-mercaptoethanol (14.4 M) (Stratagene) was added to these cells, 
mixed by pipetting and incubated on ice for 10 minutes. The cells were then transferred 
to the pre-cooled eppendorf. As a control to check the transformation efficiency, 2 µl of 
uncut plasmid was added to a separate pre-cooled tube containing 50 µl of cells. The 
transformation mixtures were incubated on ice for 20 min. The samples were then heat 
shocked in a water bath at 42°C for ~ 45-50 seconds. The samples were placed 
immediately back on ice for a further 2 min. Then 950 µl room temperature SOC broth 
(Bioline) was added and the reactions were incubated for 1.5 h at 37°C with shaking at 
150 rpm. 200 µl of the transformation reactions were plated onto LB amp plates 
supplemented with 0.5 mM Isopropyl-β-D-thio-galactoside (IPTG) (Promega) and 80 
µg/ml of X-Gal (Promega). The plates were then incubated at 37°C overnight. 
2.3.13 PCR screening of transformants  
Following incubation, individual colonies were selected from the transformation plates 
using a sterile loop for each colony, restreaked on fresh LB amp plates and incubated at 
37°C overnight. Boilates were prepared from the restreaks, using a sterile loop, a small 
amount of growth was picked from each of the transformants and re-suspended in 100 
µl of Milli-Q water. The suspension was heated for 10 minutes at 95 °C and spun at 
13,000 rpm for 5 minutes. 1 µl of the supernatant was used as template DNA in a 20 µl 
PCR reaction.  
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2.3.14 Insertion of a Kanamycin cassette 
Prior to ligation with the kanamycin cassette, the plasmid DNA containing the gene to 
be mutated was digested and purified. Samples were checked for purity using the 
Nanodrop. A BamHI fragment of plasmid pJMK30 containing the Kanr cassette was 
ligated into the digested plasmid DNA as follows:- 
Plasmid DNA digested with unique restriction enzyme (~250 ng/µl)    2 µl 
Digested Kanamycin cassette (~ 20 ng/µl)      5 µl 
10 X Ligase buffer         1 µl 
T4 DNA Ligase (3 Weiss units/µl)       2 µl 
The ligation reaction was mixed by gentle pipetting, briefly spun down and incubated 
overnight at 4°C. Following incubation, the reaction mixture was transformed into 
DH5α cells and plated onto LB amp kan plates then incubated at 37°C overnight. 
Positive transformants selected on LB amp kan plates were restreaked onto fresh LB 
amp kan plates and incubated overnight at 37°C. Transformants were screened by PCR 
using gene specific primers to confirm the presence of a larger band due to the insertion 
of the Kmr cassette. Plasmid DNA was isolated from the positive colonies. Insertion and 
orientation of kanamycin cassette was confirmed using kan Forward/Gene specific 
Forward to check that the Kmr cassette was in the correct orientation. The Kmr cassette 
does not have a transcriptional terminator, which thereby allows formation of 
multicistrionic mRNA allowing the Kmr cassette to be in the same position and 
direction as the gene of interest, thereby reducing the possibility of polar effects (van 
Vliet et al., 1998). 
2.3.15 DNA sequencing 
To confirm that positive transformants contained the kanamycin cassette, sequencing 
was performed by adding 1 µl of the plasmid DNA (~ 0.5 µg) into two 0.6 ml 
eppendorfs, followed by 8 µl of ABI® prism terminator ready reaction mix (ABI®, 
Carlsbad, CA, USA) and 1 µl (100 pmol) of either the forward or reverse primer into the 
respective tubes, in a final volume of 20 µl. Tubes were placed into a GeneAmp 9600 
thermal cycler (Perkin Elmer, Beaconsfield, UK). The program used was as follows:  
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• 25 cycles of denaturation at 96°C for 10 seconds 
• Annealing at 50°C for 5 seconds 
• Extension at 60°C for 4 minutes. 
After the run was complete the reaction mixture was transferred into a sterile 1.6 ml 
eppendorf containing 80 µl of 75% (v/v) isopropanol, vortexed briefly and incubated for 
1 hour at -20°C, centrifuged at 13,000 rpm for 30 minutes and the supernatant removed 
and discarded. Next, 400 µl of 75% (v/v) ethanol was added, the tubes were vortexed 
briefly and spun at 13,000 rpm for 15 minutes. The supernatant was removed and 
discarded and the tubes were spun briefly to collect any residual ethanol, which was 
also discarded. Tubes were then allowed to air dry for approximately 20 minutes. DNA 
sequencing was performed by Dr Ozan Gundogdu or Ellie Thompson at the Faculty of 
Infectious & Tropical Diseases sequencing facility. DNA sequencing data was analysed 
with sequence Navigator software Chromas (Applied Biosystems, Warrington, UK). 
2.3.16 Electroporation of C. jejuni 
100 µl aliquots of C. jejuni electrocompetent cells (see section 2.1.6) were removed 
from the -80°C freezer and allowed to thaw on ice for 10 min. A 1.6 ml eppendorf was 
prepared with 2 µl of plasmid DNA (~0.5-1.0 µg), then 30 µl of the thawed 
electrocompetent cells were added. The contents were gently mixed and incubated on 
ice for a further 10 minutes. The mixture was then transferred to a pre-chilled 
electroporation (2 mm gap) cuvette (Gene Pulser, Bio-Rad, CA, USA). Electroporation 
was performed using a Gene Pulser Xcell electroporation system (Bio-Rad) with the 
following settings: 25 µFD, 2.5 Kv and 200 Ω. Following electroporation, 100 µl of 
room temperature SOC broth (Bioline) was added to the cuvette and mixed thoroughly 
by pipetting. The contents of the cuvette were then pipetted onto the centre of a BA 
plate and incubated for 24 h at 37°C in the VAIN. Bacterial growth was collected using 
a sterile cotton swab and resuspended in 1 ml of Brucella broth, then 200 µl of this 
suspension was plated onto a fresh BA plate supplemented with the appropriate 
antibiotic(s) and incubated for 2-3 days. The resulting colonies were restreaked and 
boilate PCR was performed on the colonies to confirm homologous recombination of 
the correct construct. 
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2.3.17 Inverse Polymerase Chain Reaction Mutagenesis  
Where the gene to be mutated did not contain a unique BglII, BclI or BamHI site, 
inverse polymerase chain reaction mutagenesis (IPCRM) was performed. IPCRM 
primers were designed by selecting around two regions of 15-20 nucleotides in the 
centre of the gene to be mutated with an interspacing region of 20-25 nucleotides with 
the 5’ primer downstream of the 3’ primer. The 5’ end of the IPCRM primer included 
ATC residues to allow efficient restriction enzyme digestion followed by the BglII 
sequence AGATCT.  
IPCRM primers were resuspended in filter sterilised Milli-Q water according to 
manufacturer’s instructions and then diluted down to a final concentration of 100 µM.  
IPCRM reactions were performed using cloned fragments of the gene to be mutated at a 
diluted concentration (~ 0.1-10 ng). The plasmid template concentration was reduced to 
minimise false positives following transformation into DH5α cells. 
 
IPCRM pre-mix was prepared:- 
Buffer  I (10X)                 10 µl 
Accuprime Taq DNA Hi fi (5 U/µl)                0.4 µl 
dNTPS in buffer I concentration of                        400 µM 
Milli-Q water                      to 100 µl 
IPCRM reactions were set up:- 
IPCRM premix -               98.4 µl 
DNA (0.1-10 ng)                                   1.0 µl 
IPCRM primers (100 pmol/µl )                                  0.6 µl 
IPCRM program:- 
Step 1. 94°C for 2 min 
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Step 2. Denature at 94°C for 1 min 
Step 3. Anneal at 45°C for 1 min 
Step 4. Extension at 72°C for X mins (X= size of plasmid in KB x 1.5) 
Repeat steps 2-4 40 times 
Step 5. 72°C for 8 min 
10-15 µl of the IPCRM reaction was loaded onto an agarose gel and the remainder of 
the reaction was purified with Qiagen QIAquick® PCR purification kit. Samples were 
checked on the Nanodrop ND-1000 spectrophotometer. Following purification, the 
IPCRM product was digested with BglII and DpnI for 3 hours at 37°C. DpnI was used 
to digest methylated template DNA that would produce false positives (Shenoy and 
Visweswariah, 2003).  
Digestions were set up as follows:- 
IPCRM product (10-500 ng/µl)              20 µl 
BglII (20 units)                 2 µl 
Dpn1 (20 units)                 2 µl 
NEBuffer 2 (10X)               10 µl 
Milli-Q water                   to 100 µl 
Restriction digested products were purified using the QIAquick® PCR purification kit. 
Purified samples were checked for purity using the Nanodrop. At this stage, the digested 
Kanr cassette by BamHI was ligated with the digested IPCRM product:- 
IPCRM product digested with BglII and DpnI (~250 ng/µl)                 2 µl 
Pre-digested Kanamycin cassette with BamHI (~20 ng/µl)                 5 µl 
10 X ligase buffer                     1 µl 
T4 DNA/NEB Ligase (3 Weiss units/µl)             2 µl 
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The reaction was incubated overnight at 4°C and then ligation reactions were 
transformed into DH5α cells.  
2.3.18 Construction of complements 
Complementation procedures were performed by inserting a copy of the functional gene 
into the mutant chromosome using the C. jejuni NCTC11168H & 81-176 
complementation vector pRRC (Karlyshev and Wren, 2005).  
2.4 Outer membrane vesicles assays 
OMVs were isolated as described previously (Elmi et al., 2012). Briefly, C. jejuni 
strains from 24 h BA plates were resuspended in 1 ml Brucella broth and inoculated in 
75 cm2 tissue culture flasks (NUNCTM, Roskilde, Denmark) containing 25 ml of 
Brucella broth to an OD600 of 0.1. Following a 14 h incubation with shaking, OD600 
measurements of the bacterial suspensions from the flasks were recorded and the 
bacterial suspension was transferred into sterile 50 ml centrifuge tubes (Corning, NY, 
USA). The bacterial cells were removed from the culture fluid by centrifugation at 4000 
rpm for 1 h at 4oC in a Beckman Coulter (Allegra™ X-22R) centrifuge, (Beckman 
Instruments, Palo Alto, CA, USA) and the supernatant was filtered through a 0.22 µm 
membrane (Millipore) to remove broken cells and other debris collecting the cell-free 
supernatant into 50 ml centrifuge tubes. Absence of viable bacteria was confirmed by 
plating OMV samples on BA plates and incubating both aerobic and microaerobic 
conditions for 48 h. The filtrate was concentrated to 2 ml by ultra-filtration using an 
Amicon Ultra-15 Centrifugal Filter Devices with a nominal 10 kDa cutoff (Millipore) 
and centrifugation at 4000 rpm for 90 min at 4oC. The concentrated filtrate was 
transferred into an Ultra-clear centrifuge tube (Beckman Coulter) and centrifuged at 
45,000 rpm for 3 hours at 4oC using a TLS 55 rotor (Beckman Instruments, Palo Alto, 
CA, USA). After ultracentrifugation, the resulting pellet was resuspended in 200 µl PBS 
and stored at -20oC.  
2.4.1 Pre-treatment of C. jejuni OMVs with Caco-2 IECs 
Caco-2 cells were seeded (~ 1 x 105 cells per well) in a 24 well plate and incubated with 
10 µg OMVs at 37°C in a CO2 incubator 1 h. The cells were washed with PBS and then 
infected with live C. jejuni (~ 1 x 108 cfu/ml). The monolayers were incubated for 24 h 
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at 37°C in a CO2 incubator. After the desired incubation time was complete, the 
supernatant was gently removed from the wells and the cells were washed three times 
with 1 ml of pre-warmed PBS which removed the unadhered C. jejuni bacteria. The 
numbers of adhered and invaded bacteria were enumerated as described previously. 
2.4.2 C. jejuni fibronectin binding assays 
Fibronectin binding assays were performed as described previously (Konkel et al., 
2010). Briefly, the wells of 96-well flat-bottom plates (Costar, Corning, NY) were 
coated with a 1 mg/ml solution of fibronectin in 0.05 M Tris-buffered saline, pH 7.5 
(Sigma) overnight at 4°C. For a control, wells were also coated with 1% (w/v) BSA in 
PBS. C. jejuni was harvested from 24 h BA plate and re-suspended in PBS at an OD600 
of 0.1 (~ 1 x 107 cfu). Wells were rinsed with PBS and 100 µl of the bacterial 
suspension was added to each well and incubated at 37°C in a CO2 incubator for 1 h.  
The wells were washed three times with PBS and adherent bacteria were removed by 
the addition of 0.05% (w/v) Trypsin / 0.02% (w/v) EDTA in Hanks’ Balanced Salt 
Solution. To enumerate the number of adherent bacteria, serial dilutions of the trypsin 
suspension were plated on BA plates. 
2.4.3 Statistical Analysis 
Statistical analysis was performed using Prism software (GraphPad Software). Data are 
presented as mean ± standard deviation (SD). All experiments represent three biological 
replicates performed in triplicate for each experiment. Variables were compared using 
Student's t test, p values of p <0.05 were considered significant and p <0.001 were 
considered highly significant. 
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Chapter 3. Reinvestigation of C. jejuni adhesion to and 
invasion of intestinal epithelial cells 
3.1 Introduction 
C. jejuni adhesion to, invasion of and survival within IECs has been widely studied 
using standard in vitro tissue culture assays (see Section 1.2.3). C. jejuni strains are 
known to exhibit differences in the ability to adhere and invade different cell lines. 
(Newell et al., 1985, Konkel and Joens, 1989, Everest et al., 1992, Friis et al., 2005). 
Multiple mechanisms of invasion have been reported (see Section 1.5.1). As such, there 
is currently considerable confusion in the literature regarding C. jejuni invasion 
mechanisms and also the inhibition of C. jejuni invasion by modulating host cell 
pathways (see Section 1.5.3). The initial aim of this study was to reinvestigate C. jejuni 
adhesion to and invasion of intestinal epithelial cells using two independent widely 
studied wild-type strains. 11168H is a hypermotile derivative of the sequence strain 
NCTC11168 (Karlyshev et al., 2004), that displays high levels of colonisation in a 
chick model (Jones et al., 2004) and as such is considered a better strain to use to 
investigate host-pathogen interactions. C. jejuni 81-176 is a gastroenteritis isolate from 
a multistate outbreak from contaminated milk (Korlath et al., 1985a) and one of the 
most invasive C. jejuni laboratory strains (Friis et al., 2005).  
3.2. Results 
3.2.1 Motility  
C. jejuni motility plays an important role in infection of humans and colonisation of 
other animals (Black, Levine et al. 1988). Prior to investigating adhesion to and 
invasion of IECs, comparative differences in the motility of the C. jejuni wild-type 
strains were investigated. Motility assays were performed as described in Section 2.1.8. 
Surprisingly, the 81-176 wild-type strain displayed a more motile phenotype than the 
11168H wild-type strain (see Figure 3.1). 
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A)          
              
   (B) 
 
Figure 3.1 Motility assays. Bacteria were grown for 24 h on blood agar. A suspension was 
prepared and adjusted to an OD600 of 0.1. 2 µl of this suspension was pipetted into the centre of 
soft agar plates and incubated at 37°C. The level of motility was assessed by measuring the 
diameter of growth at 24 h, 48 h and 72 h. (A) Differences in level of motility for the 11168H 
and 81-176 wild-type strains. (B) A representative image showing the motility of (1) 81-176 and 
(2) 11168H at 48 h. Data is representative of three independent experiments. Asterisks denote a 
statistically significant difference (* = p <0.05) for the 81-176 wild-type compared to the 
11168H wild-type. 
1 
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3.2.2 The C. jejuni 81-176 wild-type strain exhibits higher levels of interaction with 
and invasion of Caco-2 IECs. 
Comparison of the two 11168H and 81-176 wild-type strains after 3 h, 6 h and 24 h co-
culture with Caco-2 IECs, revealed significant differences for both interaction and 
invasion (see Figure 3.2).  
The 81-176 wild-type strain interacted and invaded at a significantly higher level than 
the 11168H wild-type strain. Previous studies have suggested that 81-176 is much more 
invasive in standard tissue culture assays (Oelschlaeger et al., 1993, Hu and Kopecko, 
1999). Therefore the 81-176 wild-type strain was selected for use in further 
experiments. 
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(A)       
       
   (B) 
 
Figure 3.2 Interaction (adhesion and invasion) and invasion assays. C. jejuni wild-type 
strains 11168H & 81-176 were co-cultured with Caco-2 IECs over a period of 3 h, 6 h and 24 h. 
For interaction assays (A) Caco-2 IECs were lysed with 0.2% (v/v) Triton X-100 and interacting 
bacteria enumerated. For invasion assays (B) Caco-2 IECs were incubated for 2 h with 
gentamicin (150 µg/ml) to kill any extracellular bacteria, the IECs were then lysed with Triton 
X-100 and intracellular bacteria enumerated. Asterisks denote a statistically significant 
difference (** = p <0.01, *** = p <0.001) for the 81-176 wild-type compared to the 11168H 
wild-type. Data are representative of triplicate independent experiments. 
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3.2.3 Inhibitors of bacterial invasion of eukaryotic cells 
The inhibitors of bacterial invasion used in this study were selected for the ability to 
target host cell structures or effector proteins which have been previously shown to be 
hijacked for bacterial invasion (Wells et al., 1998, Yoshida and Sasakawa, 2003, 
Pizarro-Cerda and Cossart, 2006, Krachler et al., 2011). The purpose of this study was 
to determine whether microfilaments, microtubules, caveolae-mediated endocytosis, 
clathrin-mediated endocytosis and host cell signalling pathways (PI3-Kinase) are 
targeted during C. jejuni invasion of IECs. 
Table 3.1 List of inhibitors of bacterial invasion used in this study. 
Inhibitor Inhibitor action Inhibitor mechanism 
Cytochalasin D (CytD) Microfilament disruption 
Blocks actin polymerisation by 
binding to fast growing 
microfilament ends, blocking both 
assembly and disassembly of 
individual the actin monomers. 
Methyl-beta-cyclodextrin 
(MβCD) 
Inhibits caveolae 
mediated endocytosis  
Depletes cholesterol from cell 
membrane/lipid rafts 
Colchicine Microtubule disruption 
Disrupts cell division by interfering 
with the assembly and disassembly 
of tubulin into microtubule 
polymers 
Wortmannin 
Inhibits 
phosphatidylinositol 3-
kinase (PI 3-kinase) 
Covalently binds to the catalytic 
pll0 subunit of mammalian PI-3 
kinase 
Monodansylcadaverine 
(MDC)  
Blocks clathrin-
mediated endocytosis 
Inhibits clustering and 
internalisation of ligand-receptor 
complexes into clathrin-coated 
vesicles 
 
The concentration of each inhibitor was selected for maximal inhibitory effect without 
affecting the integrity of the epithelial cell monolayer based on published studies (see 
Table 2.2.13).  
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3.2.4 Investigation of the cytotoxicity of individual inhibitors 
Prior to incorporating pharmacological inhibitors into interaction and invasion assays, 
cytotoxicity assays and confocal microscopy was performed to ensure that the 
individual inhibitors had no effect on the viability of the Caco-2 IECs and that the 
results observed following co-culture were due to the interaction between C. jejuni and 
the Caco-2 IECs. The cytotoxic effect of the individual inhibitors was similar to that of 
DMEM with no inhibitor added and was not statistically different. 
  
 
Figure 3.3 Cytotoxic effect of biochemical inhibitors on Caco-2 intestinal epithelial cells. 
Caco-2 IECs were pre-treated with each of the respective inhibitors for 1 h, supernatants 
removed and monolayers washed 3 times with PBS. Fresh media was added and the IECs 
incubated for a further 24 h. The cytotoxic effect on the Caco-2 IECs was measured by 
quantifying the release of cytosolic lactate dehydrogenase (LDH) as a measure of cell damage. 
Total lysis of cells following treatment with 1% (v/v) Triton X-100 represented the 100% 
cytotoxicity control. (ns = no significant difference). Data are representative of triplicate 
independent experiments. 
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In addition to performing cytotoxicity assays, the integrity of the cells following 
treatment with individual inhibitors and DMSO was investigated using confocal 
microscopy to visually ensure cell integrity. No significant differences between the pre-
treated and untreated Caco-2 IECs was observed. A representative image comparing 
CytD pre-treated Caco-2 IECs with untreated Caco-2 IECs is shown (see Figure 3.4) 
(A)          
 
(B) 
 
Figure 3.4 Confocal imaging of Caco-2 IECs following pre-treatment with selected 
inhibitors. Caco-2 IECs were grown on cover slips in 24 well plates for 7 days and pre-treated 
with each of the respective inhibitors for 1 h, supernatants removed and IECs washed 3 times 
with PBS. The cover slips were fixed and stained with Phalloidin for actin (red) and DAPI for 
nuclein (blue) (A) control Caco-2 IECs with no inhibitor pre-treatment and (B) Caco-2 IECs 
following pre-treatment with 2 µM CytD.  
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As none of the inhibitors of bacterial invasion had a significant negative effect on IEC 
viability, the effect of the inhibition of eukaryotic cell processes on bacterial adhesion 
and invasion was investigated. 
3.2.5 Disruption of microfilaments by inhibition of actin polymerisation using 
Cytochalasin D enhances C. jejuni invasion 
Microorganisms have been found to utilise the host cell cytoskeleton to allow uptake 
into the host cell or to promote movement from within the cell (Rosenshine et al., 
1994). Invasion assays are a functional way of ascertaining whether pathogens are 
exploiting the host cell machinery. Cytochalasin D (CytD) has been shown to inhibit the 
entry into host cells of Listeria monocytogenes (Cossart, 1995), Shigella flexneri 
(Mounier et al., 1997) and enteropathogenic E. coli (Sanger et al., 1996). Differing 
results have been reported with the use of CytD on C. jejuni invasion where some 
researchers have shown a decrease in invasion (Monteville et al., 2003b), whilst others 
have reported an increase (Bouwman et al., 2013).  
Interaction and invasion assays were performed in order to study the effect of CytD on 
C. jejuni interaction and invasion of Caco-2 IECs. CytD (2 µM) was added 1 h prior to 
infection with live bacterial cells. The 81-176 wild-type strain displayed an increase in 
both interaction and invasion levels upon co-culture with Caco-2 IECs pre-treated with 
CytD compared to the untreated Caco-2 IECs.  
Bacterial interactions with Caco-2 IECs pre-treated with CytD were initially reduced at 
the 3 h time-point, followed by a significant increase in interacting bacteria observed at 
the 6 h and 24 h time points. C. jejuni invasion was significantly increased in Caco-2 
IECs pre-treated with CytD at the 3 h, 6 h and 24 h time-points, with numbers of 
invading bacteria reaching over (106 cfu) compared to (105 cfu) observed in the 
untreated Caco-2 IECs. 
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(A) 
      
(B) 
      
Figure 3.5. Inhibition of Interaction (adhesion and invasion) assays. Caco-2 IECs were pre-
treated with CytD (2 µM) for 1 h prior to infection. C. jejuni 81-176 were co-cultured with 
Caco-2 IECs that were pre-treated with CytD or a control with no inhibitor treatment, over a 
period of 3 h, 6 h and 24 h. For interaction assays (A), Caco-2 IECs were lysed with 0.2% (v/v) 
Triton X-100 and interacting bacteria enumerated. For invasion assays (B), Caco-2 IECs were 
incubated for 2 h with gentamicin (150 µg/ml) to kill any extracellular bacteria, IECs were then 
lysed with Triton X-100 and intracellular bacteria enumerated. Asterisks denote a statistically 
significant difference (* = p <0.05; ** = p <0.01; *** = p <0.001) for 81-176 post CytD 
compared to 81-176 with no pre-treatment. Data are representative of triplicate independent 
experiments. 
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3.2.6 Disruption of lipid rafts by removal of cholesterol from the cell plasma 
membrane using methyl-beta-cyclodextrin reduces C. jejuni invasion 
Cyclodextrins are capable of depleting cholesterol from the cell membrane and 
therefore prevent endocytosis involving caveolae entry (Rohde et al., 2003). The use of 
MβCD has been found to be more efficient in comparison to other cyclodextrins (Klein 
et al., 1995). Bacterial internalisation has been found to be reduced by sequestering of 
cholesterol (Lafont, 2012). MβCD has been shown to block internalisation of C. jejuni 
into Caco-2, T84 and INT407 IECs, suggesting that caveolae-mediated endocytosis may 
play a role in internalisation (Wooldridge et al., 1996b, Hu et al., 2006c, Krause-
Gruszczynska et al., 2007a, Watson and Galan, 2008b). 
The ability of C. jejuni to interact with and invade Caco-2 IECs pre-treated with MβCD 
(5 µM) was investigated at 3 h, 6 h and 24 h time-points.  
Pre-treatment with MβCD significantly reduced the number of interacting bacteria with 
Caco-2 IECs at the 3 h time point to 106 cfu compared to 107 cfu observed in the 
untreated Caco-2 IECs. By the 6 h time point, there was no difference observed in the 
numbers of interacting bacteria. At the 24 h time point, a significant decrease in 
interacting bacteria was observed with numbers dropping below 107 cfu compared to 
the untreated Caco-2 IECs. Pre-treatment of Caco-2 IECs with MβCD had a more 
significant effect on the number of intracellular bacteria with a severe reduction over the 
infection period, with only a slight increase from the 3 h time point (103 cfu) to the 6 h 
and 24 h time-points (104 cfu) in comparison to no MβCD pre-treatment (105 cfu). This 
data suggests that caveolae-mediated endocytosis plays a role in both C. jejuni 
interactions with and invasion of Caco-2 IECs.  
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(A)  
 
(B) 
 
Figure 3.6 Inhibition of Interaction (adhesion and invasion) and invasion assays. Caco-2 
IECs were pre-treated with MβCD (5 µM) for 1 h prior to infection. C. jejuni 81-176 were co-
cultured with Caco-2 IECs that were pre-treated with MβCD or a control with no inhibitor 
treatment, over a period of 3 h, 6 h and 24 h. For interaction assays (A), Caco-2 IECs were lysed 
with 0.2% (v/v) Triton X-100 and interacting bacteria enumerated. For invasion assays (B), 
Caco-2 IECs were incubated for 2 h with gentamicin (150 µg/ml) to kill any extracellular 
bacteria, IECs were then lysed with Triton X-100 and intracellular bacteria enumerated. 
Asterisks denote a statistically significant difference (** = p <0.01; *** = p <0.001; ns = no 
significant difference) for 81-176 post MβCD compared to 81-176 with no pre-treatment. Data 
are representative of triplicate independent experiments. 
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3.2.7 Disruption of microtubules using colchicine reduces C. jejuni invasion. 
Microtubules have been implicated in the invasion mechanisms of C. jejuni, Citrobacter 
freundii and enteropathogenic E. coli (EPEC) (Donnenberg et al., 1990, Oelschlaeger et 
al., 1993, Hu and Kopecko, 1999, Biswas et al., 2003). C. jejuni invasion of INT407 
IECs was blocked in the presence of colchicine (Biswas et al., 2003) but the same effect 
was not observed in T84 IECs (Wine et al., 2008). Tubulin is essential for cell division 
and previous studies have found that colchicine is able to bind to the subunit of tubulin 
heterodimers forming a tubulin–colchicine complex which inhibits the polymerisation 
of tubulin and therefore affected cytoskeletal changes (Wei et al., 2013). In this study, 
inhibition of microtubules reduced the numbers of C. jejuni interacting with and 
invading Caco-2 IECs. 
The ability of C. jejuni to interact with and invade Caco-2 IECs in the presence of 
colchicine (5 µg) was investigated at 3 h, 6 h and 24 h time-points. Pre-treatment with 
colchicine significantly reduced C. jejuni interaction with Caco-2 IECs at the 3 h time-
point, with numbers of interacting bacteria recovering by the 24 h time-point. Pre-
treatment with colchicine significantly reduced the number of intracellular C. jejuni ~ 
(103 cfu) compared to no colchicine pre-treatment (~ 105 cfu) at all time points.  
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(B) 
     
Figure 3.7 Inhibition of Interaction (adhesion and invasion) and invasion assays. Caco-2 
IECs were pre-treated with colchicine (5 µg) for 1 h prior to infection. C. jejuni 81-176 were co-
cultured with Caco-2 IECs that were pre-treated with colchicine or a control with no inhibitor 
treatment, over a period of 3 h, 6 h and 24 h. For interaction assays (A), Caco-2 IECs were lysed 
with 0.2% (v/v) Triton X-100 and interacting bacteria enumerated. For invasion assays (B), 
Caco-2 IECs were incubated for 2 h with gentamicin (150 µg/ml) to kill any extracellular 
bacteria, IECs were then lysed with Triton X-100 and intracellular bacteria enumerated. 
Asterisks denote a statistically significant difference (** = p <0.01; *** = p <0.001) for 81-176 
post colchicine compared to 81-176 with no pre-treatment. Data are representative of triplicate 
independent experiments. 
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3.2.8 Disruption of the Phosphatidylinositol 3-kinase pathway with wortmannin 
reduces C. jejuni invasion  
Bacteria can interact with host cells via engagement of receptors on the host surface 
with those on the microbial surface. This process enables cross-talk to take place, 
triggering cell signalling events which in turn disrupt or subvert numerous eukaryotic 
cell activities, manipulate the host cell cytoskeleton and trigger bacterial entry, 
promoting survival and replication (Fasano, 1998). 
PI3-kinases are signal transducer enzymes, involved in cell growth, motility, 
differentiation, proliferation, survival and intracellular trafficking (Fry, 1994, Rameh 
and Cantley, 1999, Katso et al., 2001). Microbial activation of PI3-Kinase leads to 
dramatic changes in the host cell, triggering of Rac1 downstream leads to massive 
cytoskeletal deformation, actin rearrangements and membrane ruffling (Hawkins et al., 
1995, Pizarro-Cerda and Cossart, 2004). In the presence of wortmannin, both C. jejuni 
invasion and host cell GTPase activation were inhibited in INT407 cells (Krause-
Gruszczynska et al., 2011). 
The ability of C. jejuni to interact with and invade Caco-2 IECs pre-treated with 
wortmannin (1 µM) was investigated at 3 h, 6 h and 24 h time-points. Pre-treatment 
with wortmannin initially produced a reduction in the number of interacting bacteria at 
the 3 h time point (<106 cfu) compared to the control with no inhibitor added (107 cfu). 
The number of interacting bacteria recovered at the 6 h and 24 h to levels still lower 
than those observed with no inhibitor. Pre-treatment with wortmannin significantly 
reduced the number of intracellular C. jejuni to (~103 cfu) at 3 h, 6 h and 24 h time-
points compared to the numbers observed with no inhibitor (~105 cfu).  
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Figure 3.8 Inhibition of Interaction (adhesion and invasion) and invasion assays. Caco-2 
IECs were pre-treated with wortmannin (1 µM) for 1 h prior to infection. C. jejuni 81-176 were 
co-cultured with Caco-2 IECs that were pre-treated with wortmannin or a control with no 
inhibitor treatment, over a period of 3 h, 6 h and 24 h. For interaction assays (A), Caco-2 IECs 
were lysed with 0.2% (v/v) Triton X-100 and interacting bacteria enumerated. For invasion 
assays (B), Caco-2 IECs were incubated for 2 h with gentamicin (150 µg/ml) to kill any 
extracellular bacteria, IECs were then lysed with Triton X-100 and intracellular bacteria 
enumerated. Asterisks denote a statistically significant difference (* = p <0.05; ** = p <0.01; 
*** = p <0.001) for 81-176 post wortmannin compared to 81-176 with no pre-treatment. Data 
are representative of triplicate independent experiments. 
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3.2.9 Disruption of clathrin-mediated endocytosis with monodansylcadaverine 
reduces C. jejuni invasion. 
Monodansylcadaverine (MDC) is a pharmacological inhibitor of clathrin-mediated 
endocytosis and has been used extensively in numerous mammalian cell lines (Davies et 
al., 1980, Bradley et al., 1993, Wang and Liu, 2003, Panicker et al., 2006). MDC acts 
by directly inhibiting enzymes of the transglutaminase family which are involved in the 
post-transcriptional transamidation of a number of proteins (Lorand and Graham, 2003, 
Mishra and Murphy, 2004). In particular, the transglutaminases play key roles in the 
activation of RhoGTPase proteins, which are involved in regulation and control of the 
cell actin and cytoskeletal mechanics (Etienne-Manneville and Hall, 2002, Singh et al., 
2003). Disruption of transglutaminase with MDC was found to interfere with the actin 
dynamics of the cell (Heuser and Anderson, 1989, Kang et al., 1995, Singh et al., 2003). 
MDC was also shown to inhibit the numbers of intracellular C. jejuni in numerous cell 
lines such as INT407, T84, Hep2 and Caco-2 IEC’s (Konkel et al., 1992b, Oelschlaeger 
et al., 1993, Wooldridge et al., 1996b, Kopecko, 2000, Biswas et al., 2000).  
The ability of C. jejuni to interact with and invade Caco-2 IECs in the presence of MDC 
(0.5 mM) was investigated at 3 h, 6 h and 24 h time-points. Pre-treatment with MDC 
reduced the number of interacting bacteria at the 3 h and 6 h time points with the 
numbers recovering by 24 h compared to the controls with no inhibitor added. Pre-
treatment with MDC significantly reduced the numbers of intracellular bacteria at 3 h 
(<104 cfu), at 6 h (>104 cfu) and at 24 h time-points (<104 cfu) compared to no MDC 
treatment (~105 cfu). 
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Figure 3.9 Inhibition of Interaction (adhesion and invasion) and invasion assays. Caco-2 
IECs were pre-treated with MDC (0.5 mM) for 1 h prior to infection. C. jejuni 81-176 were co-
cultured with Caco-2 IECs that were pre-treated with MDC or a control with no inhibitor 
treatment, over a period of 3 h, 6 h and 24 h. For interaction assays (A), Caco-2 IECs were lysed 
with 0.2% (v/v) Triton X-100 and interacting bacteria enumerated. For invasion assays (B), 
Caco-2 IECs were incubated for 2 h with gentamicin (150 µg/ml) to kill any extracellular 
bacteria, IECs were then lysed with Triton X-100 and intracellular bacteria enumerated. 
Asterisks denote a statistically significant difference (** = p <0.01; *** = p <0.001) for 81-176 
post MDC compared to 81-176 with no pre-treatment. Data are representative of triplicate 
independent experiments. 
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3.2.10 Comparison of the inhibition of C. jejuni 81-176 wild-type strain interactions 
with and invasion of Caco-2 intestinal epithelial cells. 
The inhibitors employed in this study produced either an increase or a decrease in the 
numbers of interacting and invading bacteria. Table 3.2 and Table 3.3 show the 
comparative effect of each inhibitor on C. jejuni interaction and invasion respectively. 
Table 3.2 Effect of inhibitors on C. jejuni ability to interact with Caco-2 intestinal 
epithelial cells 
Inhibitor Effect on C. jejuni interaction with Caco-2 
IECs 
Cytochalasin D   Interaction 
Methyl-beta-cyclodextrin   Interaction, then  Interaction 
Colchicine  Interaction 
Wortmannin  Interaction, then  Interaction 
Monodansylcadaverine   Interaction, then  Interaction 
 
Table 3.3 Effect of inhibitors on C. jejuni ability to invade Caco-2 intestinal 
epithelial cells 
Inhibitor Effect on C. jejuni invasion of Caco-2 IECs 
Cytochalasin D   Invasion  
Methyl-beta-cyclodextrin   Invasion 
Colchicine  Invasion 
Wortmannin  Invasion 
Monodansylcadaverine   Invasion 
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The number of C. jejuni interacting with or invading Caco-2 IECs was calculated as a 
percentage of the initial inoculum (see Table 3.4 and Table 3.5) 
Table 3.4 Percentage of the initial inoculum of C. jejuni interacting with Caco-2 
IECs following pre-treatment with individual inhibitors. 
 
Table 3.5 Percentage of the initial inoculum of C. jejuni invading Caco-2 IECs 
following pre-treatment with individual inhibitors. 
Inhibitor 3 h 6 h 24 h 
Cytochalasin D 314.3 764.1 574.1 
Methylbetacyclodextrin 0.7 4.7 4.5 
Colchicine 2.1 0.5 2.2 
Wortmannin 2.0 47.4 1.8 
Monodansylcadaverine 3.5 19.2 2.1 
 
3.3 Imaging of C. jejuni adhesion to and invasion of Caco-2 intestinal 
epithelial cells 
In order to visualize C. jejuni within IECs, a number of different strategies were 
attempted. Expression of the Green fluorescent protein (GFP) from the jellyfish 
Aequorea victoria is a useful method for visualising in vivo host-pathogen interactions, 
in particular the study of bacteria within a host cell (Prasher et al., 1992, Chalfie et al., 
1994, Inouye and Tsuji, 1994). GFP-tagged bacteria have previously been used in 
Inhibitor 3 h 6 h 24 h 
Cytochalasin D 51.7 115.6 146.1 
Methylbetacyclodextrin 8.8 93.0 60.8 
Colchicine 0.2 32.7 88.0 
Wortmannin 13.7 33.1 88.6 
Monodansylcadaverine 34.9 45.1 109.3 
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ecological studies monitoring bacterial populations in activated sludge communities, in 
symbiotic relationships with plant cells, infection of macrophages and in survival 
studies of E. coli (Kremer et al., 1995, Gage et al., 1996, Eberl et al., 1997, Yrlid et al., 
2001). The use of GFP has many advantages over conventional antibody staining, 
including a visual check for viability of the bacteria and a confirmation of the presence 
of bacteria. In addition expression of GFP in bacteria is less disruptive to the 
biomechanics of the bacterial cell than staining (Errampalli et al., 1999). The major 
disadvantage of existing GFP-like reporter proteins (GFP or eGFP) is that these GFP 
proteins require oxygen as a co-factor to enable post-translational folding of the GFP 
protein and allow the expression of the fluorescence chromophores, although this can be 
remedied with further genetic mutagenesis procedures (Cubitt et al., 1995). Due to the 
strict microaerobic growth requirements of C. jejuni, GFP expressing C. jejuni produced 
very low levels of fluorescent signal following infection of Caco-2 IECs (Labigne-
Roussel et al., 1987, Guerry et al., 1994, Miller et al., 2000), therefore an alternative 
florescence reporter system was investigated. The flavin mononucleotide (FMN)-based 
fluorescent proteins from the Evoglow® series were developed to overcome the above 
restrictions. These proteins can be used as fluorescent reporters in both aerobic and 
anaerobic biological systems. 
In order to study the localisation of C. jejuni within intestinal epithelial cells, C. jejuni 
expressing eGFP and Evoglow® were constructed to investigate the behaviour of the 
bacteria once inside the host cell. 
3.3.1 Construction of Evoglow® expressing C. jejuni strains 
Evoglow genes pp1 (441 bp) and bs1 (411 bp) were inserted into either C. jejuni 81-176 
or 11168H wild-type strains using the C. jejuni complementation vector pRRC 
(Karlyshev and Wren, 2005). The coding regions for pp1 and bs1 were amplified from 
the respective Evoglow® plasmid (pGLOW) by PCR using primers pGLOW-pp1-
Forward/pGLOW-pp1-Reverse and pGLOW-bs1-Forward/pGLOW-bs1-Reverse which 
also introduced an XbaI site at the 5′ end and at the 3′ end. Following digestion with 
XbaI, each PCR product was ligated into the pRRC vector. The pRRC-pp1/bs1 
constructs were transformed into E. coli DH5α cells and plated out on LB chl agar 
plates. Positive colonies selected by growth on LB chl agar were screened using boilate 
PCR to check for the presence of pp1/bs1. Each construct was checked by PCR, 
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sequenced and electroporated into either the 81-176 or 11168H wild-type strain. 
Positive clones were selected on blood agar plates containing chloramphenicol. 
Confirmation of the presence of pp1 and bs1 was performed by PCR using the pRRC-
Forward and pGLOW-pp1/bs1-Reverse primers (see Figure 3.10). The amplified size of 
pp1 is 441 bp, the amplified size of bs1 is 411 bp and successful insertion of each gene 
fragment into the pRRC vector produced a total amplified size for pRRC-pp1 construct 
of 566 bp and for pRRC-bs1 construct of 536 bp. 
Eg: (pRRC-Forward primer amplified (125 bp) + pp1 gene specific reverse (441 bp) = 
566 bp) and (pRRC- Forward primer amplified (125 bp) + bs1 gene specific reverse 
(411 bp) = 536 bp). 
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3.3.2 Construction of eGFP construct expressing C. jejuni strains 
The eGFP plasmids were obtained from Dr Dominic Mills (LSHTM). C. jejuni 
competent cells were prepared and 1 µg of the purified eGFP plasmid DNA was used to 
transform the C. jejuni 81-176 or 11168H wild-type strains. Positive clones were 
selected on blood agar plates containing chloramphenicol. Plates were incubated for 24 
h under microaerobic conditions. Positive colonies were tested by PCR using eGFP-
Forward and eGFP-Reverse primers for the presence of eGFP gene (720 bp) and 
confocal microscopy for the expression of the eGFP.  
                   1         2         3        4         5         6         7        8           9       10       11     12 
 
 
Figure 3.10. PCR verification of Evoglow® genes and C. jejuni expressing Evoglow® and 
eGFP genes. Lane 1: 1 Kb ladder (Bioline). Lane 2: Negative control. Lane 3: Evoglow® bs1. 
Lane 4: Evoglow® pp1. Lane 5: pRRC-bs1-construct. Lane 6: pRRC-pp1-construct. Lane 7: 
11168H Evoglow® bs1. Lane 8: 81-176 Evoglow® bs1. Lane 9: 11168H Evoglow® pp1. 
Lane 10: 81-176 Evoglow® pp1. Lane 11: eGFP 11168H. Lane 12: eGFP 81-176 
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3.3.3 Comparison of eGFP versus Evoglow® expressing C. jejuni strains   
Following construction of eGFP and Evoglow® expressing C. jejuni wild-type strains, 
mean fluorescence intensity (MFI) was analysed and compared using confocal 
microscopy. The eGFP expressing strains displayed higher levels of fluorescence 
compared to the Evoglow® expressing C. jejuni strains (see Figure 3.11).  
 (A)                                  (B) 
  
(C) 
  
Figure 3.11 Confocal images of C. jejuni strains expressing eGFP. C. jejuni strains 
expressing eGFP were harvested from overnight broth cultures and samples were prepared for 
confocal microscopy by placing a suspension of the bacterial culture onto a sterile slide. A 
cover slip was placed on top, sealed with nail varnish and visualised using a confocal 
microscope. (A) 81-176 expressing eGFP (B) 11168H expressing eGFP (C) 81-176 wild-type 
control.  
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C. jejuni strains expressing Evoglow® (pp1 or bs1) were also investigated using 
confocal microscopy and displayed significantly lower levels of fluorescence compared 
to the eGFP expessing C. jejuni 81-176 and 11168H strains (see Figure 3.12). 
(A)              (B) 
     
(C) 
    
Figure 3.12 Confocal microscopy images of C. jejuni expressing Evoglow. C. jejuni strains 
expressing Evoglow® were harvested from overnight cultures and samples were prepared for 
confocal microscopy by placing a suspension of the bacterial culture onto a sterile slide. A 
cover slip was placed on top, sealed with nail varnish and visualised using a confocal 
microscope. (A) C. jejuni 11168H expressing Evoglow® pp1 and (B) C. jejuni 81-176 
expressing Evoglow® bs1 (C) 81-176 wild-type control. 
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3.3.4 Comparison of the fluorescence intensity of C. jejuni expressing eGFP and 
Evoglow® using Volocity software. 
In order to quantify the levels of fluorescence emitted from C. jejuni strains expressing 
either eGFP or Evoglow®, volocity software was used to measure the mean 
fluorescence intensity. A Zeiss LSM510 confocal microscope was used to 
capture images of eGFP or Evoglow® expressing C. jejuni strains. Image capture 
settings were not altered between samples to ensure the fluorescent intensities of the 
different samples were comparable. Images were imported into Volocity software and 
the fluorescence intensities of the bacteria were quantified. The results were calculated 
using Volocity software and statistical analysis was performed using GraphPad Instat 
statistical software. 
 
Figure 3.13 Volocity software screen grab displaying the quantification of fluorescence 
from confocal images. Confocal image results were loaded into Volocity software and mean 
fluorescence was calculated for eGFP and Evoglow® expressing C. jejuni strains. 
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Quantification of the fluorescence intensity produced by eGFP and Evoglow® 
expressing C. jejuni strains was plotted in Graphpad. The eGFP expressing C. jejuni 
strains produced a significantly higher level of fluorescence compared to the 
Evoglow®. E. coli expressing eGFP was grown aerobically and included as a control. 
 
Figure 3.14 Comparison of the mean fluorescence intensity of eGFP and Evoglow® 
expressing C. jejuni strains. Mean fluorescence intensity of C. jejuni expressing eGFP or 
Evoglow® was quantified using Volocity software. Asterisks denote a statistically significant 
difference (*** = p <0.001). Data is representative of three independent experiments. 
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3.3.5 Infection of Caco-2 intestinal epithelial cells with Evoglow® expressing C. 
jejuni  
In order to view the interaction of Evoglow® expressing C. jejuni with Caco-2 IECs, 
following infection, the IECs were stained with DAPI and Phalloidin and viewed with 
the confocal microscope. eGFP expressing C. jejuni was also tested but resulted in only 
a few bacteria been visualised (data not shown).  
 
Figure 3.15 Confocal images of C. jejuni expressing Evoglow® co-cultured with Caco-2 
intestinal epithelial cells. C. jejuni 81-176 expressing Evoglow® were co-cultured with Caco-2 
IECs for 3 h. The slides were fixed and stained with Phalloidin for actin (red) and nuclein for 
DNA (blue), then analysed for green fluorescent bacteria (indicated by white arrows) with the 
confocal microscope. 
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3.3.6 Anti-C. jejuni antibody staining to distinguish between adhered and invaded 
bacteria using Caco-2 IECs 
Following the unsuccessful attempts at visualising Evoglow® expressing C. jejuni 81-
176 or 11168H, antibody staining was utilised to study the localisation of both 
extracellular and intracellular C. jejuni following co-culture with Caco-2 IECs. To 
distinguish between extracellular and intracellular bacterial localisation, non-
permeabilised cells were stained with rabbit anti-C. jejuni antibody (Abcam) followed 
by Alexa Fluor 488 conjugated Goat anti-rabbit IgG (Molecular Probes). Cells were 
then stained with anti C. jejuni antibody in the presence of saponin (Sigma, 10% stock 
diluted 1:20 in PBS+5% FCS) to permeabilise cells, followed by Alexa fluor 568 
labelled goat anti-rabbit IgG (Molecular Probes). The latter treatment allowed for 
additional staining of extracellular Alexa fluor 488-labelled bacteria leading to a yellow 
appearance (merging of green Alexa fluor 488 and red Alexa fluor-568). In contrast, 
intracellular bacteria remained red, only acquiring the Alexa fluor 568 stain. Cell nuclei 
were counterstained with DAPI. Coverslips were then mounted in Vectashield (Vector 
Laboratories) and imaged on a Zeiss LSM 510 confocal microscope.  
(A)  
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(B) 
  
(C) 
 
Figure 3.16 Demonstration of C. jejuni interaction with and invasion of Caco-2 IECs by 
confocal microscopy. Bacteria were co-cultured with Caco-2 IECs grown on cover slips for 2 
h. IECs were fixed and then stained with anti-C. jejuni antibody. (A) 2 h extracellular (yellow) 
and intracellular (red) C. jejuni 81-176 (B) 2 h extracellular (yellow) and intracellular (red) C. 
jejuni 11168H. (C) Caco-2 IECs control. Representative images from two experiments 
(performed in triplicate) are shown. 
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Demonstration of both extracellular (yellow) C. jejuni and intracellular (red) C. jejuni 
81-176 wild-type in Caco-2 IECs after 2 h infection (see Figure 3.17).  
(A)  
 
 (B) 
 
Figure 3.17 Demonstration of extracellular and invading C. jejuni of Caco-2 IECs by 
confocal microscopy. (A) Extracellular (yellow) C. jejuni 81-176 after 2 h infection, (B) 
Intracellular (red) C. jejuni 81-176 after 2 h infection. 
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3.4 Discussion  
The aim of this chapter was to reinvestigate C. jejuni adhesion to and invasion of IECs. 
Initial work was carried out to choose a suitable strain for the above inhibition of 
invasion studies. C. jejuni displays varying levels of invasion depending on the cell line 
being utilised (see Section 1.2.4). Phenotypic characterisation showed that 81-176 
displayed marginally increased levels of motility compared to 11168H. The 81-176 
wild-type strain displayed higher numbers of bacteria interacting with and invading both 
Caco-2 and T84 IECs than the 11168H wild-type strain. Due to the 81-176 wild-type 
strain exhibiting higher levels of invasion, this strain was chosen to use in further 
studies for a better indication of inhibitor activity. 
3.4.1 Inhibition of invasion studies 
Tissue culture studies with C. jejuni using IECs have shown that C. jejuni is capable of 
utilising a number of host cellular pathways to gain access to the host cell (Oelschlaeger 
et al., 1993, Russell and Blake, 1994, Hu and Kopecko, 1999, Kopecko et al., 2001b, 
Monteville et al., 2003b). Such studies have revealed that C. jejuni invasion routes may 
not be distinct, but require different cellular factors such as microtubules, 
microfilaments or lipid rafts (Young et al., 2007, van Putten et al., 2009, Bouwman LI 
2012). These cellular pathways have previously been reported to be disrupted using 
different biochemical inhibitors, but the effect on C. jejuni interaction and invasion of 
IECs has produced varying results creating confusion in the literature.  
The host cell structure is composed of numerous building blocks of complex proteins 
such as actin which make up the microfilaments and tubulin that make up the 
microtubules (Granger et al., 2014). These structures have been shown to play pivotal 
roles in the mechanics of the host cell (Stossel, 1993, Small, 1994, Lauffenburger and 
Horwitz, 1996, Mitchison and Cramer, 1996). The disruption of microfilaments using 
CytD, a potent inhibitor of actin polymerisation, resulted in significant increases in 
invading bacteria. This increase in the numbers of intracellular C. jejuni within IECs 
pre-treated with CytD could be a result of the actin disruption and retractions, allowing 
C. jejuni bacteria to gain access to the subcellular space of the IECs via the base of the 
IEC. A previous study reported that some strains of C. jejuni were capable of efficiently 
gaining access to the subcellular space possibly by entering through M cells, with 
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migrating bacteria moving underneath the IEC and then entering, thereby avoiding the 
potentially hostile environment (Everest et al., 1993, Walker et al., 1988, van Alphen et 
al., 2008). Disruption of actin could possibly allow more access to these subspaces.  
Other researchers have reported that pre-treatment of IECs with CytD enhances C. 
jejuni internalisation, possibly by removal or damage of the actin structure, therefore 
actin depolymerisation and subsequent polymerisation are probably required for C. 
jejuni entry (Hu and Kopecko, 1999, Watson and Galan, 2008b).However, other 
researchers reported a decrease in C. jejuni invasion in the presence of CytD and the 
mixed involvement of both microtubules and microfilaments during 81-176 invasion 
(Monteville et al., 2003b, Schlaepfer et al., 1999). These differences could be attributed 
to the different methods employed such as centrifugation of monolayers in order to aid 
contact between bacteria and the IEC (Flanagan et al., 2009, Novik et al., 2010). The 
gentamicin protection assay (GPA) step can also be variable in both concentration and 
time-length, as some researchers use 250 µg/ml for 3 h (Buelow et al., 2011a), whereas 
another group reported 150 µg/ml for 2 h to be sufficient to kill extracellular bacteria 
(Novik et al., 2010). In this study 150 µg/ml of gentamicin for 2 h was found to be 
sufficient in killing extracellular bacteria. 
The infection period of IECs is another variable, a minimum of 30 minutes to 3 h 
incubation periods have been utilised (Monteville et al., 2003a). Different strains of C. 
jejuni and different IEC lines have been used in C. jejuni invasion studies which may 
explain some of the differences reported (Friis et al., 2005, O. Croinin and Backert, 
2012). In some inhibition of invasion studies with C. jejuni, inhibitors have been kept in 
the media throughout the infection period, whereas in this study Caco-2 IECs were pre-
treated with the inhibitor and then washed prior to addition of bacteria (Oelschlaeger et 
al., 1993, Watson and Galan, 2005). 
The next pathway to reinvestigate was the role of caveola-mediated endocytosis in C. 
jejuni internalisation. These microdomains are found in the host cell membrane and 
contain cholesterol, proteins, sphingolipids and can act as surface platforms that allow 
bacterial interactions, binding and even internalisation (Pike, 2003, Lafont and van der 
Goot, 2005). Bacteria have been shown to utilise these microdomains and an advantage 
of this pathway is the avoidance of fusing with lysosomes (Zaas et al., 2005). In this 
study, the use of MβCD as a cholesterol depleting agent showed that interactions and 
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invasion of C. jejuni with Caco-2 IECs were significantly reduced. A slight increase in 
the numbers of interacting bacteria was observed at the 6 h time-point, possibly due the 
bacteria making use of other cellular pathways, hence the increase in the number of 
interacting bacteria at later time-points. It has also been reported that infection of IECs 
with C. jejuni can cause an accumulation of lipid rafts localised to one area, whereby 
interaction between C. jejuni and lipid rafts is therefore increased, leading directly to 
interactions with more of the cholesterol enriched domains (Lafont and van der Goot, 
2005, Kalischuk et al., 2009). 
Similar results published using MβCD and other cholesterol depleting agents are 
consistent in that C. jejuni cellular invasion requires cholesterol to be present in the cell. 
Bacteria such as Salmonella enterica serotype Typhimurium and C. jejuni have been 
found to utilise caveolae for internalisation as treatment of IECs with Fillipin III (which 
also binds to cholesterol) or MβCD, caused inhibition of bacterial internalization (Lim 
et al., 2010). Previous studies have also shown that disruption of lipid rafts using 
Fillipin III or MβCD produced a reduction in 81-176 and N82 wild-type invasion of 
Caco-2, T84 and INT407 IECs (Wooldridge et al., 1996b, Hu et al., 2006c, Watson and 
Galan, 2008b, Lim et al., 2010).  
However, a study by Watson and Galan theorised that C. jejuni internalisation was not 
strictly due to the removal of cholesterol from lipid rafts, but the presence of certain 
proteins, such as caveolae or caveolin-1 playing a role in the host cell signalling events 
required for C. jejuni bacterial internalisation (Watson and Galan, 2008a). Studies by 
Konkel et al. indicate that C. jejuni internalisation occurs via a caveolae-independent 
manner (Konkel et al., 2013). To add to the confusion, previous work has supported the 
hypothesis that C. jejuni internalisation occurs in a caveolae-dependent manner, this is 
because caveolin-1 is a cholesterol-binding protein and treating cells with a cholesterol-
depleting agent would also therefore disrupt the levels of caveolin-1 present (Watson 
and Galan, 2008b, Konkel et al., 2013). Disruption and/ or removal of caveolin-1 in 
HeLa cells by treatment with caveolin-1 siRNA had no effect on C. jejuni invasion and 
treatment of Caco-2 IECs with MβCD inhibited C. jejuni internalisation. Further to this, 
the results showed that the action of MβCD is not specifically to target and disrupt the 
caveolae, but to cause the overall disruption of all lipid rafts and hence the removal of 
all cholesterol in the cell. Therefore, blocking the potential action of C. jejuni in 
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triggering the signalling cascade inside the cell by close interactions with fibronectin on 
the outside of the cell (Konkel et al., 2013).  
In eukaryotes, microtubules are important structural components of cells (Valiron et al., 
2001). MTs serve as tracks within the cell cytoplasm allowing vesicles and proteins to 
be trafficked via motor-driven transport (Watson and Galan, 2008b, Granger et al., 
2014). MTs have been found to play vital roles in the maintenance of cell shape and 
chromosome segregation in mitosis and as such microtubules are dynamic structure and 
function (Winsor and Schiebel, 1997, Granger et al., 2014). To investigate the potential 
involvement of MTs in internalisation of C. jejuni, disruption of MTs in Caco-2 IECs 
with the inhibitor colchicine resulted in a significant reduction in the levels of 
interacting and invading bacteria. The results obtained in this study show that over the 
infection period, the interaction with and invasion of Caco-2 IECs by C. jejuni changed 
dramatically and the results were similar to previous reports, showing that C. jejuni 
exhibited a reduction in invasion in the presence of MT inhibitors (Oelschlaeger et al., 
1993, Kopecko et al., 2001a, Biswas et al., 2003).  
The exact role of MTs in C. jejuni invasion is not fully understood and the reduction in 
invasion is thought to be due to the MTs role in stimulating focal adhesion contacts and 
modulation of the cells adhesion ability to the ECM, as the use of MT inhibitors 
increases this adhesion to the ECM (Ballestrem et al., 2000). Another possible 
explanation for the role of MTs is the involvement of these structures in trafficking 
proteins into the cell, following uptake of C. jejuni by MTs, the bacteria could also be 
transported to the perinuclear region at the centre of the cell allowing direct interaction 
with the host cell machinery (Konkel and Cieplak, 1992, Clausen et al., 1997, Hu and 
Kopecko, 1999). A similar process has been observed in C. freundii whereby the 
invading bacteria replicates in an actin-dependent lamellipodia (Badger et al., 1999).  
The inhibitory effect of microtubule-depolymerising agents on the entry of C. jejuni 
strain 81-176 has been noted previously (Oelschlaeger et al., 1993, Hu and Kopecko, 
1999, Bacon et al., 2000, Kopecko et al., 2001a). This data is comparable with the 
results observed in this study with colchicine, as the number of interacting and invading 
C. jejuni were significantly reduced in comparison with the no colchicine controls. 
However, the results reported in the literature with regard to C. jejuni invasion and the 
involvement of MTs is varied. Some researchers report a reduction in C. jejuni invasion 
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in the presence of MT inhibitors and C. jejuni 81-176 is the only strain that has been 
found to be internalised via the microtubule-dependent pathway (Oelschlaeger et al., 
1993, Hu and Kopecko, 1999, Kopecko et al., 2001a). In contrast to these results, 
previous work has shown that there was no reduction in C. jejuni invasion of Caco-2 
IECs following inhibition of MTs and other studies have reported the involvement of 
both MFs and MTs in internalisation of C. jejuni 81-176 (Russell and Blake, 1994, 
Monteville et al., 2003b). The differences observed between the above two studies 
could be due to the fact that Kopecko’s group experiments involved maintaining the 
inhibitor in the medium, the cell lines used were Caco-2 and INT407 IECs, grown for 
24 h to partial confluency, an MOI of 20 was used and monolayers were not 
centrifuged. Incubations were performed for 2 h and the lysis step was performed at 
room temperature (Hu and Kopecko, 1999). In contrast, Konkel’s group pre-incubated 
the INT407 IECs with inhibitors for 45 minutes, prior to the addition of 5 x 107 cfu of 
F38011 wild-type strain, followed by centrifugation of the monolayers. The inhibitors 
were maintained throughout the infection period. Adhesion assays were performed after 
a 2 h incubation and invasion assays were performed after a 3 h incubation (Monteville 
et al., 2003b). Russell and Blake reported no involvement of MFs or MTs with the 81-
176 wild-type in Caco-2 IECs. In Russell and Blakes study, Caco-2 IECs were grown 
for around 72 h, pre-treatment of IECs was performed 30 minutes prior to the addition 
of 3 x 109 cfu of the 81-176 wild-type and incubations were performed for 30 min to 2.5 
h. This group reported that centrifugation of the bacteria onto the monolayers for 10 
minutes at 500 or 1000 rpm resulted in a significant increase (42% and 83%) in the 
number of cell-associated bacteria, compared to no centrifugation step (Russell and 
Blake, 1994). It is clear that there is no standardised technique and a wide variety of 
experimental variations have been reported, resulting in the significant levels of 
confusion in the literature with regard to C. jejuni invasion mechanisms. 
The main reason for the diarrhoeal symptoms of C. jejuni infection is presumed to be 
due to the tissue damage incurred during the course of infection, as previous studies on 
intestinal biopsies from infected patients have shown that C. jejuni is capable of 
invading the gut and the same observation has also been made using in vitro tissue 
culture studies (van Spreeuwel et al., 1985, Oelschlaeger et al., 1993). Despite this 
evidence, our understanding of the molecular mechanisms involved in tissue damage 
are in their infancy compared to our knowledge of other enteropathogens such as 
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Escherichia coli, Shigella species, Salmonella species and Yersinia species (Young et 
al., 2007). Recent studies have showed that Rho GTPases Rac1 and Cdc42 play a role 
in the membrane ruffling observed prior to C. jejuni internalisation (Krause-
Gruszczynska et al., 2007a). Previous studies have found that C. jejuni invasion of 
INT407 IECs requires a functional bacterial CadF, leading to activation of host cell 
proteins, such as Paxillin (an integrin associated protein), resulting in cytoskeletal 
changes and allowing internalization of C. jejuni (Monteville and Konkel, 2002, 
Monteville et al., 2003a). Recent data has shown that FAK and protein kinases such as 
EGFR and platelet derived growth factor receptor (PDGFR) are stimulated by C. jejuni 
and are involved in the uptake of cells (Krause-Gruszczynska et al., 2007a, Krause-
Gruszczynska et al., 2011, Boehm et al., 2012, Eucker and Konkel, 2012a). 
In this study, the use of wortmannin, a potent inhibitor of PI3-kinase was used to assess 
the possible role of host cell kinases in C. jeuni internalisation. The results obtained 
using this inhibitor produced a significant reduction in the number of interacting and 
invading C. jejuni. Previous studies with wortmannin have produced a significant 
reduction in the number of intracellular C. jejuni N82 in Caco-2 IECs following an 
incubation period of 3 h (Wooldridge et al., 1996b). Another group reported that the 
pre-treatment of Caco-2 IECs with Staurosporine (a general inhibitor of tyrosine 
phosphorylation) significantly reduced the invasion ability of a number of C. jejuni 
strains, indicating that tyrosine protein kinase activity in host cells may be essential for 
C. jejuni invasion (Biswas et al., 2004). This study used a large number of strains and 
inhibition of invasion studies were performed similar to Konkel’s method with 
inhibitors maintained throughout the 3 h infection period (Biswas et al., 2004). 
These results indicate that C. jejuni is capable of activating down-stream signalling 
pathways by activating integrin receptors, as blocking the activity of host proteins, such 
as PI3-kinase and MAP kinases, inhibits C. jejuni bacterial invasion. (Hu et al., 2006b). 
The results observed here are similar to those reported by other researchers, as 
pharmacological studies using specific inhibitors of host cell proteins have found that 
EGF, PDGFR, PI3-kinase, protein kinase C (PKC) and MAPKs are utilised by C. jejuni 
and have been reported to play key roles in the events leading to C. jejuni internalisation 
(Wooldridge et al., 1996b, MacCallum et al., 2005, Hu et al., 2006b, Watson and 
Galan, 2008b). However, some reports contradict the effect of wortmannin on C. jejuni 
invasion as treatment of INT407 IECs with wortmannin had no significant effects on C. 
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jejuni invasion (Biswas et al., 2000). Biswas et al. reported that wortmannin (1 mM) 
exhibited an insignificant effect (<10%) on the internalisation of C. jejuni into INT407 
IECs following an infection period of 3 h. Again, the bacterial strain used, the cell line, 
type and concentration of inhibitor, monolayers being centrifuged and infection period 
are variables that could result in disparate results. 
In order to ascertain whether clathrin-mediated endocytosis is required for C. jejuni 
internalisation, Caco-2 IECs were pre-treated with MDC which resulted in a significant 
reduction in the number of interacting and invading bacteria compared to no pre-
treatment controls. This indicates that some receptors required for C. jejuni interactions 
are located in coated pits in the cell membrane (Ketley and Konkel, 2005, Hu et al., 
2006c). MDC has previously been found to block internalisation of numerous C. jejuni 
strains including 81-176 (Konkel et al., 1992b, Oelschlaeger et al., 1993, Wooldridge et 
al., 1996a, Kopecko, 2000), indicating a likely role for clathrin-mediated endocytosis in 
C. jejuni entry. 
A number of other pathogens have also been found to utilise the clathrin-mediated 
pathway. S. aureus entry into host cells requires several host mechanisms including 
clathrin-coated pits and receptor-mediated endocytosis (Ellington et al., 1999). Previous 
studies showed that cell invasion by C. jejuni and C. freundii may involve clathrin-
receptor-mediated endocytosis (Oelschlaeger et al., 1993). Contrasting data to this 
reported that no inhibition of C. jejuni internalisation occurred in Caco-2 IECs when the 
inhibitor MDC was used, suggesting that this pathway was not an important entry route 
in C. jejuni invasion (Russell and Blake, 1994). The differences reported could possibly 
be due to differences in experimental technique, as Oelschlaeger et al. used C. jejuni 81-
176 wild-type strain and the INT407 cell line or the human bladder cell line T24, with 
an OD600 of ~ 0.4-0.6 bacteria added to the IECs and monolayers were then centrifuged 
at 200 rpm to aid contact. The Inhibitor MDC (250 mM) was maintained throughout the 
incubation period (2 h) (Oelschlaeger et al., 1993). In contrast, Russell and Blake used 
Caco-2 IECs, the MDC concentration used was 0.5 mM to 1 mM and maintained 
throughout the 2.5 h infection period. An OD600 0.8 was used to infect the Caco-2 IECs 
and monolayers were centrifuged for 10 minutes to aid contact between bacteria and 
IECs. 
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An important and protective feature of the gut epithelium in vivo is cell polarity. 
Polarised intestinal epithelial cells display distinct apical and basolateral surfaces 
separated by tight junctions and also possess microvilli structures with a well-defined 
brush border expressing several defined marker proteins (Backert et al., 2013). 
Therefore polarised cell models are particularly useful for studying microbial 
interactions, disruption of TEER and route of invasion.  Many important gut pathogens 
such as Listeria, Salmonella and Shigella have developed strategies to cross this 
epithelial barrier, gain access to submucosal tissues, triggering tissue damage and 
causing disease in humans. For example, Salmonella invades differentiated Caco-2 cells 
via the apical surface (Finlay and Falkow, 1989) whereas Shigella invades differentiated 
Caco-2 IECs via the basolateral surface (Mounier et al., 1997). Y. pseudotuberculosis 
invades undifferentiated cells that express large amounts of the β1 integrin receptor for 
invasin, (a bacterial effector protein associated with uptake by epithelial cells) (Isberg 
and Van Nhieu, 1994). In contrast, L. monocytogenes is capable of entering through the 
entire surface of non-polarised Caco-2 IECs but only through the basolateral surface of 
polarised Caco-2 monolayers (Gaillard and Finlay, 1996). TEM studies have revealed 
that C. jejuni invasion proceeds from the apical to the basolateral surface of Caco-2 
IECs by passing both through and between cells (Konkel et al., 1992c).  
C. jejuni has previously been reported to traverse intact monolayers without causing 
significant disruption to the TEER (Konkel et al., 1992c). In contrast, infection of cell 
monolayers with S. typhimurium has been found to cause significant disruption to the 
TEER and changes in cell morphology. C. jejuni invasion of IECs was peformed in this 
study using polarised intact monolayers, thereby more closely mimicking the in vivo 
conditions present in the human gut. C. jejuni does not efficiently invade polarised 
Caco-2 IECs apically or induce membrane ruffling in this cell line. This could be due to 
the fact that the ECM components of Caco-2 and T84 IECs are basolaterally located and 
since the basolateral membrane is rich in ECM components such as fibronectin, laminin 
and collagen, thus a polarised monolayer would prove difficult to invade by C. jejuni. 
Ideally, C. jejuni basolateral invasion of Caco-2 and T84 IECs could also have been 
investigated using IECs grown on Transwells filters, such studies should enhance the 
data obtained from this study. 
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The literature reports surrounding C. jejuni invasion of IECs is varied and confusing (O. 
Croinin and Backert, 2012). The interactions appear to be complex in comparison to 
other enteric pathogens such as S. flexneri, S. typhimurium and Yersina species which 
enter host cells via a MF-dependent process (Clerc and Sansonetti, 1987, Finlay et al., 
1991, Jones et al., 1993). The literature seems to show that the specificity of cell line 
and the presence or absence of specific receptors may be involved in the preferential 
mechanisms of endocytosis of the bacteria into the different cell lines (O. Croinin and 
Backert, 2012). In summary, the current data seems to suggest that different strains of 
C. jejuni invasion strategies may require MTs or MFs, both or neither. After decades of 
research the C. jejuni mediated triggers that lead to MT or MF rearrangements and 
eventual internalization are yet to be fully elucidated (O. Croinin and Backert, 2012). 
The percentage of the initial inoculum of interacting C. jejuni recovered following 
inhibition of interaction at the 24 h time point showed the number of interacting C. 
jejuni recovered was highest for the IECs pre-treated with CytD, followed by MDC. 
The biggest difference observed was in the percentage of the initial inoculum of 
intracellular C. jejuni recovered where pre-treatment of IECs with CytD at the 24 h 
time-point showed a higher number of intracellular bacteria being recovered compared 
to between 1% and 4% of intracellular bacteria recovered for the remaining inhibitors, 
indicating a possible role for the actin cytoskeleton in C. jejuni internalisation. 
Inhibitors of bacterial invasion produced varying results in the numbers of interacting 
with and invading bacteria, indicating that C. jejuni is able to invade more when the 
actin structure was disrupted, equally the disruption of MTs indicated that this is a 
pathway utilised by C. jejuni 81-176 strain and this reflects data from previous studies 
that have reported this strain invades IECs apically, by a strong MT dependent pathway 
(Hu and Kopecko, 1999, Bacon et al., 2000). In addition, 81-176 was significantly 
reduced in invasion after MβDC treatment and PI3-kinase inhibition, an indication that 
C. jejuni is capable of the stimulation of putative receptor(s) located in these caveola 
sites which in turn could activate the PI3-kinase and MAP kinases, eventually leading to 
cytoskeletal rearrangements (Oelschlaeger et al., 1993, Wooldridge et al., 1996b, Hu 
and Kopecko, 1999, Biswas et al., 2000, Hu et al., 2006c). 
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3.4.2 Visualisation of C. jejuni within IECs 
The next part of this study was to visually determine the co-localisation of C. jejuni 
within Caco-2 IECs, using either eGFP or Evoglow® expressing C. jejuni strains and 
anti-C. jejuni antibody labelling to determine the location of both intracellular and 
extracellular bacteria. Evoglow® was chosen on the basis that the expression of these 
fluorescent proteins did not require oxygen as a co-factor and therefore would be more 
suitable for studies performed under low oxygen conditions. Prior to testing the strains 
in confocal studies, the levels of mean fluorescence intensity were compared to 
ascertain whether there were any significant differences in fluorescence. To determine 
the mean fluorescence intensity of eGFP and Evoglow® expressing C. jejuni strains, the 
levels of fluorescence emitted was measured using Volocity software. The analysis of 
the confocal data was imported in to the Volocity software showed that eGFP 
expressing C. jejuni produced significantly higher levels of fluorescence compared to 
the Evoglow® expressing C. jejuni. Therefore, both eGFP and Evoglow® expressing C. 
jejuni were tested in confocal microscopy studies. 
Interaction and invasion assays were performed using the eGFP and Evoglow® 
expressing C. jejuni strains to ensure the presence of either the eGFP or Evoglow® 
genes did not affect the interaction and invasion ability of these strains. No significant 
differences were observed in interactions with and invasion of Caco-2 IECs compared 
to the control 81-176 and 11168H wild-type strains (see Section 3.2.2). 
Following infection of Caco-2 IECs with Evoglow® expressing C. jejuni, little or no 
bacteria were observed either extracellularly or intracellularly. The experiments were 
repeated with the same results observed on each occasion. The Evoglow® expressing C. 
jejuni was effective in fluorescence intensity during growth in the VAIN. However, the 
fluorescence signal seemed to reduce significantly once co-cultured with Caco-2 IECs. 
eGFP expressing C. jejuni were also tested to measure the fluorescence signal. The 
eGFP expressing C. jejuni produced sufficient fluorescence to warrant testing this strain 
during invasion of Caco-2 IECs. The eGFP expressing C. jejuni was used to infect 
Caco-2 IECs, however following the required incubation period, only a few bacteria 
were visible and the fluorescent signal reduced significantly whilst being observed. The 
same result was observed on each occasion.  
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Due to the difficulties encountered with the use of eGFP and Evoglow® fluorescence in 
microscopy studies, anti-C. jejuni antibody staining was performed to distinguish 
between extracellular and intracellular C. jejuni, to track the route, course and co-
localisation of the bacteria within the IECs. Caco-2 IECs were infected with the 81-176 
wild-type strain and incubated for 2 h, 3 h and 6 h. After 2 h of infection, both 
extracellular and intracellular C. jejuni were observed. Few bacteria were found to be 
internalised, whilst the majority were extracellular. Previous studies have reported the 
efficiency of internalisation was the highest at the lower end of the MOI (0.02) and 
decreased with higher MOIs due to AAG of C. jejuni at higher MOIs and the maximum 
MOI reported for INT407 IECs was 200 with invasion occurring at the 4 h time-point 
(Hu and Kopecko, 1999). A large contrast, in comparison to S. typhi which was capable 
of invading within 1 h of infection of INT407 IECs (Hu and Kopecko, 1999). The 
numbers of C. jejuni internalised depend on the growth phase of the bacteria and the age 
of the cell line being utilised, as the highest efficiency of invasion of Caco-2 IECs has 
previously been observed at lower MOI (0.02) in 1 day old Caco-2 IECs. C. jejuni was 
found to enter 7 to 15 day old differentiated Caco-2 IECs at substantially lower invasion 
efficiencies (Hu et al., 2008). The low levels of internalised bacteria under standard 
tissue culture conditions in this study reflect the results reported in the literature (Friis et 
al., 2005).  
Previous studies on C. jejuni in host cell association assays showed that C. jejuni was 
capable of interacting with around 80% of INT407 IECs, in contrast, only 20% of Caco-
2 IECs were reported to interact with by C. jejuni (Hu et al., 2008). C. jejuni invasion of 
INT407 IECs was rapid and occurred within 10 min, increasing gradually over the 
infection period with around 2 bacterial cells being internalised. In contrast, Caco-2 
IECs internalised far fewer bacterial cells (1-20 C. jejuni) after a 2 h infection period 
(MacCallum et al., 2005, Hu et al., 2008). The researchers suggested that these large 
variations in numbers of C. jejuni being internalised was possibly due the Caco-2 IECs 
undergoing differentiation, resulting in the lack of availability of a putative invasion 
receptor (Levy et al., 1994). The presence of certain M-like Caco-2 IECs containing 
internalised C. jejuni were found to collapse during the infection period suggested that a 
small number of the differentiated IECs were still susceptible to C. jejuni invasion 
(MacCallum et al., 2005, Hu et al., 2008). C. jejuni 81-176 intracellular survival studies 
using T84 IECs reported that the following internalisation the bacteria were shown to be 
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contained within CCVs and that the bacteria were capable of survival within IECs and 
this intracellular survival decreased over the 24 h period. Internalisation of the bacteria 
into macrophages resulted in rapid killing (Russell and Blake, 1994, Watson and Galan, 
2008b). 
3.4.3 Limitations of the study 
Due to time constraints in this study, one cell line was utilised for inhibition of invasion 
studies. The use of other cell lines would provide further data in characterising the 
possible cellular pathways this bacterium utilises for entry. In addition, different strains 
of C. jejuni could be used, different combinations of inhibitors with the use of the C. 
jejuni mutants constructed in this study to further characterise the possible cellular 
pathways. Variations on assay time length as in this study, the dynamics of C. jejuni 
interactions with and invasion of Caco-2 IECs showed clear differences in numbers of 
bacteria interacting with and invading IECs. In addition, the tissue culture studies 
performed did not involve centrifuging the monolayers to aid contact between bacteria 
and IECs so as to study the realistic behaviour of the interactions between C. jejuni and 
the IEC. eGFP and Evoglow® expressing C. jejuni strains failed to provide data that 
would allow the tracking, visualisation and localisation of the wild-type and the 
mutants. The problems encountered involved a lack of fluorescence signal once C. 
jejuni was internalised into IECs, this procedure was time consuming and despite 
fluorescence being detectable under microaerobic conditions the results were non 
reproducible with IEC infection studies under standard tissue culture conditions. 
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Chapter 4. Reinvestigation of the role of CiaB in C. jejuni 
invasion of intestinal epithelial cells 
4.1 Introduction 
The adhesion of C. jejuni to host IECs, activation of host cytoskeletal rearrangements 
and eventual bacterial entry into the host cell has been found to be an essential early 
process in the course of C. jejuni pathogenesis and was first evident from human 
intestinal biopsy samples (van Spreeuwel et al., 1985). The method by which C. jejuni 
achieves this is still unclear, yet a multitude of bacterial factors have been reported to be 
involved in C. jejuni invasion of IECs, such as motility, involvement of flagella, 
glycosylation, capsule and adherence proteins on the surface of C. jejuni (Grant et al., 
1993, Pei et al., 1998, Bacon et al., 2001, Konkel et al., 2001, Szymanski et al., 2002). 
Research has shown that mutation of genes encoding proteins involved in these 
processes have resulted in a reduction in attachment and invasion of human cell lines, 
mice or chicken cell lines (Hendrixson and DiRita, 2004, Watson and Galan, 2008b, 
Novik et al., 2010). C. jejuni was reported to trigger membrane ruffling via direct 
contact with the host cell followed by insertion with first the flagella tip, then with the 
opposite flagella end (Krause-Gruszczynska et al., 2007a, Krause-Gruszczynska et al., 
2011, O. Croinin and Backert, 2012). Work by Konkel's group found that C. jejuni 
synthesised a set of proteins upon co-culturing with INT407 IECs, termed 
Campylobacter invasion antigens (Cia proteins) (Konkel et al., 1999c). Campylobacter 
invasion antigen B (CiaB) is the most widely studied and was found to exhibit a weak 
amino acid similarity to T3SS effector systems present in other pathogens, CiaB has 
been found to exhibit 45% similarity to Salmonella invasion protein B (SipB) from 
Salmonella typhimurium. CiaB also showed 40.6% amino acid similarity to Shigella 
flexneri invasion plasmid antigen B (IpaB) and Yersinia outer protein B (YopB) from 
Yersinia pseudotuberculosis (Konkel et al., 1999b).  
Mutation of ciaB did not affect the adherence of C. jejuni to INT407 IECs, but the 
numbers of intracellular bacteria were significantly reduced (Monteville and Konkel, 
2002). CiaB was also found to be important in the secretion of other Cia proteins 
(Konkel et al., 1999b). CiaB was reported to be directly translocated into the host cell, 
indicating a role as a potential bacterial effector molecule (Konkel et al., 1999b). 
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Further studies found CiaB secretion to be affected when genes encoding proteins 
involved in flagella biosynthesis were mutated, suggesting that secretion of CiaB 
required the presence of a fully functional flagella (Konkel et al., 2004). Little is known 
about the bacterial virulence factors that are potentially involved in mediating C. jejuni 
entry and intracellular survival. Non-motile mutants are significantly decreased in 
ability to invade IECs (Wassenaar et al., 1991, Grant et al., 1993, Yao et al., 1994). 
However, this data still fails to answer the question of whether the flagellar structure has 
a direct role in enabling C. jejuni internalisation or whether the non-motile mutants are 
severely hampered in entering cells, possibly suggesting that it is motility that is 
required for invasion (Szymanski et al., 1995). To date, four Cia proteins have been 
identified CiaB, (Konkel et al., 1999b). CiaI (Buelow et al., 2011b), CiaC (Neal-
McKinney and Konkel, 2012) and CiaD (Samuelson et al., 2013). However, other 
researchers have cast doubt over the role of CiaB as a 81-176 ciaB mutant showed no 
difference in invasion ability compared to the wild-type strain (Novik et al., 2010). The 
aim of this chapter was to reinvestigate the role of CiaB in C. jejuni interactions with 
and invasion of IECs.  
Results 4.2 
4.2.1 Chromosomal location of ciaB 
The chromosomal location of the ciaB gene in C. jejuni 81-176 and 11168H strains was 
viewed in Artemis software, with adjacent genes listed below. 
C. jejuni 81-176 ciaB upstream genes are Cjj81-176_0923/cstA (probable MCP protein 
methyltransferase/chemotaxis and motility), prsA (ribose-phosphate 
pyrophosphokinase) and 81-176 ciaB downstream genes are hup (DNA binding 
protein), cysK (cysteine synthase A), Cjj81-176_0915 (putative hydrolase), Cjj81-
176_0913 (DNA binding protein). 
C. jejuni 11168H ciaB upstream genes are Cj0916c (conserved hypothetical protein), 
cstA (carbon starvation protein A), prsA (ribose-phosphate pyrophosphokinase), 
Cj0919c (putative ABC-type amino-acid transporter permease) and 11168H ciaB 
downstream are hupB (DNA binding protein), cysM (cysteine synthase B), Cj0906 
(putative periplasmic protein). In both 81-176 and 11168H strains, the upstream genes 
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are similar except in 81-176 the presence of a gene encoding a putative hydrolase is 
different to the putative periplasmic protein present in 11168H. The downstream genes 
are the same in both 81-176 and 11168H respectively. 
(A) 
 
(B) 
 
Figure 4.1 Artemis Images displaying the positions of ciaB and the location of both the up 
and downstream genes in C. jejuni 81-176 (A) & 11168H (B) 
4.2.2 Construction of 81-176 & 11168H ciaB mutants 
Defined isogenic ciaB mutants were constructed in both 81-176 and 11168H wild-type 
strains. The primers ciaB-Forward-81-176/ciaB-Reverse-81-176 and ciaB-Forward-
11168H/ciaB-Reverse-11168H were designed for the amplification of ciaB from 81-176 
& 11168H genomic DNA (gDNA) respectively. PCR reactions were set up using the 
designed primers; PCR products analysed by agarose gel electrophoresis and purified 
using the Qiagen PCR clean up kit. Each purified PCR product was ligated into the 
pGEMT-easy vector, transformed into XL-2 Blue MRF’ competent cells and plated out 
on LB amp agar plates. Colonies selected by growth on LB amp agar were screened by 
boilate PCR to check for the presence of ciaB. Plasmid DNA from positive colonies was 
sequenced to confirm the presence of the correct gene. The cloned ciaB gene fragment 
was disrupted by insertion of a kanamycin cassette (Kmr) (Trieu-Cuot et al., 1985). The 
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Kmr cassette was excised by BamHI from the plasmid pJMK30 (van Vliet et al., 1998). 
The pGEMT-easy-ciaB-81-176/11168H constructs were digested with BglII and ligated 
with the Kmr cassette to form pGEMT-easy-ciaB-81-176/11168H-Kmr. These 
constructs were then transformed into XL-2 Blue MRF’ competent cells, plated onto LB 
amp kan agar plates and incubated at 37°C for 24 h. Transformants were screened by 
PCR using ciaB–gene specific and Kmr-specific primers. Constructs with the Kmr 
cassette in the same orientation as ciaB were selected and electroporated into the 81-176 
or 11168H wild-type strains. Electroporated bacteria were plated onto blood agar plates 
and incubated at 37°C under microaerobic conditions for 2 to 3 days. Cells were 
harvested and resuspended in 0.5 ml PBS. Two hundred microliters of this suspension 
was spread onto blood agar plates containing kanamycin. Plates were incubated at 37°C 
under microaerobic conditions for 2 to 3 days. Putative ciaB mutants were screened by 
PCR and sequencing using gene specific primers to confirm insertion and correct 
orientation of the kanamycin cassette. 
4.2.3 Construction 81-176 & 11168H ciaB complements 
As this study used both C. jejuni wild-type strains, complementation procedures were 
also performed in both strains to confirm that the phenotypes observed were due to the 
mutation and not due to random DNA changes or polar effects. This was performed by 
inserting a copy of the functional ciaB gene and 20 extra bases of the upstream 
sequence into the chromosomes of the mutants. Complementation in 81-176 and 
11168H was performed using a C. jejuni complementation vector pRRC (Karlyshev and 
Wren, 2005). The coding region for ciaB was amplified by PCR using primers 
ciaBcomp-Forward-81-176/ciaBcomp-Reverse-81-176 and ciaBcomp-Forward-11168H 
/ciaBcomp-Reverse-11168H which introduced an XbaI site at both the 5′ and 3′ ends, as 
well as the native ribosome binding site for ciaB. Following digestion with XbaI, each 
PCR product was ligated into the pRRC vector which contains a chloramphenicol 
resistance cassette, transformed into DH5α competent cells and plated onto LB chl agar, 
then incubated at 37°C for 24 hours. Transformants selected on LB chl agar were 
screened by PCR using ciaBcomp-Forward-81-176/ciaBcomp-Reverse-81-176 and 
ciaBcomp-Forward-11168H/ciaBcomp-Reverse-11168H primers and sequencing to 
ensure no mutations had been introduced into the functional ciaB gene. These constructs 
were then electroporated into the respective ciaB mutant. Positive clones were selected 
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on blood agar plates containing chloramphenicol and kanamycin. Confirmation of the 
presence of both the mutated ciaB gene and the functional ciaB was performed by PCR 
using the ciaBcomp-Forward/ciaBcomp-Reverse and ciaB gene-specific Forward 
/Reverse primers and also by sequencing.  
The size of ciaB is 1.86 kb, the amplified size of the ciaB gene fragment is 1.8 kb and 
successful insertion of the 1.4 kb kanamycin cassette produced a amplified size of 3.2 
kb.  
       1        2      3      4         5       6         7        8 
 
Figure 4.2. PCR verification of C. jejuni wild-types, ciaB mutants and ciaB complements. 
Lane 1: 1 Kb ladder (Bioline). Lane 2: Negative control. Lane 3: 11168H ciaB. Lane 4: 
11168H ciaB mutant. Lane 5: 11168H ciaB complement. Lane 6: 81-176 ciaB. Lane 7: 81-176 
ciaB mutant. Lane 8: 81-176 ciaB complement. 
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4.2.4 Characterisation of 81-176 and 11168H ciaB mutants 
Following the construction of the 81-176 and 11168H ciaB mutants, initial phenotypic 
characterisation studies for growth rate, motility and autoaggregation were performed. 
4.2.4.1 Growth rate assays and cfu counts  
To assess the effect of the mutation in ciaB, growth rate experiments were performed. 
OD600 readings were recorded every 2 h over a 32 h growth period as an indication of 
bacterial growth.  
Both the 81-176 and 11168H ciaB mutants displayed similar growth rates compared to 
the respective wild-type strain (see Figure 4.3). The 81-176 and 11168H ciaB 
complements displayed a higher growth rate levels at the 24 h time point compared to 
both the respective wild-type strain and mutant.  
The numbers of colony forming units (cfu) at different time-points were also 
investigated for the 81-176 and 11168H wild-type strains, ciaB mutants and 
complements (see Figure 4.4). The 81-176 ciaB mutant displayed slightly reduced 
growth rate levels at 12 h, 18 h and 24 h compared to the wild-type strain. Similarly, the 
11168H ciaB mutant displayed slightly reduced cfu counts, specifically at the 18 h and 
24 h time-points compared to the wild-type strain. The ciaB complements exhibited 
higher cfu numbers at 24 h.  
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   (B) 
        
Figure 4.3 Growth rates of 81-176 and 11168H wild-type strains, ciaB mutants and ciaB 
complements. C. jejuni strains from 24 h plates were inoculated at OD600 0.1 into 10 ml of pre-
incubated brucella broth and grown at 37°C microaerobically with shaking at 75 rpm. (A) 81-
176 wild-type, ciaB mutant and complement (B) 11168H wild-type ciaB mutant and 
complement. Growth was assessed by recording OD600 readings of the cultures every 2 h. The 
data represents the mean of triplicate independent experiments. 
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(A) 
 
(B) 
 
Figure 4.4 Growth curve cfu counts for 81-176 and 11168H wild-type strains, ciaB 
mutants and complements. C. jejuni strains from 24 h plates were inoculated at OD600 0.1 into 
10 ml of pre-incubated brucella broth and grown at 37°C microaerobically with shaking at 75 
rpm. At the desired time-point, 1 ml of brucella broth was removed and serial dilutions were 
performed from 10-1 to 10-7 and 200 µl of the final dilution was plated out onto blood agar 
plates. Colonies were enumerated following incubation at 37°C for 2 to 3 days. (A) 81-176 
wild-type, ciaB mutant and complement (B) 11168H wild-type, ciaB mutant and complement. 
Asterisks denote a statistically significant difference (* = p <0.05, ** = p <0.01, ns = no 
significant difference). The data represents triplicate independent experiments. 
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4.2.4.2 Motility 
C. jejuni displays rapid and darting motility, enabling the organism to colonise the 
intestines of humans and animals. (Morooka et al., 1985, Black et al., 1988, Wassenaar 
et al., 1991, Poly and Guerry, 2008). To study the effects of the mutation of ciaB on C. 
jejuni motility, motility assays were performed. The 81-176 ciaB mutant was 
significantly reduced in motility compared to 81-176 wild-type strain. The 11168H ciaB 
mutant also displays significantly reduced motility compared to the 11168H wild-type 
strain. Both 81-176 and 11168H ciaB complements did not restore the wild-type 
phenotype.  
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(B) 
 
(C) 
 
Figure 4.5 Motility assays. Bacteria were grown for 24 h on blood agar under microaerobic 
conditions. A suspension was prepared and adjusted to an OD600 of 0.1. 2 µl of this suspension 
was pipetted into the centre of soft agar plates and incubated at 37°C under microaerobic 
conditions. The level of motility was assessed by measuring the diameter of growth at 24 h, 48 h 
and 72 h. (A) Differences in motility levels of C. jejuni 81-176 ciaB mutant, ciaB complement 
and 81-176 wild-type. (B) Differences in motility levels of C. jejuni 11168H ciaB mutant, ciaB 
complement and 11168H wild-type. (C) Representative image showing the motility of ciaB 
mutants and wild-types at 48 h. (C):1 11168H ciaB mutant (C):2 81-176 ciaB mutant (C):3 
11168H wild-type and (C):4 81-176 wild-type. Asterisks denote a statistically significant 
difference (** = p <0.01, *** = p<0.001). Data are representative of three independent 
experiments. 
1 
3 4 
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4.2.4.3 Autoaggregation Assays 
Autoaggregation (AAG) of C. jejuni plays a role during interactions with and invasion 
of host cells (Guerry et al., 2006).	  However, the role of AAG in C. jejuni pathogenesis 
is yet to be fully determined. The amount of AAG also varies between C. jejuni strains 
(Misawa and Blaser, 2000). AAG has been found to play a role in resistance to host 
defences such as phagocytosis, in biofilm formation and in adherence to host cells 
(Skurnik, Bolin et al. 1984, Galdiero, Romano Carratelli et al. 1988, Chiang, Taylor et 
al. 1995, Frick, Morgelin et al. 2000, Sherlock, Vejborg et al. 2005). 
In order to investigate the effect of the ciaB mutations on C. jejuni AAG, ciaB mutants 
were tested and compared to the 81-176 and 11168H wild-type strains. RpoN is an 
alternative sigma factor involved in the transcription of genes encoding proteins 
involved in flagella biosynthesis (Hendrixson et al., 2001). 81-176 and 11168H rpoN 
mutants which lack a functional flagella and do not autoaggregate were included as 
AAG negative controls.  
The 81-176 ciaB mutant was significantly increased in AAG compared to the 81-176 
wild-type strain. The 81-176 wild-type AAG phenotype was restored in the 81-176 ciaB 
complement. There was no significant difference in the levels of AAG observed 
between the 11168H ciaB mutant and 11168H wild-type strain. The 11168H ciaB 
complement was significantly reduced in AAG. 
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Figure 4.6 Autoaggregation assays for the 81-176 & 11168H wild-type strains, ciaB 
mutants and ciaB complements. Bacteria were grown for 24 h on blood agar under 
microaerobic conditions. A suspension was prepared and adjusted to an OD600 of 1.0 in PBS. 
Suspensions (2 ml) were incubated for 24 h at 37ºC under microaerobic conditions. AAG was 
analysed by measuring the decrease in optical density of the upper 1 ml of suspended cells after 
24 h. An OD600 of 1.0 was considered 0% AAG and an OD600 of 0 considered 100% AAG. (A) 
& (C): OD600 readings after 24 hour incubation. (B) & (D): Percentage of AAG of suspended 
cells. Asterisks denote a statistically significant difference (* = p < 0.05, ** = p < 0.01). Data 
are representative of triplicate individual experiments. 
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4.2.4.4 Galleria mellonella infection model 
G. mellonella larvae have been widely used as a non-mammalian model for bacterial 
infection studies (Champion et al., 2009). Larvae can be infected at 37°C and possess 
specialised phagocytic cells called haemocytes (Bergin, Reeves et al. 2005). These cells 
mimic mammalian phagocytic cells and produce bactericidal compounds such as 
superoxide (Bergin, Reeves et al. 2005).  
Infection with both 81-176 and 11168H ciaB mutants resulted in reduced cytotoxicity 
compared to the respective wild-type strain over 72 h. The 11168H ciaB complement 
exhibited slightly higher cytotoxicity than the 81-176 ciaB complement, which 
exhibited only a partial restoration of the wild-type phenotype.  
        
 
Figure 4.7 Effect of C. jejuni 81-176 wild-type strain, ciaB mutant and ciaB complement in 
the Galleria mellonella model of infection. G. mellonella larvae were injected with a 10 µl 
inoculum of 24 h C. jejuni culture diluted to an OD600 of 0.1 by microinjection in the right 
foremost leg, giving an infectious dose of approximately 106 cfu. The larvae were incubated at 
37°C with survival recorded at 24 h intervals. PBS and no injection controls were also included. 
For each experiment, 10 G. mellonella larvae were infected and the experiments were repeated 
in triplicate. The asterisks denote a statistically significant difference (*** = p <0.001). 
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Figure 4.8 Effect of C. jejuni 11168H wild-type strain, ciaB mutant and ciaB complement 
in the Galleria mellonella model of infection. G. mellonella larvae were injected with a 10 µl 
inoculum of 24 h C. jejuni culture diluted to an OD600 of 0.1 by microinjection in the right 
foremost leg, giving an infectious dose of approximately 106 cfu. The larvae were incubated at 
37°C with survival recorded at 24 h intervals. PBS and no injection controls were also included. 
For each experiment, 10 G. mellonella larvae were infected and the experiments were repeated 
in triplicate. The asterisks denote a statistically significant difference (*** = p <0.001). 
4.2.5 Interaction and invasion assays 
The effect of the mutation in ciaB on C. jejuni interactions with IECs was investigated.  
4.2.5.1 The role of CiaB of C. jejuni interactions with and invasion of Caco-2 IECs 
There was a significant reduction in the ability of the 81-176 ciaB mutant to interact 
with and invade Caco-2 IECs in comparison to the 81-176 wild-type strain. The 81-176 
ciaB mutant exhibited a significantly reduced ability to interact with Caco-2 IECs 
compared to the wild-type strain with numbers of interacting bacteria increasing to over 
the infection period (see Figure 4.9). The 81-176 ciaB complement exhibited a delayed 
ability to interact with Caco-2 IECs but at the 6 h and 24 h time-point, the levels were 
similar to the 81-176 wild-type strain. The 81-176 ciaB mutant also displayed a 
significant reduction in invasion with numbers of intracellular bacteria gradually 
decreasing by 24 h (see Figure 4.10). The 81-176 ciaB complement did not restore the 
wild-type phenotype and displayed an even lower number of intracellular bacteria at all 
time-points.  
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Figure 4.9 Interaction (adhesion and invasion) assays Bacteria were co-cultured with Caco-2 
IECs for 3 h, 6 h and 24 h. Caco-2 IECs were lysed with Triton X-100 and interacting bacteria 
were enumerated. Asterisks denote a statistically significant difference (** = p <0.01, *** = p 
<0.001) for the 81-176 ciaB mutant compared to the wild-type. Data are representative of 
triplicate independent experiments. 
 
 
Figure 4.10 Invasion assays. Bacteria were co-cultured with Caco-2 IECs for 3 h, 6 h and 24 h. 
Caco-2 IECs were incubated with gentamicin (150 µg/ml) for 2 h to kill extracellular bacteria, 
then lysed and numbers of intracellular bacteria assessed. Asterisks denote a statistically 
significant difference (*** = p <0.001) for the 81-176 ciaB mutant compared to the wild-type 
strain. Data are representative of triplicate independent experiments. 
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4.2.5.2 The role of CiaB in C. jejuni interactions with and invasion of T84 IECs 
There was also a significant difference between the ability of the ciaB mutant to interact 
with and invade T84 IECs in comparison to the 81-176 wild-type strain. The 81-176 
ciaB mutant exhibited a significantly reduced ability to interact with T84 IECs 
compared to the wild-type strain (see Figure 4.11). The wild-type phenotype was 
partially restored by the 81-176 ciaB complement. The 81-176 ciaB mutant also 
displayed a significant reduction in invasion, (see Figure 4.12). The 81-176 ciaB 
complement partially restored the wild-type phenotype. 
 
Figure 4.11 Interaction (adhesion and invasion) assays. Bacteria were co-cultured with T84 
IECs for 3 h, 6 h and 24 h. T84 IECs were lysed with Triton X-100 and interacting bacteria 
were enumerated. Asterisks denote a statistically significant difference (*** = p <0.001) for the 
81-176 ciaB mutant compared to the wild-type strain. Data are representative of triplicate 
independent experiments. 
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Figure 4.12 Invasion assays. Bacteria were co-cultured with T84 IECs for 3 h, 6 h and 24 h. 
T84 IECs were incubated with gentamicin (150 µg/ml) for 2 h to kill extracellular bacteria, then 
lysed and numbers of intracellular bacteria assessed. Asterisks denote a statistically significant 
difference (*** = p <0.001) for the 81-176 ciaB compared to the wild-type strain. Data are 
representative of triplicate independent experiments. 
Table 4.1 Summary of the effect of the mutation in ciaB on C. jejuni interactions 
with Caco-2 IECs.  
Bacterial 
strain 
Effect of 
interaction 
with Caco-2 
IECs (3 h) 
Effect of 
interaction 
with Caco-2 
IECs (6 h) 
Effect of 
interaction 
with Caco-2  
IECs (24 h) 
 
81-176 wild-
type 
< 107 cfu < 107 cfu < 107 cfu 
ciaB mutant > 106cfu > 106cfu > 106cfu 
ciaB 
complement 
> 106cfu > 106 cfu > 107 cfu 
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Table 4.2 Summary of the effect of the mutation in ciaB on C. jejuni invasion of 
Caco-2 IECs.  
Bacterial 
strain 
Effect of 
invasion of 
Caco-2 IECs 
(3 h) 
Effect of 
invasion of 
Caco-2 IECs 
(6 h) 
Effect of 
invasion of 
Caco-2 IECs 
(24 h) 
 
81-176 wild-
type 
< 105 cfu < 105 cfu < 105 cfu 
ciaB mutant > 104cfu > 103cfu > 103cfu 
ciaB 
complement 
> 102cfu > 102 cfu > 103 cfu 
 
Table 4.3 Summary of the effect of the mutation in ciaB on C. jejuni interactions 
with T84 IECs.  
Bacterial 
strain 
Effect of 
interaction 
with T84 
IECs (3 h) 
Effect of 
interaction 
with T84 IECs 
(6 h) 
Effect of 
interaction 
with T84 
IECs (24 h) 
 
81-176 wild-
type 
>107 cfu >107 cfu < 107 cfu 
ciaB mutant > 106cfu > 106cfu > 106cfu 
ciaB 
complement 
> 106cfu > 106 cfu > 106 cfu 
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Table 4.4 Summary of the effect of the mutation in ciaB on C. jejuni invasion of 
T84 IECs.  
Bacterial 
strain 
Effect of 
interaction 
with T84 
IECs (3 h) 
Effect of 
interaction 
with T84 IECs 
(6 h) 
Effect of 
interaction 
with T84 
IECs (24 h) 
 
81-176 wild-
type 
< 104 cfu > 104 cfu > 104 cfu 
ciaB mutant > 102cfu > 103cfu > 103cfu 
ciaB 
complement 
> 103cfu > 103 cfu > 104 cfu 
 
4.2.6 Intracellular survival assays  
Our knowledge of C. jejuni interactions with, invasion of and survival within intestinal 
epithelial cells is limited compared to other enteropathogenic bacteria (Watson and 
Galan, 2008b, Bouwman et al., 2013). However studies have revealed that C. jejuni can 
evade phagocytosis and survive for a certain period intracellularly and also trigger the 
release of host cytokines (Kiehlbauch et al., 1985, Jones et al., 2003, Watson and Galan, 
2008b). The exact process of how this invasion and intracellular survival occurs is still 
unclear (Backert and Hofreuter, 2013). C. jejuni avoids delivery to the lysosomes and 
resides within Campylobacter containing vacuoles (CCV) (Watson and Galan, 2008b, 
Pryjma et al., 2012).  
To study the effect of the mutation of ciaB on the ability of C. jejuni to survive 
intracellularly in Caco-2 IECs, intracellular survival assays were performed. The 81-176 
ciaB mutant exhibited significantly reduced intracellular survival levels compared to the 
wild-type strain (see Figure 4.13). The 81-176 ciaB complement did not fully restore the 
wild-type phenotype. The percentage survival of 81-176 wild-type, ciaB mutant and 
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complement was also calculated (see Table 4.5) which indicated reduced intracellular 
survival of the ciaB mutant. 
 
Figure 4.13 Intracellular survival assay. The 81-176 wild-type, ciaB mutant and complement 
were co-cultured with Caco-2 IECs for 3 h, washed three times with PBS, then incubated with 
gentamicin (150 µg/ml) for 2 h to kill extracellular bacteria, followed by further incubation with 
gentamicin for 19 h at a reduced concentration (10 µg/ml). The monolayers were then washed 
three times in PBS, lysed with Triton X-100 and numbers of intracellular bacteria assessed. 
Asterisks denote a statistically significant difference (** = p <0.01, *** = p <0.001, ns = no 
significant difference). Data represents triplicate independent experiments.  
 
Table 4.5 Percentage survival of intracellular of 81-176 wild-type strain, ciaB 
mutant and complement after 19 h within Caco-2 IECs.  
 
 
 
 
 
 
 
Bacterial Strain % survival after 19 h 
81-176 wild-type 10.10 
81-176 ciaB mutant 0.72 
81-176 ciaB complement 11.70 
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4.2.7 Macrophage survival assays 
Once inside the host relatively little is known about the intracellular life cycle of C. 
jejuni, although it is presumed that C. jejuni behaves in a similar way to other 
enteropathogens with well characterised intracellular lifestyles and that C. jejuni may 
have evolved specific mechanisms to enable the survival of the bacteria in the harsh 
intracellular environment of the host cell (Watson and Galan, 2008b, Backert and 
Hofreuter, 2013). Macrophage survival assays were performed as described previously 
(Watson and Galan, 2008b) using J774A.1 mouse macrophages (Sikic Pogacar et al., 
2009). There was no significant difference in macrophage survival ability between the 
ciaB mutant and wild-type strain at 4 h (see Figure 4.14). However a significantly 
reduced intracellular survival level was observed at the 16 h time-point for the ciaB 
mutant compared to the wild-type strain. The ciaB complement displayed similar levels 
of survival to the wild-type at time 0 h and displayed significantly increased survival 
levels at the 4 h time point, however at the 16 h time point no bacteria were recovered. 
 
Figure 4.14 Macrophage survival assays. The 81-176 wild-type strain, ciaB mutant and ciaB 
complement were co-cultured with J774A.1 mouse macrophages for 3 h. The cells were washed 
three times in PBS, followed by incubation in DMEM containing gentamicin (150 µg/ml) for 2 
h to allow killing of extracellular bacteria. The macrophages were then incubated in DMEM 
containing a reduced concentration of gentamicin (10 µg/ml) and bacterial survival determined 
at 0 h, 4 h and 16 h. At each time point, the macrophages were washed three times with PBS 
and lysed by adding 0.2% (v/v) Triton X-100 in PBS and the number of intracellular bacteria 
were assessed. The asterisks denote a statistically significant difference (** =p <0.01, ns = no 
significant difference). Data represents triplicate independent experiments.  
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4.2.8. Sensitivity of C. jejuni to Triton X-100 
To ascertain whether the above results were due to a genuine ciaB mutant phenotype 
and not due to increased sensitivity to Triton X-100 or gentamicin, sensitivity assays 
were performed on all the mutants and wild-type strains with 0.2% (v/v) Triton X-100 
or gentamicin (150 µg/ml). No significant differences were observed between the levels 
of sensitivity to Triton X-100 (see Figure 4.15) or gentamicin (data not shown) between 
the respective wild-type strains and ciaB mutants, though the 11168H ciaB complement 
exhibited slightly decreased levels of sensitivity to Triton X-100.  
(A) 	  
        
(B)	  
       
Figure 4.15. Sensitivity of C. jejuni strains to Triton X-100. Bacteria was grown for 24 h on 
blood agar. The bacteria were resuspended in PBS and adjusted to an OD600 of 0.1. Triton X-
100 was added to a final concentration of 0.2% (v/v) and after incubation at 37°C with 5% CO2 
for 20 min the number of viable bacteria was determined. (A) 81-176 wild-type strain, ciaB and 
ciaB complement (B) 11168H wild-type strain, ciaB and ciaB complement. Asterisks denote a 
statistically significant difference (* = p <0.05, ns = no significant difference). Data represents 
triplicate independent experiments.  
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4.2.9 Vertical Diffusion Chamber assays 
A major limitation of in vitro models used to study gastrointestinal infections is that 
standard tissue culture conditions include high oxygen levels which generally favour 
eukaryotic cell survival and do not allow the true observation of the biological 
interactions of the bacteria with the host cell (Mills et al., 2012). In the case of C. jejuni, 
a number of different cell culture assays have been used to investigate the interactions 
of C. jejuni with host cells. Caco-2 (Everest et al., 1992), INT407 (Konkel et al., 1992b) 
and T84 (Monteville and Konkel, 2002) IEC lines have all been used extensively to 
study the adhesion and invasion capabilities of different C. jejuni strains. However, it 
has been reported that the levels of bacterial adhesion and invasion for C. jejuni with 
IECs are dramatically lower than for other enteric pathogens (Friis et al., 2005).  
The use of a Vertical Diffusion Chamber (VDC) system allows the co-culture of 
bacteria and host cells under different medium and gas conditions (Cottet et al., 2002a, 
Schuller and Phillips, 2010, Mills et al., 2012).  
The 81-176 ciaB mutant exhibited significantly reduced invasion of both Caco-2 and 
T84 IECs compared to the wild-type strain (see Figure 4.16), however the numbers of 
intracellular bacteria were slightly higher when using T84 IECs. The C. jejuni rpoN 
mutant is non-motile and aflagellate and therefore unable to secrete CiaB and was 
included as a non-motile control (Mills et al., 2012).  
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(A) 
   
(B)  
 
Figure 4.16 Vertical Diffusion Chambers assays. Bacteria were co-cultured with Caco-2 or 
T84 IECs in a Vertical Diffusion chamber at a multiplicity of infection (MOI) of approximately 
100:1 under microaerobic conditions for 6 h and the numbers of intracellular bacteria were 
assessed. Caco-2 or T84 IECs were incubated with gentamicin (150 µg/ml) for 2 h to kill 
extracellular bacteria, then lysed and numbers of intracellular bacteria assessed. 81-176 wild-
type strain, ciaB and rpoN mutants co-cultured with (A) Caco-2 or (B) T84 IECs. The asterisks 
denote a statistically significant difference (*** = p<0.001). Data are representative of triplicate 
independent experiments. 
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4.2.10 ELISA assays 
IL-8 is a well characterised marker of the host immune response to pathogens 
(Oppenheim et al., 1991) and interaction with and invasion of IECs by C. jejuni triggers 
both innate and adaptive immune responses (Chen et al., 2006, Rathinam et al., 2008). 
Cytokines of the TNFα family have been found to play central roles in the development 
of a stable immune system and protection from pathogens (Pfeffer, 2003).  
Supernatants from uninfected T84 cells and T84 cells infected with 81-176 or 11168H 
wild-type strains, ciaB mutants and ciaB complement at an MOI of 100:1 for 24 h were 
collected. The levels of IL-8 and TNFα secretion were assessed. 
No significant differences were observed in the induction of IL-8 between the 81-176, 
11168H wild-type strains, ciaB mutants and ciaB complement (see Figure 4.17).  
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(A) 	  	   	   	   	   	  	  
 
  (B)	  
 
Figure 4.17. The role of CiaB in C. jejuni induction of IL-8 from T84 IECs. The 81-176 and 
11168H wild type strains, ciaB mutants and ciaB complements were assessed. The levels of IL-
8 secreted after 24 h C. jejuni interaction (MOI 100:1) with T84 IECs were quantified using a 
human IL-8 ELISA. (ns = no significant difference). Data are representative of triplicate 
independent experiments. 
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Both 81-176 and 11168H ciaB mutants induced reduced TNFα in comparison to the 
respective wild-type strains. The 81-176 ciaB complement did not restore the wild-type 
phenotype (see Figure 4.18).	  
(A) 
       
(B) 
      
Figure 4.18. The role of CiaB in TNFα induction from T84 IECs. The 81-176 and 11168H 
wild type strains, ciaB mutants and ciaB complements strains were assessed. The levels of 
TNFα secreted after 24 h C. jejuni interaction (MOI 100:1) with T84 IECs were quantified 
using a human TNFα ELISA. The asterisks denote a statistically significant difference (* =p< 
0.05, ns = no significant difference). Data are representative of triplicate independent 
experiments. 
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Following 6 h infection of T84 IECs in the VDC system, the levels of IL-8 and TNFα 
were assessed in the basolateral compartment. The 81-176 ciaB mutant induced a 
reduced IL-8 response from T84 IECs compared to the wild-type and only a slight 
reduction was observed in TNFα induction from T84 IECs by the ciaB mutant 
compared to the wild-type (see Figure 4.19).  
(A) 
 
(B) 
          
Figure 4.19. The role of CiaB in IL-8 and TNFα induction from T84 cells in the VDC 
system. T84 IEC responses to 6 h co-incubation with C. jejuni 81-176 wild type strain and ciaB 
mutant (MOI 100:1). The levels of IL-8 and TNFα secreted during C. jejuni interaction with 
T84 cells in the VDC were quantified using a human IL-8 or human TNFα ELISA. (A) IL-8 and 
(B) TNFα. Uninfected IECs were used included as controls. The asterisks denote a statistically 
significant difference (* = p< 0.05, ** = p<0.01). Data are representative of triplicate 
independent experiments.  
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4.2.11 Role of outer membrane vesicles in C. jejuni interactions with IECs 	  
Many Gram-negative pathogenic and non-pathogenic bacteria have been found to 
produce outer membrane vesicles (OMVs) (Kuehn and Kesty, 2005, Ellis and Kuehn, 
2010). OMVs have also been found to contain virulence factors which play a role in 
pathogenesis (Ellis and Kuehn, 2010). Numerous Gram-negative bacteria including E. 
coli, P. aeruginosa, C. jejuni and H. pylori have been shown to produce OMVs 
(Horstman and Kuehn, 2000, Kesty et al., 2004, Kuehn and Kesty, 2005, McBroom and 
Kuehn, 2007, Ellis and Kuehn, 2010, Kulp and Kuehn, 2010). 
Caco-2 IECs were pre-incubated with OMVs for 24 h to ascertain whether OMVs 
would affect C. jejuni interactions with and invasion IECs 
Pre-incubation with OMVs (10 µg) isolated from the 81-176 produced a significant 
increase in the number of interacting bacteria compared to the control with no treatment 
(see Figure 4.20). Pre-incubation with OMVs (10 µg) isolated from the 81-176 ciaB 
mutant produced a significant reduction in interacting bacteria compared to the control 
with no treatment. Pre-incubation with OMVs isolated from the ciaB complement 
restored the wild-type phenotype (see Figure 4.20). Pre-incubation with OMVs isolated 
from the ciaB mutant or ciaB complement (10 µg) resulted in a significant reduction in 
intracellular bacteria. 
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(A) 
 
(B)  
 
Figure 4.20 Effect of pre-incubation of C. jejuni OMVs on bacterial interactions with and 
invasion of Caco-2 IECs. OMVs (10 µg) isolated from C. jeuni 81-176 wild-type strain, ciaB 
mutant and ciaB complement were pre-incubated with Caco-2 IEC for 24 h. Monolayers were 
washed three times with PBS. Bacteria was harvested from 24 h plates, resuspended in PBS and 
adjusted to an OD600 of 0.1. Bacteria was co-cultured with Caco-2 IECs for 24 h. (A) Caco-2 
IECS were lysed with Triton X-100 and interacting bacteria were enumerated. (B) For invasion, 
Caco-2 IEC cells were incubated with gentamicin (150 µg/ml) for 2 h to kill extracellular 
bacteria, then lysed and numbers of intracellular bacteria assessed. Asterisks denote a 
statistically significant difference (* =p <0.05; ** = p <0.01, ns = no significant difference). 
Data are representative of triplicate independent experiments.  
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4.3 Discussion 
Numerous reported studies using a variety of different cells lines and animal models 
have shown that mutations in C. jejuni genes encoding proteins involved with 
adherence, glycosylation, motility and capsule synthesis, result in reduced interactions 
with and invasion levels of IECs (Grant et al., 1993, Pei et al., 1998, Bacon et al., 2001, 
Konkel et al., 2001, Szymanski et al., 2002, Hendrixson and DiRita, 2004, Kakuda and 
DiRita, 2006, Watson and Galan, 2008b). However there is no direct correlation that 
any specific virulence factor is involved in the invasion process (O. Croinin and 
Backert, 2012). One such virulence factor is CiaB and the role of this protein in C. 
jejuni invasion is contentious as CiaB is reported to be delivered directly into the host 
cell cytoplasm via the flagellar (Konkel et al., 2004). In addition the same group 
reported that a F38011 ciaB mutant was capable of interacting with INT407 IECs 
following a 2 h incubation period to levels similar to the wild-type strain, however 
internalisation of the ciaB mutant was severely affected after a 3 h incubation period 
(Konkel et al., 1999b). However, a 81-176 ciaB mutant was reported to display no 
differences in invasion, bringing into question the role of CiaB in C. jejuni invasion 
(Novik et al., 2010).  
In this study, ciaB mutants and complements were constructed in both the 81-176 and 
11168H wild-type strains. Phenotypic characterisation of ciaB mutants was performed 
and no significant differences were observed in growth rates compared to the respective 
wild-type strains. Both 81-176 and 11168H ciaB complements exhibited increased 
growth rates in comparison to the wild-type strains and ciaB mutants and this was also 
reflected in the number of cfu counts enumerated at selected time-points points. C. 
jejuni motility has been linked to the ability of the bacteria to invade and is essential for 
colonisation of both human and animal models (Guerry, 2007). Both 81-176 and 
11168H ciaB mutants were significantly reduced in motility compared to the wild-type 
strains, but still displayed some motility. The wild-type phenotype was not restored by 
the ciaB complement. It is not clear from the literature whether other research groups 
also showed a reduction in motility for their ciaB mutants studied. 
Both 81-176 and 11168H ciaB mutants and complements were constructed. The role of 
CiaB in interactions with and invasion of Caco-2 and T84 IECs was investigated over a 
3 h, 6 h and 24 h infection period. Initially, the 81-176 ciaB mutant exhibited reduced 
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interactions with Caco-2 IECs compared to the wild-type strain, with the number of 
interacting bacteria increasing over the 6 h and 24 h infection time-points. The 81-176 
ciaB complement initially exhibited a reduction in interacting bacteria at 3 h and 
recovered to the wild-type levels by 6 h. In the invasion assay, the 81-176 ciaB mutant 
exhibited a significant reduction in the numbers of invading bacteria. The 81-176 ciaB 
complement also exhibited reduced numbers of intracellular bacteria, with a slight 
increase observed at the later time-points.  
The interaction and invasion assays were also performed using T84 IECs to study the 
role of CiaB in interactions with and invasion of a second cell line. The number of 81-
176 ciaB mutant bacteria interacting with T84 IECs was significantly reduced compared 
to the wild-type. The 81-176 ciaB complement was initially reduced but then recovered 
over the 6 h and 24 h infection period to wild-type levels. Previous work reported 
similar levels of interactions with and invasion of T84 IECs with the 81-176 wild-type 
strain after a 3 h infection period, however, the same study also reported that the 
F38011 ciaB mutant was not reduced in interactions with T84 IECs compared to the 
wild-type (Monteville and Konkel, 2002). In contrast another study reported no 
significant reduction in invasion of T84 IECs with a 81-176 ciaB mutant after a 2 h 
infection period and a similar study also failed to report any significant reductions in the 
ciaB mutant invasion of INT407 IECs (Goon et al., 2006, Novik et al., 2010). 
Furthermore, there have been no published studies on the invasion of Caco-2 IECs by a 
ciaB mutant which makes it difficult to compare these findings to the existing body of 
knowledge. The reduced motility of the 81-176 ciaB mutant may have affected the 
initial delay in interactions with Caco-2 IECs and as the 81-176 ciaB mutant exhibited 
increased levels of AAG, this may account for the increased interactions with and 
invasion of Caco-2 and T84 IECs observed over the infection time-points. The ciaB 
complement restored the wild-type phenotype in interactions with Caco-2 IECs, but 
failed to restore the wild-type invasion phenotype. However the ciaB complement 
restored the wild-type phenotype in both interactions with and invasion of T84 IECs. 
The results obtained in this study using a 81-176 ciaB mutant are very different to those 
reported in the literature; a possible reason could be due to the variation in experimental 
procedures. For example, Konkel’s work used a C. jejuni F38011 wild-type strain, the 
IEC line used was INT407 and in contrast to this study, higher numbers of bacterial 
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numbers (5 x107 cfu) were used to infect the cells, followed by centrifuging the 
monolayers for 10 minutes to increase contact of the bacteria with the IECs and 
incubation times were between 30 minutes to 2 h (Konkel et al., 1999b). In contrast 
Novik et al. used the 81-176 wild-type strain, the T84 IEC line and infected with an 
OD600 of 0.1, monolayers were centrifuged for 5 minutes and incubated for 2 h (Novik 
et al., 2010).  
A key virulence determinant is the ability of C. jejuni to enter and survive intracellularly 
within IECs by residing in membrane-bound compartments (CCVs), modifying the 
internal conditions of the CCV which provides protection from the host immune system 
and avoiding delivery to the lysosomes and in addition intracellular replication of C. 
jejuni 81-176 has also been observed (Hickey et al., 2005, Watson and Galan, 2008b, 
Buelow et al., 2011a). Exactly how C. jejuni is able to modify the CCV environment is 
still unknown (Day et al., 2000, Watson and Galan, 2008b, Backert and Hofreuter, 
2013). This study showed that intracellular survival of the 81-176 ciaB mutant was 
significantly reduced compared to the wild-type strain and the wild-type phenotype was 
not restored by the 81-176 ciaB complement. As CiaB expression has also been 
reported to be required for the secretion of other Cia proteins (see Section 1.5.4), 
specifically a deficiency in the secretion of CiaI reported to play a role in intracellular 
survival by modification of the CCV environment, mutation of ciaB may result in the 
absence of CiaI and may affect C. jejuni intracellular survival. A C. jejuni ciaI mutant 
exhibited reduced intracellular survival in INT407 IECs (Novik et al., 2010, Buelow et 
al., 2011b). Previous studies report that C. jejuni loses viability within IECs over 
extended incubation periods and no intracellular replication is thought to occur (Konkel 
et al., 1992b). 
AAG is a well known virulence marker in a number of pathogenic Gram-negative 
bacteria, including C. jejuni (Misawa and Blaser, 2000).The 81-176 ciaB mutant 
exhibited significantly increased AAG. The 11168H ciaB mutant displayed no 
significant differences in AAG and the 11168H ciaB complement was significantly 
reduced in AAG compared to the wild-type strain. The role of CiaB was investigated in 
the G. mellonella model where the 81-176 ciaB mutant exhibited significantly reduced 
cytotoxicity in the larvae with over 70% of the larvae surviving at the 72 h infection 
period. The 81-176 ciaB complement partially restored wild-type levels of cytotoxicity 
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but with levels considerably lower than that of the wild-type strain. The 11168H ciaB 
mutant also exhibited a reduced cytotoxicity compared to the wild-type with 60% of the 
larvae surviving at 72 h but only 20% of the larvae survived after infection with the 
11168H ciaB complement at 72 h.  
To further study the intracellular survival ability of C. jejuni ciaB mutants, macrophage 
survival assays were performed. Previous studies have shown that macrophages are 
capable of killing C. jejuni within 24 h of internalisation (Watson and Galan, 2008a). In 
this study the survival of the 81-176 ciaB mutant was significantly reduced at the 16 h 
time-point, with no survival of bacteria observed compared to the wild-type. The 81-
176 ciaB complement exhibited significantly increased levels of intracellular survival 
within macrophages at the 4 h time point compared to the wild-type and no bacteria 
were recovered at the 16 h time-point.  
To further investigate the role of CiaB in invasion of Caco-2 and T84 IECs, VDC 
assays were performed. This system allowed a more accurate investigation of the 
interaction between C. jejuni and the IECs in an environment that more closely mimics 
the in vivo conditions encountered in the human gut. The 81-176 ciaB mutant was 
significantly reduced in invasion of both Caco-2 IECs and T84 IECs after a 6 h 
infection period, compared to the wild-type strain. A 81-176 rpoN mutant was included 
as a non-motile control with no Cia secretion (Fernando et al., 2007b). In the complete 
absence of motility, the 81-176 rpoN mutant was still able to interact with and invade 
IECs, though at significantly reduced levels compared to the wild-type strain and the 
ciaB mutant, exhibited reduced motility and no secretion of CiaB yet was still capable 
of invasion. As motility is reported to be required for C. jejuni invasion (Poly and 
Guerry, 2008) yet in this study a non-motile mutant is still capable of invasion of IECs. 
The VDC data showed higher levels of interactions with and invasion of Caco-2 and 
T84 IECs compared to the results obtained from standard tissue culture assays. The 
number of intracellular ciaB mutant recovered after a 6 h infection period of T84 IECs 
in the VDC was significantly higher than the numbers of intracellular bacteria 
enumerated under standard tissue culture conditions. These results show that C. jejuni 
invasion ability is dynamic depending on the experimental conditions and increased 
especially when co-cultured with IECs in the VDC (Mills et al., 2012). In line with the 
reduced intracellular survival ability of the ciaB mutant and reduced levels of invasion 
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of Caco-2 and T84 IECs, CiaB could be playing a role in intracellular survival of C. 
jejuni. However, similarly to the results obtained from the interaction and invasion 
assays with the ciaB mutant, although significantly reduced, the ciaB mutant was still 
capable of surviving and invading IECs over extended periods of infection and this data 
is in contrast to a previous study reporting that C. jejuni was not capable of survival 
within the IECs for extended periods (De Melo et al., 1989). 
The role of C. jejuni in triggering the host immune response has been previously 
investigated and the results have been varied, dependent on the cell line and bacterial 
strain used (Backert and Hofreuter, 2013). Induction of IL-8 is reported to be an early 
signature of infection by enteric bacteria and also thought to be a signal of the acute 
inflammatory response to C. jejuni (Jung et al., 1995, Hickey et al., 1999). The levels of 
IL-8 induction from T84 IECs following infection with the 81-176 and 11168H ciaB 
mutants were not significantly different compared to the levels induced by the 
respective wild-type strains and similar levels of IL-8 induction have been shown 
following infection of INT407 IECs with 81-176. In addition, invasive C. jejuni strains 
have been shown to induce higher levels of IL-8 (Oelschlaeger et al., 1993, Hickey et 
al., 1999). The 81-176 ciaB complement induced slightly higher levels of IL-8 
compared to the wild-type and the 11168H ciaB complement. Both 81-176 and 11168H 
wild-type strains induced similar levels of IL-8 secretion from T84 IECs.  
In the induction of TNFα, both wild-type strains induced similar levels of TNFα. In 
contrast, both 81-176 and 11168H ciaB mutants induced reduced levels of TNFα 
compared to the respective wild-type strain. The 81-176 ciaB complement did not 
restore the wild-type phenotype. The supernatants from the VDC were probed for IL-8 
and TNFα following a 6 h infection with the 81-176 wild-type and ciaB mutant. 
Infection of T84 IECs with the ciaB mutant in the VDC resulted in a significant 
reduction in IL-8 h and TNFα induction compared to the wild-type at 6 h which concurs 
with the hypothesis that C. jejuni displays dynamic interactions with IECs when under 
microaerobic conditions in the VDC than when in standard tissue culture. In contrast to 
no significant differences in IL-8 induction observed following infection with the ciaB 
mutant under standard tissue culture conditions, the IL-8 levels induced were still 
significantly higher under standard in vitro assay culture conditions than those induced 
following co-culture of the ciaB mutant in the VDC. The differences observed could 
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potentially be due to the incubation period, as the standard in vitro tissue culture assays 
were incubated for 24 h, whilst the VDC infection period was 6 h. Whether this is 
reflective of the real in vivo interactions of C. jejuni with IECs would require further 
study.  
The role of OMVs isolated from the ciaB mutant in invasion was investigated as the 
hypothesis proposed was that pre-incubation of Caco-2 IECs with C. jejuni OMVs prior 
to infection with live bacterial cells could exhibit effects on the bacterial interactions 
with and invasion of Caco-2 IECs. Pre-incubation with OMVs 10 µg isolated from ciaB 
mutant resulted in a significant reduction in interacting bacteria compared to the control 
with no pre-incubation. Equally, a significant reduction in intracellular bacteria was also 
observed after pre-incubation with OMVs 10 µg isolated from ciaB mutant compared to 
the control with no pre-incubation. Pre-incubation of Caco-2 IECs with OMVs 10 µg 
isolated from 81-176 wild-type significantly increased bacterial interactions with Caco-
2 IECs compared with the no pre-treatment control. Previous studies at LSHTM found 
that proteomic analysis of OMVs isolated from the 11168H wild-type found that neither 
CiaB, CiaC or CiaI were associated with OMVs and that the production of OMVs by C. 
jejuni was not a route for secretion for these Cia proteins (Elmi et al., 2012).  
In summary, the mutation of ciaB clearly affects C. jejuni, with varying results in both 
81-176 and 11168H strains including reduced interactions with and invasion of IECs, 
This supports Konkel’s work, in addition it is difficult to compare the ciaB T84 IEC 
invasion data from this study to that reported by Novik et al. Although the report 
suggests no differences in invasion of the 81-176 ciaB mutant compared to the wild-
type, there is clearly a reduction observed, as the ciaB mutant was ~ 80% reduced 
compared to the wild-type. However, the data is difficult to compare with complete 
accuracy due to the ways the data were measured (Novik et al., 2010). 
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Chapter 5. Reinvestigation of the roles of CadF and FlpA in 
C. jejuni adhesion to and invasion of intestinal epithelial cells	  
5.1 Introduction  
The ability of pathogenic bacteria to adhere to host tissues is an important early event in 
colonisation (Roberts, 1990, Isberg and Van Nhieu, 1994, Alrutz and Isberg, 1998). C. 
jejuni virulence factors that contribute to pathogenesis are multifactorial and include 
motility, host cell adherence, invasion, protein secretion, manipulation of host cell 
signalling and evasion of host immune defences (Konkel et al., 2001, Wilson, 2002). 
When microbial pathogens gain access to the host and colonise tissues, these pathogens 
can utilise components of the host cell extracellular matrix (ECM) to adhere to and enter 
host cells. The ECM can be subdivided into two families, collagens such as laminin and 
glycoproteins such as fibronectin (Mecham, 2011). The host ECM components are a 
network of proteins each with a role in building the architecture of the cell and in cell 
adhesion (Carsons, 1989, Hynes, 1990, Yamada, 2012). Fibronectin is a large 
glycoprotein found on the surface of mammalian cells (McKeown-Longo, 1987), with a 
number of domains that exhibit specific binding properties with other host cell proteins 
and ECM proteins (Romberger, 1997, Kleba et al., 2002). Fibronectin is a component of 
the ECM, present in plasma and connective tissue, serving many in vivo functions such 
as maintenance of the cell, organisation of tissues, substrate binding and a role in cell 
motility (Romberger, 1997). Many pathogens have evolved ways to target and utilise 
this large glycoprotein, by expressing fibronectin binding proteins on the bacterial 
surface (Signas et al., 1989, Kreikemeyer et al., 1995).  
Invasion of the epithelial cells lining the intestinal tract is hypothesised to be essential 
for the development of C. jejuni-mediated enteritis (Young et al., 2007, Dasti et al., 
2010). Studies have indicated that bacterial ability to bind to fibronectin is a key feature 
in successful cell invasion (Monteville and Konkel, 2002, Krause-Gruszczynska et al., 
2007b, Krause-Gruszczynska et al., 2011). Previous studies have identified a number of 
adhesins expressed by C. jejuni that allow binding to cultured epithelial cells (Konkel et 
al., 1992a). C. jejuni expresses a number of outer membrane proteins that have been 
reported to act as adhesins by binding to specific receptors on the host cell surface and 
allowing interaction with host cells (Young et al., 2007). One of the most well 
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characterised C. jejuni adhesins is CadF, a 37 kDa protein with binding affinity to 
fibronectin (Konkel et al., 1997). CadF was shown to bind to INT407 membrane 
fractions (Moser et al., 1997). Further studies highlighted the importance of CadF as 
cadF mutants were unable to colonise chickens (Ziprin et al., 1999). In addition, C. 
jejuni possesses another adhesin FlpA that also contains fibronectin binding amino-acid 
domains. FlpA was found to play a significant role in the colonisation of chickens, as 
mutations in flpA completely prevented the colonisation of chicks (Flanagan, Neal-
McKinney et al. 2009). A flpA mutant also displayed a reduction in adherence to 
INT407 cells (Konkel, Larson et al. 2010). Studies have shown that CadF and FlpA also 
play a role in activation of host cell proteins such as small Rho GTPases Rac1 and 
Cdc42, leading to membrane ruffling and dynamic changes in the host cell and are thus 
required for bacterial entry into the host cell (Krause-Gruszczynska et al., 2007b, 
Krause-Gruszczynska et al., 2011). This part of the study will reinvestigate the role of 
CadF and FlpA in C. jejuni adhesion to and invasion of intestinal epithelial cells. In 
particular the use of the Galleria infection models, VDC and OMVs will provide new 
data on these reported C. jejuni determinants. 
5.2 Results  
5.2.1 Chromosomal location of cadF and flpA  
The Chromosomal location of cadF and flpA in 81-176 and 11168H strains was viewed 
in Artemis software, with up and downstream genes listed below.  
C. jejuni 81-176 cadF upstream genes are rpsI (ribosomal protein), Cjj81-176_1474 
rpIM, (Type II protein secretion system D protein/ ribosomal protein S13), Cjj81-
176_1475 (unknown function) and the downstream genes are: Cjj81-176_1470 ctsF 
(pseudo/general secretory pathway protein), Cjj81-176_1469 (putative pyruvate-
flavodoxin oxidoreductase) (see Figure 5.1).  
C. jejuni 11168H cadF upstream genes are rpsI (ribosomal protein) Cj1481c rpIM, 
(ribosomal protein S13), Cj1482c (unknown function). The 11168H cadF downstream 
genes are: Cj1477c (hydrolase), Cj1476c (putative pyruvate-flavodoxin oxidoreductase) 
and ctsR (orf) (see Figure 5.1). 
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In both 81-176 and 11168H strains, the genes upstream and downstream of cadF are the 
same except that the ctsF gene in 81-176 is different to Cj1477c gene encoding a 
hydrolase. 
(A) 
    
(B) 
    
Figure 5.1 Artemis Images displaying the positions of cadF genes in C. jejuni 81-176 (A) 
and 11168H (B) 
C. jejuni 81-176 flpA upstream genes are Cjj81-176_1296 ribosomal large subunit 
pseudouridine synthase A / (putative antimicrobial efflux pump). The downstream 
genes are Cjj81176_1294 trmB (tRNA (guanine-N7-)-methyltransferase activity), lolD 
(putative ABC transporter ATP-binding protein), Cjj81-176_1292 (deoxycytidine 
triphosphate deaminase/putative cell division protein), Cjj81-176_1291 (putative biotin 
carboxyl carrier protein of acetyl-CoA carboxylase/fatty acid biosynthesis/family 
peptidase M24/M37), pyrH (enzymatic reaction of uridylate kinase), rpoZ (promotes 
RNA assembly). 
C. jejuni 11168H flpA upstream genes are Cj1280 (putative ribosomal protein synthesis 
and modification/ribosomal pseudoridine synthase) and Cj1285c (conserved 
hypothetical protein/putative periplasmic solute binding protein). The downstream 
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genes are, trmB (tRNA (guanine-N7-)-methyltransferase activity), Cj1227c (two 
component regulator/ABC transporter ATP binding), Cj1276c (putative integral 
membrane protein), Cj1275c (putative periplasmic protein), pyrH (enzymatic reaction 
of uridylate kinase), rpoZ (promotes RNA assembly).  
In both 81-176 and 11168H, the genes adjacent to flpA are the same except that the 
genes downstream of flpA in 81-176 contain a Cjj_1292 which encodes a putative cell 
division protein not present in 11168H. 
(A) 
 
(B) 
 
Figure 5.2 Artemis Images displaying the positions of flpA genes in C. jejuni 81-176 (A) 
and 11168H (B) 
5.2.2 Construction of 81-176 and 11168H cadF mutants 
C. jejuni genomic DNA (gDNA) was extracted and primers cadF-Forward-81-
176/cadF-Reverse-81-176 and cadF-Forward-11168H/cadF-Reverse-11168H were 
designed for the amplification of the cadF genes from 81-176 and 11168H gDNA 
respectively. PCR reactions were set up using the appropriate primers. Each PCR 
product was analysed by agarose gel electrophoresis and purified using the Qiagen PCR 
clean up kit. Each purified PCR product was ligated into the pGEMT-easy vector 
(Promega). Each pGEMT-easy-cadF construct was transformed into E. coli SCS110 
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competent cells and plated out on LB amp agar plates. Positive colonies selected by 
growth on LB amp agar were screened using boilate PCR to check for the presence of 
cadF then sequenced to confirm cloning of the correct gene fragment. Each cloned gene 
fragment was disrupted by insertion of a Kmr cassette (Trieu-Cuot et al., 1985). The 
Kmr cassette was excised using BamHI from plasmid pJMK30 (van Vliet et al., 1998). 
pGEMT-easy-cadF plasmid DNA was digested with BclI and ligated with the Kmr 
cassette to form pGEMT-easy-cadF-Kmr. These constructs were then transformed into 
E. coli SCS110 competent cells and transformants selected on LB amp kan agar. 
Transformants were screened by boilate PCR using cadF-gene specific and Kmr-
specific primers. pGEMT-easy-cadF-Kmr constructs with the Kmr cassette in the same 
orientation as the cadF gene were selected and electroporated into either the 81-176 or 
11168H wild-type strain. Electroporated bacteria were plated onto blood agar plates and 
incubated at 37°C under microaerobic conditions for 2 to 3 days. Cells were harvested 
and resuspended in 0.5 ml PBS. Two hundred microliters of this suspension was spread 
onto blood agar plates containing kanamycin and incubated for 3 to 5 days. Putative 
cadF mutants were screened using PCR and sequencing. Gene specific primers were 
used to confirm presence of cadF and to confirm insertion and correct orientation of the 
kanamycin cassette. 
5.2.3 Construction of 81-176 and 11168H flpA mutants using Inverse PCR 
Mutagenesis 
Inverse PCR mutagenesis (IPCRM) can be performed when the gene to be mutated does 
not contain a BamHI, BclI or BglII restriction site. The Cjj81-176_1295 and Cj1279c 
genes were amplified by PCR using flpA-Forward-81-176/flpA-Reverse-81-176 and 
flpA-Forward-11168H/flpA-Reverse-11168H from C. jejuni and 11168H gDNA 
respectively (see Figure 5.3). Each PCR product was analysed by agarose gel 
electrophoresis and purified using the Qiagen PCR clean up kit. Each purified PCR 
product was ligated into the pGEMT-easy vector (Promega). Each pGEMT-easy-flpA 
construct was transformed into XL-2 Blue MRF’ competent cells and plated out on LB 
amp agar plates. Positive colonies selected by growth on LB amp agar were screened 
using boilate PCR to check for the presence of flpA, then sequenced to confirm cloning 
of the correct gene fragment. A BglII restriction site was introduced using primers flpA–
IPCRM-Forward and flpA–IPCRM-Reverse. IPCRM was performed on cloned 
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pGEMT-easy-flpA fragments at a diluted concentration of approximately 0.1-10 ng. The 
reduced concentration of template DNA was used to minimise the number of false 
positives after transformation into XL-2 Blue MRF’ competent cells. IPCRM products 
were analysed on an agarose gel. The amplified IPCRM product was purified using the 
QIAquick PCR Purification kit. The amplified IPCRM product was then digested with 
BglII and DpnI for 3 h at 37°C, then purified using the Qiagen PCR clean up kit. 
Digestion using DpnI was performed to ensure the reduction/elimination of methylated 
template DNA that could lead to false positive transformation (Shenoy and 
Visweswariah, 2003). Each cloned IPCRM-flpA gene fragment was disrupted by 
insertion of Kmr (Trieu-Cuot et al., 1985). The Kmr cassette was excised using BamHI 
from plasmid pJMK30 (van Vliet et al., 1998). The Kmr cassette was ligated with the 
IPCRM-flpA to form pGEMT-easy-flpA-Kmr. These constructs were then transformed 
into XL-2 Blue MRF’ competent cells and transformants selected on LB amp kan agar. 
Transformants were screened by boilate PCR using flpA-gene specific and Kmr-specific 
primers. The pGEMT-easy-flpA-Kmr constructs with the Kmr cassette in the same 
orientation as the flpA gene were selected and electroporated into either the 81-176 or 
11168H wild-type strain. Electroporated bacteria were plated onto blood agar plates and 
incubated at 37°C under microaerobic conditions for 2 to 3 days. Cells were harvested 
and resuspended in 0.5 ml PBS. Two hundred microliters of this suspension was spread 
onto blood agar plates containing kanamycin and incubated for 3 to 5 days. Putative 
flpA mutants were screened using PCR and sequencing. Gene specific primers were 
used to confirm presence of flpA and to confirm insertion and correct orientation of the 
kanamycin cassette. 
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ATGATGAAAAGATTTCGCTTGAGTTTTTACTTGAGTTTTTTAACTCTTTTGCT
TAGCGCTTGTAGTGTTTCGCAAATGAATTCGCTAGCTTCAAGTAAAGAGCCT
GCTGTAAATGAAAGCTTGCCAAAGGTTGAAAGTTTAAAAAGTCTTAGTGAT
ATGAGTAATATGCTTTTGAATGGGAGCCTTTATATAATGAAAATATTAAAGG
ATTTTATTTGTATCGTTCTAGTGATGAAAATCCTGATTTTAAACTTGTAGGCA
CTATTAAAGATAAGTTTCAAACTCATTATGTAGATACTAAATTAGAGCCTGG
TACTAAGTATCGTTATATGATGAAAAGCTTTAATGAGCAAGGACAAATTTC
AGAAGATGGCAAGGTTATAGAAGTGAGCACAGCTCCAAGACTTGAAGCTGT
TCCTTTTGTTCAAGCTGTGACTAATTTGCCTAATCGTATTAAACTTATTTGGC
GTCCGCATCCTGATTTTAGGGTTGATTCTTATATTATTGAAAGAACCAAAGG
TGATGATAAAGAATTTAAAAAAATTGCAGAAGTAAAAAATCGTTTAAACGC
TGAATACATCGATAGTGATTTAAAGCCTAATGAAAATTCAAGTTATAGAATT
ATTGCTGTGAGTTTTAATGGGATAAAGAGTGGGTCAAGTCAAGTTGTAAGTT
CTACAAGCAAGGCTTTACCTCCTCAAGTTGAGCATTTAAGTGCTAGCACAGA
TGGTTCTAGTAAAATCATTTTAACTTGGGATGCTCCTACGTATGAAGATTTT
TCTTATTATAAAGTTTATTCTACGAGCTCAAGCTTCCTTCCTTTTAGTGTTTT
GGCAAAGACTGATAAAAATTCTTATGAGGATATAGTAGAAGGAGCAGGTAA
AAGCAAGTATTATAAAGTAACAATGGTGGATAAAGATGGTCTTGAAAGTCC
TATGCCAAAAGATGGTGTAGAAGGTAAAACTTTAGGCAACCCTTTGGCTCC
TAGTATTATTTTGGCTCAAAGTACAAGCGAAGGGATAAATTTAGAATGGAG
TGATAATGATACTAGAGCTGTTGAGTATGAAGTAAGACGCTATGGCGGGGA
GCAAAATGCAGTTTTTAAAGGCATTAAAGAAAAGCGATTAAAAGATGTAAA
AGCTTTGCCAGGGGTGGAATATAGTTATGAAGTTATTGCTATTGATTCAGCC
GGGCTTCGTTCAGAACCTTCAAGCAAAGTTAAGGCGGCTCAGTA 
flpA-IPCRM F - ATCAGATCT GCAAGGCTTTACCTCCTCAAG 
flpA-IPCRM R - ATCAGATCT ACCCACTCTTTATCCCATT  
Figure 5.3. PCR and IPCRM primers designed for construction of the flpA mutant. The 5’-
end of the IPCRM primers contained three extra residues to allow efficient functionality of the 
BglII restriction site. This was followed by the BglII complementary sequence – AGATCT.  
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5.2.4 Construction of 81-176 and 11168H cadF and flpA complements 
As this study used both C. jejuni wild-type strains, complementation procedures were 
also performed in both strains to confirm that the phenotypes observed were due to the 
mutation and not due to random DNA changes or polar effects. Complementation was 
performed by inserting a copy of the functional cadF or flpA gene into the respective 
mutant chromosome using a C. jejuni complementation vector pRRC (Karlyshev and 
Wren, 2005). The coding region for cadF or flpA was amplified by PCR using primer 
pairs cadFcomp-Forward-81-176/cadFcomp-Reverse-81-176, cadFcomp-Forward-
11168H/cadFcomp-Reverse-11168H, flpAcomp-Forward-81-176/flpAcomp-Reverse-
81-176 or flpAcomp-Forward-11168H/flpAcomp-Reverse-11168H which introduced an 
XbaI site at both the 5′ and 3′ ends, as well as including the native ribosomal binding 
site. Each PCR product was analysed by agarose gel electrophoresis and purified using 
the Qiagen PCR clean up kit. Each purified PCR product and the pRRC vector were 
digested with XbaI. The digested products were purified using the Qiagen PCR clean up 
kit then ligated with the pRRC vector. Each pRRC-cadF/flpA-comp construct was 
transformed into E. coli DH5α cells and plated out LB chl agar plates. Positive colonies 
selected by growth on LB chl agar were screened using boilate PCR to check for the 
presence of cadF or flpA. Plasmid DNA was extracted from positive colonies. 
Sequencing the pRRC-cadF-comp construct showed that the cadFcomp gene was in the 
incorrect orientation and also the Pfx high quality polymerase amplification of cadF had 
introduced numerous base changes into the amplified cadF gene. Despite numerous 
attempts, the same result was always observed. The pRRC-flpA-comp construct was 
more successful as the presence of the correct gene and orientation was confirmed by 
PCR and sequencing. However, following electroporation into either the 81-176 or 
11168H flpA mutants, no growth was observed. The procedure was repeated with the 
same result on each occasion. 
cadF is 960 bp, the amplified cadF gene fragment is 900 bp and successful insertion of 
the 1400 bp kanamycin cassette produced a total amplified size of 2300 bp. flpA is 1200 
bp, the amplified flpA gene fragment is 1200 bp and insertion of 1400 bp kanamycin 
cassette produced a total amplified size of 2600 bp.  
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           1        2             3    4             5                6  
 
Figure 5.4 PCR verification of C. jejuni wild-type and cadF mutants. Lane 1: 1 Kb ladder 
(Bioline). Lane 2: Negative control. Lane 3: 11168H cadF. Lane 4: 81-176 cadF. Lane 5: 
11168H cadF mutant. Lane 6: 81-176 cadF mutant. 
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Figure 5.5 PCR verification of C. jejuni wild-type flpA mutant and flpA complement: Lane 
1: 1 Kb ladder (Bioline). Lane 2: Negative control. Lane 3: 11168H flpA Lane 4: 81-176 flpA 
Lane 5: 11168H-flpA-IPCRM. Lane 6: 81-176-flpA-IPCRM. Lane 7: Digested IPCRM 
product. Lane 8:11168H flpA mutant. Lane 9: 81-176 flpA mutant. Lane 10: 11168H flpA 
complement. Lane 11: 81-176 flpA complement 
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5.2.4. Characterisation of 81-176 and 11168H cadF and flpA mutants 
Following the construction of the 81-176 and 11168H cadF and flpA mutants, initial 
phenotypic characterisation studies were performed.	  
5.2.4.1 Growth rate assays and cfu counts  
To assess the effect of the mutations of cadF and flpA, growth rate experiments were 
performed. OD600 readings were recorded every 2 hours over a 32 h growth period as an 
indication of bacterial growth.  
Both the 81-176 and 11168H cadF mutants exhibited similar growth rates compared to 
the respective wild-type strain (see Figure 5.6). The numbers of colony forming units 
(cfu) at different time-point were also investigated for the 81-176 and 11168H wild-type 
strains and cadF mutants (see Figure 5.7). The 11168H cadF displayed a slightly 
reduced cfu count in comparison to the wild-type strain at most time-points.  
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(A) 
 
 
 (B) 
 
Figure 5.6. Growth rate counts for 81-176 and 11168H wild-type strains and cadF 
mutants. C. jejuni strains from 24 h plates were inoculated at OD600 0.1 into 10 ml of pre-
incubated brucella broth and grown at 37°C microaerobically with shaking at 75 rpm. (A) 81-
176 wild-type and cadF mutant (B) 11168H wild-type and cadF mutant. Growth was assessed 
by recording OD600 readings of the cultures every 2 h. The data represents the mean of triplicate 
independent experiments. 
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(A) 
 
(B)
 
Figure 5.7 Growth curve cfu counts for 81-176 and 11168H wild-type strains and cadF 
mutants. C. jejuni strains from 24 h plates were inoculated at OD600 0.1 into 10 ml of pre-
incubated brucella broth and grown at 37°C microaerobically with shaking at 75 rpm. At the 
desired time-point, 1 ml of brucella broth was removed and serial dilutions were performed 
from 10-1 to 10-7 and 200 µl of the final dilution was plated onto blood agar plates. Colonies 
were enumerated following incubation at 37°C under microaerobic conditions for 2 to 3 days. 
(A) 81-176 wild-type and cadF mutant (B) 11168H wild-type and cadF mutant. Asterisks 
denote a statistically significant difference (* = p <0.05; ** = p <0.01; ns = not significant). The 
data represents triplicate independent experiments. 
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 The flpA mutants also displayed similar growth rates compared to the respective wild-
type strain (see Figure 5.8 and Figure 5.9). 
(A) 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
 
(B)
	  
Figure 5.8 Growth rate counts for 81-176 and 11168H wild-type strains and flpA mutants. 
C. jejuni strains from 24 h plates were inoculated at OD600 0.1 into 10 ml of pre-incubated 
brucella broth and grown at 37°C microaerobically with shaking at 75 rpm. (A) 81-176 wild-
type and flpA mutant (B) 11168H wild-type and flpA mutant. Growth was assessed by recording 
OD600 readings of the cultures every 2 h. The data represents the mean of triplicate independent 
experiments. 
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(A) 
  
 (B) 
 
Figure 5.9 Growth curve cfu counts for 81-176 and 11168H wild-type strains and flpA 
mutants. C. jejuni strains from 24 h plates were inoculated at OD600 0.1 into 10 ml of pre-
incubated brucella broth and grown at 37°C microaerobically with shaking at 75 rpm. At the 
desired time point, 1 ml of brucella broth was removed and serial dilutions were performed 
from 10-1 to 10-7 and 200 µl of the final dilution was plated onto blood agar plates. Colonies 
were enumerated following incubation at 37°C under microaerobic conditions for 2 to 3 days. 
(A) 11168H wild-type and flpA mutant (B) 81-176 wild-type and flpA mutant. Asterisks denote 
a statistically significant difference (* = p <0.05; ns = not significant). The data represents 
triplicate independent experiments.  
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5.2.4.2 Motility assays 
C. jejuni motility plays an important role in infection of humans and colonisation of 
other animals (Black, Levine et al. 1988). To study the effects of the mutations in cadF 
and flpA on C. jejuni motility, motility assays were performed.  
Both 81-176 and 11168H cadF mutants displayed a reduction in motility compared to 
the wild-type. The 81-176 cadF mutant was not as motile as the 11168H cadF mutant at 
the 72 h time-point. Both 81-176 and 11168H flpA mutants appeared to be non-motile. 
  
 
Figure 5.10. Comparison of motility of 81-176 wild-type strain compared with cadF and 
flpA mutants. Bacteria were grown for 24 h on blood agar. A suspension was prepared and 
adjusted to an OD600 of 0.1 2 µl of this suspension was pipetted into the centre of soft agar plates 
and incubated at 37°C. The level of motility was assessed by measuring the diameter of the 
growth from the centre of the inoculation point at 24 h, 48 h and 72 h. Asterisks denote a 
statistically significant difference (* = p <0.05, ** = p <0.01, *** = p <0.001). Data is 
representative of three independent experiments. 
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Figure 5.11 Comparison of motility of 11168H wild-type strain with cadF and flpA 
mutants. Bacteria were grown for 24 hours on blood agar. A suspension was prepared and 
adjusted to an OD600 of 0.1. 2µl of this suspension was pipetted into the centre of soft agar plates 
and incubated at 37°C. The level of motility was assessed by measuring the diameter of the 
growth from the centre of the inoculation point at 24 h, 48 h and 72 h. Asterisks denote a 
statistically significant difference (* = p <0.05, ** = p <0.01, *** = p <0.001). Data is 
representative of three independent experiments. 
5.2.4.3 Autoaggregation  
Autoaggregation (AAG) of C. jejuni plays a role during interactions with and invasion 
of host cells (Guerry et al., 2006).	  However the role of AAG in C. jejuni pathogenesis is 
yet to be fully determined. The amount of AAG also varies between C. jejuni strains 
(Misawa and Blaser, 2000). AAG has been found to play a role in resistance to host 
defences such as phagocytosis, in biofilm formation and in adherence to host cells 
(Skurnik, Bolin et al. 1984, Galdiero, Romano Carratelli et al. 1988, Chiang, Taylor et 
al. 1995, Frick, Morgelin et al. 2000, Sherlock, Vejborg et al. 2005). 
In order to investigate the effect of the cadF or flpA mutations on C. jejuni AAG, cadF 
and flpA mutants were tested and compared to the 81-176 and 11168H wild-type strains. 
RpoN is an alternative sigma factor involved in the transcription of genes encoding 
proteins involved in flagella biosynthesis (Hendrixson et al., 2001). 81-176 and 11168H 
rpoN mutants which lack a functional flagella and do not autoaggregate were included 
as AAG negative controls.  
The 81-176 cadF mutant exhibited significantly increased AAG levels whilst the 81-
176 flpA mutant did not exhibit any differences in AAG levels compared to the 81-176 
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wild-type. The 11168H cadF mutant was also significantly increased in AAG levels 
whilst the 11168H flpA mutant was significantly reduced in AAG levels compared to 
the 11168H wild-type.  
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(A)       
 
(B) 
 
 (C)                                    
	  
(D) 
                           
Figure 5.12. Autoaggregation assays for the 81-176 and 11168H wild-type strains, cadF 
and flpA mutants. Bacteria were grown for 24 h on blood agar. A suspension was prepared and 
adjusted to an OD600 of 1.0 in PBS. Suspensions (2 ml) were incubated for 24 h at 37ºC. AAG 
was analysed by measuring the decrease in optical density of the upper 1 ml of suspended cells 
after 24 h. An OD600 of 1.0 was considered 0% AAG and an OD600 of 0 considered 100% AAG. 
(A) and (C): OD600 readings after 24 h incubation. (B) and (D): Percentage of AAG of 
suspended cells. Asterisks denote a statistically significant difference (** = p < 0.01, *** = p 
<0.001). Data are representative of triplicate individual experiments. 
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5.2.4.4 Galleria mellonella infection model 
G. mellonella larvae have been widely used as a non-mammalian model for bacterial 
infection studies (Champion et al., 2009). Larvae can be infected at 37°C and possess 
specialised phagocytic cells called haemocytes (Bergin, Reeves et al. 2005). These cells 
mimic mammalian phagocytic cells and produce bactericidal compounds such as 
superoxide (Bergin, Reeves et al. 2005). Infection with the cadF or flpA mutants 
resulted in reduced cytotoxicity compared to the respective wild-type strain over 72 h. 
 
Figure 5.13. Effect of C. jejuni 81-176 wild-type strain, cadF and flpA mutants in the 
Galleria mellonella model of infection. G. mellonella larvae were injected with a 10 µl 
inoculum of 24 h C. jejuni culture diluted to an OD600 of 0.1 by microinjection in the right 
foremost leg, giving an infectious dose of approximately 106 cfu. The larvae were incubated at 
37°C with survival recorded at 24 h intervals. PBS and no injection controls were also included. 
For each experiment, 10 G. mellonella larvae were infected and the experiments were repeated 
in triplicate. The asterisks denote a statistically significant difference (*** = p <0.001).  
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Figure 5.14. Effect of C. jejuni 11168H wild-type strain, 11168H cadF and flpA mutants in 
the Galleria mellonella model of infection. G. mellonella larvae were injected with a 10 µl 
inoculum of 24 h C. jejuni culture diluted to an OD600 of 0.1 by microinjection in the right 
foremost leg, giving an infectious dose of approximately 106 cfu. The larvae were incubated at 
37°C with survival recorded at 24 h intervals. PBS and no injection controls were also included. 
For each experiment, 10 G. mellonella larvae were infected and the experiments were repeated 
in triplicate. The asterisks denote a statistically significant difference of (*** = p <0.001).  
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5.2.5 81-176 cadF and flpA mutants exhibit reduced binding to fibronectin  
Previous studies have shown that C. jejuni CadF and FlpA are both microbial surface 
components recognising adhesive matrix molecules (Konkel et al., 2005, Flanagan et 
al., 2009). The binding of these outer membrane proteins to fibronectin on the host cell 
surface allows for bacterial attachment (Monteville and Konkel, 2002, Schwarz-Linek et 
al., 2004, Konkel et al., 2005, Krause-Gruszczynska et al., 2007a). The C. jejuni FlpA 
amino acid sequence harbours fibronectin type III domains and studies with C. jejuni 
strain F38011 showed that flpA mutants exhibited a reduction in ability to bind to 
chicken epithelial cells (Flanagan et al., 2009). Fibronectin binding assays demonstrated 
that both 81-176 cadF and flpA mutants exhibited significantly reduced ability to bind 
to fibronectin compared to the wild-type strain. The 81-176 rpoN mutant was included 
as a control.  
 
Figure 5.15. Fibronectin binding assays. The wells of 96-well flat-bottom plates were coated 
with a 1 mg/ml solution of fibronectin in 0.05 M Tris-buffered saline, pH 7.5 and incubated 
overnight at 4°C. C. jejuni 81-176 wild-type strain, cadF and flpA mutants were harvested from 
overnight plate cultures and resuspended in PBS at an OD600 of 0.1. Wells were rinsed with 
PBS, then 100 µl aliquots of the bacterial suspensions were added to each well and incubated at 
37°C in a CO2 incubator for 1 h. The wells were washed three times with PBS, then adherent 
bacteria were removed by the addition of 0.05% (w/v) Trypsin. To enumerate the number of 
adherent bacteria, serial dilutions of the trypsin suspension were plated on blood agar plates. 
Asterisks denote a statistically significant difference (** = p < 0.01; ns = not significant). The 
data are representative of triplicate independent experiments 
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5.2.6 Interaction and invasion assays 
The effect of the mutations in cadF and flpA on C. jejuni interactions with IECs was 
investigated.  
5.2.6.1 The role of CadF in C. jejuni interactions with and invasion of Caco-2 IECs 
There was a significant reduction in the ability of the 81-176 cadF mutant to interact 
with and invade Caco-2 IECs in comparison to the 81-176 wild-type strain. The 81-176 
cadF mutant exhibited a significantly reduced ability to interact with Caco-2 IECs 
compared to the wild-type strain (see Figure 5.16). The 81-176 cadF mutant also 
displayed a significant reduction in invasion (see Figure 5.17). 
              
 
Figure 5.16. Interaction (adhesion and invasion) assays. Bacteria were co-cultured with 
Caco-2 IECs for 3 h, 6 h and 24 h. Caco-2 IECs were lysed with Triton X-100 and interacting 
bacteria were enumerated. Asterisks denote a statistically significant difference (*** = p 
<0.001) for the 81-176 cadF mutant compared to the wild-type strain. Data are representative of 
triplicate independent experiments. 
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Figure 5.17 Invasion assays. Bacteria were co-cultured with Caco-2 IECs for 3 h, 6 h and 24 h. 
Caco-2 IECs were incubated with gentamicin (150 µg/ml) for 2 h to kill extracellular bacteria, 
then lysed and numbers of intracellular bacteria assessed. Asterisks denote a statistically 
significant difference (** = p < 0.01, *** = p <0.001) for the 81-176 cadF mutant compared to 
the wild-type strain. Data are representative of triplicate independent experiments. 
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5.2.6.2 The role of CadF in C. jejuni interactions with and invasion of T84 IECs  
There was also a significant difference between the ability of the 81-176 cadF mutant to 
interact with and invade T84 IECs in comparison to the 81-176 wild-type strain. The 
81-176 cadF mutant exhibited a significantly reduced ability to interact with T84 IECs 
(see Figure 5.18). The 81-176 cadF mutant also displayed a significant reduction in 
invasion (see Figure 5.19). 
 
 
 
Figure 5.18 Interaction (adhesion and invasion) assays. Bacteria were co-cultured with T84 
IECs for 3 h, 6 h and 24 h. T84 IECs were lysed with Triton X-100 and interacting bacteria 
were enumerated. Asterisks denote a statistically significant difference (** = p <0.01, *** = p 
<0.001) for the 81-176 cadF mutant compared to the wild-type strain. Data are representative of 
triplicate independent experiments. 
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Figure 5.19 Invasion assays. Bacteria were co-cultured with T84 IECs for 3 h, 6 h and 24 h. 
T84 IECs were incubated with gentamicin (150 µg/ml) for 2 h to kill extracellular bacteria, then 
lysed and numbers of intracellular bacteria assessed. Asterisks denote a statistically significant 
difference (*** = p <0.001) for the 81-176 cadF mutant compared to the wild-type strain. Data 
are representative of triplicate independent experiments. 
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5.2.6.3 The role of FlpA in C. jejuni interactions with and invasion of Caco-2 IECs  
The 81-176 flpA mutant also exhibited a significantly reduced ability to interact with 
Caco-2 cells compared to the wild-type strain (see Figure 5.20). A significant reduction 
in invasion levels by the flpA mutant was also observed (see Figure 5.21).  
 
Figure 5.20 Interaction (adhesion and invasion). Bacteria were co-cultured with Caco-2 IECs 
for 3 h, 6 h and 24 h. Caco-2 IECs were lysed with Triton X-100 and interacting bacteria were 
enumerated. Asterisks denote a statistically significant difference (*** = p <0.001) for the 81-
176 flpA mutant compared to the wild-type strain. Data are representative of triplicate 
independent experiments. 
 
Figure 5.21 Invasion assays. Bacteria were co-cultured with Caco-2 IECs for 3 h, 6 h and 24 h. 
Caco-2 IECs were incubated with gentamicin (150 µg/ml) for 2 h to kill extracellular bacteria, 
then lysed and numbers of intracellular bacteria assessed. Asterisks denote a statistically 
significant difference (*** = p <0.001) for the 81-176 flpA mutants compared to the wild-type 
strain. Data are representative of triplicate independent experiments. 
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5.2.6.4 The role of FlpA in C. jejuni interactions with and invasion of T84 IECs 
The 81-176 flpA mutant was also significantly reduced in interactions with and invasion 
of T84 IECs compared to the 81-176 wild-type strain (see Figure 5.22 and Figure 5.23). 
    
Figure 5.22 Interaction (adhesion and invasion) assays. Bacteria were co-cultured with T84 
intestinal epithelial cells for 3 h, 6 h and 24 h. T84 IECs were lysed with Triton X-100 and 
interacting bacteria were enumerated. Asterisks denote a statistically significant difference (** = 
p <0.01, *** = p <0.001) for the 81-176 flpA mutant compared to the wild-type strain. Data are 
representative of triplicate independent experiments. 
 
Figure 5.23 Invasion assays. Bacteria were co-cultured with T84 intestinal epithelial cells for 3 
h, 6 h and 24 h. T84 IECs were incubated with gentamicin (150 µg/ml) for 2 h to kill 
extracellular bacteria, then lysed and numbers of intracellular bacteria assessed. Asterisks 
denote a statistically significant difference (*** = p <0.001) for the 81-176 flpA mutant 
compared to the wild-type strain. Data are representative of triplicate independent experiments. 
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Table 5.1 Summary of the effect of the mutation in cadF and flpA on C. jejuni 
interactions with Caco-2 IECs.  
Bacterial 
strain 
Effect of 
interaction 
with Caco-2 
IECs (3 h) 
Effect of 
interaction 
with Caco-2 
IECs (6 h) 
Effect of 
interaction 
with Caco-2  
IECs (24 h) 
 
81-176 wild-
type 
< 107 cfu < 107 cfu < 107 cfu 
cadF mutant > 106 cfu > 106 cfu > 106 cfu 
flpA mutant > 106 cfu > 106 cfu > 106 cfu 
 
Table 5.2 Summary of the effect of the mutation in cadF and flpA on C. jejuni 
invasion of Caco-2 IECs.  
Bacterial 
strain 
Effect of 
invasion of 
Caco-2 IECs 
(3 h) 
Effect of 
invasion of 
Caco-2 IECs 
(6 h) 
Effect of 
invasion of 
Caco-2  IECs 
(24 h) 
 
81-176 wild-
type 
<105 cfu < 105 cfu < 105 cfu 
cadF mutant > 103 cfu > 104 cfu > 104 cfu 
flpA mutant > 102 cfu > 103 cfu > 103 cfu 
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Table 5.3 Summary of the effect of the mutation in cadF and flpA on C. jejuni 
interactions with T84 IECs.  
Bacterial 
strain 
Effect of 
interaction 
with T84 
IECs (3 h) 
Effect of 
interaction 
with T84 IECs 
(6 h) 
Effect of 
interaction 
with T84  
IECs (24 h) 
 
81-176 wild-
type 
>107 cfu >107 cfu >107 cfu 
cadF mutant <106 cfu > 106 cfu < 106 cfu 
flpA mutant > 106 cfu > 106 cfu > 106 cfu 
 
Table 5.4 Summary of the effect of the mutation in cadF and flpA on C. jejuni 
invasion of T84 IECs. 
Bacterial 
strain 
Effect of 
invasion of 
T84 IECs (3 h) 
Effect of 
invasion of T84 
IECs (6 h) 
Effect of 
invasion of 
T84  IECs 
(24 h) 
 
81-176 wild-
type 
<104 cfu >104 cfu >104 cfu 
cadF mutant >102 cfu > 102 cfu > 103cfu 
flpA mutant >102 cfu >102 cfu > 103cfu 
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5.2.7 Intracellular survival assays 
Our knowledge of C. jejuni interactions with, invasion of and survival within intestinal 
epithelial cells is limited compared to other enteropathogenic bacteria. However, studies 
have revealed that C. jejuni can evade phagocytosis and survive for a certain period 
intracellularly (Kiehlbauch et al., 1985, Watson and Galan, 2008b) and also trigger the 
release of host cytokines (Jones et al., 2003). The exact process of how this invasion 
and intracellular survival occurs is still unclear. C. jejuni avoids delivery to the 
lysosomes and resides within Campylobacter containing vacuoles (CCV) (Watson and 
Galan, 2008b, Pryjma et al., 2012). To study the effect of mutation of cadF or flpA on 
the ability of C. jejuni to survive intracellularly within Caco-2 cells, intracellular 
survival assays were performed.  
The 81-176 cadF mutant exhibited significantly reduced intracellular survival compared 
to the wild-type strain (see Figure 5.24). The 81-176 flpA mutant exhibited a reduced 
level of invasion, however no decrease in intracellular survival was observed. The 
percentage survival of 81-176 wild-type, cadF and flpA mutants was also calculated and 
the cadF mutant displayed a reduction in survival similar to the wild-type strain, 
whereas the flpA mutant showed no decrease in survival levels (see Table 5.5). 
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Figure 5.24 Intracellular survival assay. The 81-176 wild-type strain, cadF and flpA mutants 
were co-cultured with Caco-2 IECs for 3 h, washed three times with PBS, then incubated with 
gentamicin (150 µg/ml) for 2 h to kill extracellular bacteria, followed by further incubation with 
gentamicin for 19 h at a reduced concentration (10 µg/ml). The monolayers were then washed 
three times in PBS, lysed with Triton X-100 and numbers of intracellular bacteria assessed. 
Asterisks denote a statistically significant difference (* = p <0.05; ** = p <0.01, ns = no 
significant difference). Data represents triplicate independent experiments.  
 
Table 5.5 Percentage survival of intracellular 81-176 wild-type strain, cadF and 
flpA mutants after 19 h within Caco-2 IECs  
 
 
 
 
 
 
 
Bacterial Strain % survival after 19 h 
81-176 wild-type 10.10 
81-176 cadF mutant 10.54 
81-176 flpA mutant 100.0 
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5.2.8 Macrophage survival assays 
Once inside the host, relatively little is known about the intracellular life cycle of C. 
jejuni, although it is possible that C. jejuni behaves in a similar way to other 
enteropathogens with well characterised intracellular survival strategies and that C. 
jejuni may have evolved specific mechanisms to survive intracellularly (Watson and 
Galan, 2008b). Macrophage survival assays were performed as described previously 
(Watson and Galan, 2008b) using J774A.1 mouse macrophages (Sikic Pogacar et al., 
2009). The 81-176 cadF mutant exhibited a significant reduction in macrophage 
survival, with no bacteria observed after 16 h compared to the wild-type strain (see 
Figure 5.25). The 81-176 flpA mutant also exhibited a significant reduction in 
macrophage survival after 4 h, but at 16 h, macrophage survival was similar to the wild-
type strain. 
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Figure 5.25 Macrophage survival assays. The 81-176 wild-type strain, cadF and flpA mutants 
were co-cultured with J774A.1 mouse macrophages for 3 h. The cells were washed three times 
in PBS, followed by incubation in DMEM containing gentamicin (150 µg/ml) for 2 h to allow 
killing of extracellular bacteria. The macrophages were then incubated in DMEM containing a 
reduced concentration of gentamicin (10 µg/ml) and bacterial survival determined at 0 h, 4 h 
and 16 h. At each time point, the macrophages were washed three times with PBS and lysed by 
adding 0.2% (v/v) Triton X-100 in PBS and the number of intracellular bacteria were assessed. 
The asterisks denote a statistically significant difference (** = p <0.01). Data represents 
triplicate independent experiments.  
5.2.9 Sensitivity of C. jejuni to Triton X-100 and gentamicin 
To ascertain whether the above results were due to genuine cadF or flpA mutant 
phenotypes and not due to increased sensitivity to Triton X-100 or gentamicin, 
sensitivity assays were performed on all the mutants and respective wild-type strains 
with 0.2% (v/v) Triton X-100 or gentamicin (150 µg/ml). No significant differences 
were observed between the levels of sensitivity to Triton X-100 (see Figure 5.26) or 
gentamicin (data not shown) between the 81-176 and 11168H wild-type strains and the 
respective cadF or flpA mutants.  
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 (A)     
   
(B) 
 
Figure 5.26 Sensitivity of C. jejuni strains to Triton X-100. Bacteria was grown for 24 h on 
blood agar. The bacteria were resuspended in PBS and adjusted to an OD600 of 0.1. Triton X-
100 was added to a final concentration of 0.2% (v/v) and after incubation at 37°C with 5% CO2 
for 20 minutes the number of viable bacteria was determined. (A) 11168H wild-type strain, 
cadF and flpA mutants (B) 81-176 wild-type strain, cadF and flpA mutants. (ns = no significant 
difference). Data represents triplicate independent experiments.  
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5.2.10 Vertical Diffusion Chamber Assays 
A major limitation of in vitro models used to study gastrointestinal infections is that 
standard tissue culture conditions include high oxygen levels which generally favour 
eukaryotic cell survival and do not allow the true observation of the biological 
interactions of the bacteria with the host cell (Mills et al., 2012)m. In the case of C. 
jejuni, a number of different cell culture assays have been used to investigate the 
interactions of C. jejuni with host cells. Caco-2 (Everest et al., 1992), INT407 (Konkel 
et al., 1992b) and T84 (Monteville and Konkel, 2002) cell lines have all been used 
extensively to study the adhesion and invasion capabilities of different C. jejuni strains. 
However, the levels of bacterial adhesion and invasion for C. jejuni with IECs are 
dramatically lower than for other enteric pathogens (Friis et al., 2005).  
The use of a Vertical Diffusion Chamber (VDC) system allows the co-culture of 
bacteria and host cells under different medium and gas conditions (Cottet et al., 2002a, 
Schuller and Phillips, 2010, Mills et al., 2012). The 81-176 cadF and flpA mutants both 
exhibited significantly reduced invasion of Caco-2 IECs compared to the wild-type 
strain and a reduced invasion ability of cadF and flpA mutants was also observed using 
T84 IECs, however the numbers of intracellular bacteria were slightly higher than when 
using Caco-2 IECs. A C. jejuni 81-176 rpoN mutant, was included as a non-motile 
control (Fernando et al., 2007a). Infection of both Caco-2 and T84 IECs with the rpoN 
mutant, resulted in significantly reduced numbers of intracellular bacteria compared to 
the wild-type.  
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(A) 
 
 (B) 
 
Figure 5.27 Vertical Diffusion Chambers assays. 81-176 wild-type strain, cadF, flpA and 
rpoN mutants co-cultured with (A) Caco-2 or (B) T84 IECs in a Vertical Diffusion chamber at a 
multiplicity of infection (MOI) of approximately 100:1 under microaerobic conditions for 6 h 
and the numbers of intracellular bacteria were assessed. Caco-2 or T84 IECs were incubated 
with gentamicin (150 µg/ml) for 2 h to kill extracellular bacteria, then lysed and numbers of 
intracellular bacteria assessed. The asterisks denote a statistically significant difference (*** = 
p<0.001). Data are representative of triplicate independent experiments. 
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5.2.11 ELISA assays 
IL-8 is a well characterised marker of the host immune response to pathogens 
(Oppenheim et al., 1991) and interaction with and invasion of IECs by C. jejuni triggers 
both innate and adaptive immune responses (Chen et al., 2006, Rathinam et al., 2008). 
Cytokines of the TNFα family have been found to play central roles in the development 
of a stable immune system and protection from pathogens (Pfeffer, 2003).  
Supernatants from uninfected and T84 IECs infected with 81-176 or 11168H wild-type 
strains, cadF and flpA mutants at an MOI of 100:1 for 24 h were collected. The levels of 
IL-8 and TNFα secretion were assessed.  
Both the 81-176 and 11168H cadF mutants induced significantly reduced IL-8 levels in 
comparison to the respective wild-type strains. Both the 81-176 and 11168H flpA 
mutants also induced significantly reduced levels of IL-8 compared to the respective 
wild-type strains (see Figure 5.28).  
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(B) 
 
Figure 5.28 The role of CadF and FlpA in C. jejuni induction of IL-8 from T84 IECs. The 
81-176 and 11168H wild type strains, cadF and flpA mutants were assessed. The levels of IL-8 
secreted after 24 h C. jejuni interaction (MOI 100:1) with T84 IECs were quantified using a 
human IL-8 ELISA. The asterisks denote a statistically significant difference (** = p < 0.01, 
*** = p < 0.001). Data are representative of triplicate independent experiments.   
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The 11168H cadF mutant induced significantly increased levels of TNFα compared to 
the wild-type strain and whilst the 81-176 cadF mutant also induced increased TNFα 
levels compared to the wild-type strain, this was not significant. Both 11168H and 81-
176 flpA mutants induced significantly reduced levels of TNFα compared to the wild-
type strain.  
(A)   
 
(B)  
 
Figure 5.29 The role of CadF and FlpA in C. jejuni TNFα induction from T84 IECs. The 
81-176 and 11168H wild type strains, cadF and flpA mutants were assessed. The levels of 
TNFα secreted after 24 h C. jejuni interaction (MOI 100:1) with T84 IECs were quantified 
using a human TNFα ELISA. The asterisks denote a statistically significant difference (* =p< 
0.05, ** = p < 0.01, ns = no significant difference). Data are representative of triplicate 
independent experiments. 
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Following 6 h infection of T84 IECs in the VDC system, the levels of IL-8 and TNFα 
were assessed in the basolateral compartment. The 81-176 cadF and flpA mutants 
induced a reduced IL-8 and TNFα response from T84 IECs compared to the wild-type 
(see Figure 5.30). 
(A) 
 
      (B) 
 
Figure 5.30 The role of CadF and FlpA in C. jejuni induction of IL-8 and TNFα from T84 
IECs in the VDC system. T84 IEC responses to 6 h co-incubation with C. jejuni 81-176 wild 
type strain, cadF and flpA mutants (MOI 100:1). The levels of IL-8 and TNFα secreted during 
C. jejuni interaction with T84 IECs in the VDC were quantified using a human IL-8 (A) or 
human TNFα (B) ELISA. Uninfected IECs were used included as controls. The asterisks denote 
a statistically significant difference (** = p <0.01, *** = p<0.001). Data are representative of 
triplicate independent experiments.  
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5.2.12 Role of outer membrane vesicles in C. jejuni interactions with IECs  
Many Gram-negative pathogenic and non-pathogenic bacteria have been found to 
produce outer membrane vesicles (OMVs) (Kuehn and Kesty, 2005, Ellis and Kuehn, 
2010). OMVs have also been found to contain virulence factors which play a role in 
pathogenesis (Ellis and Kuehn, 2010). Numerous Gram-negative bacteria including E. 
coli, P. aeruginosa, C. jejuni and H. pylori have been shown to produce OMVs 
(Hoekstra et al., 1976, Gankema et al., 1980, Logan and Trust, 1982, Blaser et al., 
1983b, Kadurugamuwa and Beveridge, 1995, Fiocca et al., 1999, Bauman and Kuehn, 
2006). 
Caco-2 IECs were pre-incubated with OMVs for 24 h to ascertain whether OMVs 
would affect C. jejuni interactions with and invasion of IECs. 
Pre-incubation with OMVs (10 µg) isolated from 81-176 wild-type and the cadF mutant 
resulted in a significant increase in the number of interacting bacteria whilst pre-
incubation with OMVs (10 µg) isolated from the flpA mutant resulted in only a marginal 
increase compared to the control with no OMV pre-incubation (see Figure 5.31).  
Pre-incubation with OMVs (10 µg) isolated from 81-176 wild-type, the cadF and flpA 
mutants produced a significant reduction in the number of intracellular bacteria (103 
cfu) compared to the control with no OMV pre-incubation (105 cfu). No significant 
differences were observed in the numbers of intracellular bacteria after pre-incubation 
with OMVs (10 µg) from 81-176 wild-type compared to the control with no pre-
incubation (see Figure 5.31).  
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(A) 
 
(B)  
 
Figure 5.31 Effect of pre-incubation of C. jejuni OMVs on bacterial interactions with and 
invasion of Caco-2 IECs OMVs (10 µg) isolated from C. jejuni 81-176 wild-type strain, cadF 
and flpA mutants were pre-incubated with Caco-2 IEC for 24 h. Monolayers were washed three 
times with PBS. Bacteria was harvested from 24 h plates, resuspended in PBS and adjusted to 
an OD600 of 0.1. Bacteria was co-cultured with Caco-2 IECs for 24 h. (A) Caco-2 IECs were 
lysed with Triton X-100 and interacting bacteria were enumerated. (B) For invasion, Caco-2 
IEC cells were incubated with gentamicin (150 µg/ml) for 2 h to kill extracellular bacteria, then 
lysed and numbers of intracellular bacteria assessed. Asterisks denote a statistically significant 
difference (* = p <0.05; ** = p <0.01, ns = no significant difference). Data are representative of 
triplicate independent experiments.  
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5.3 Discussion 
The attachment of pathogenic bacteria to structures on the surface of IECs is critical for 
colonisation of the host and for infection (Pizarro-Cerda and Cossart, 2006). There are 
over a hundred documented bacterial adhesins that have been shown to bind to 
fibronectin, highlighting the importance of this glycoprotein as an essential target for 
pathogenic bacteria (Henderson et al., 2011, Larson et al., 2013).Two C. jejuni outer 
membrane proteins CadF and FlpA have been shown to bind to fibronectin (Konkel et 
al., 1997, Flanagan et al., 2009). Currently, the most well characterised fibronectin 
binding protein is CadF (O. Croinin and Backert, 2012). The binding of this adhesin to 
fibronectin is proposed to trigger an integrin signalling cascade within the host cell 
which promotes C. jejuni internalisation and recent studies have suggested that CadF 
and FlpA function co-operatively in binding to fibronectin and inducing uptake of the 
bacteria (Eucker and Konkel, 2012a, Backert and Hofreuter, 2013). 
For this chapter, cadF and flpA mutants were constructed in both 81-176 and 11168H 
wild-type strains. Initial phenotypic characterisation studies were performed on both 81-
176 and 11168H cadF mutants. Growth rate studies showed that cadF and flpA 
displayed a slight reduction in growth in comparison to the respective wild-type strains. 
At selected time-points, growth curve cfu counts were also performed and the results of 
these reflected the growth rates observed. The 81-176 and 11168H cadF mutant 
displayed significantly reduced growth rates at the 12 h and 18 h time-points compared 
to the wild-type, similarly the 81-176 and 11168H flpA mutant exhibited slightly 
reduced growth rates compared to the respective wild-type strains. 
Clearly, CadF and FlpA are important for adhesion, as interaction and invasion assays 
performed with cadF and flpA mutants, resulted in a significantly reduced ability of C. 
jejuni to interact with and invade Caco-2 and T84 IECs. However, an interesting finding 
observed in these experiments was the ability of the cadF and flpA mutants to recover 
over the 6 h and 24 h infection period that would indicate that other adhesins or 
bacterial virulence factors may be enabling the attachment of the bacteria over longer 
time periods. Previous studies have shown that cadF and flpA mutants, displayed 
significant reductions in interactions with INT407 IECs after a 30 min incubation 
period, the differences could have been due to experimental procedures as the INT407 
IECs were grown for 18 h, followed by the addition of F38011 wild-type strain, cadF or 
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flpA mutants (5 x 107 cfu) and monolayers were centrifuged to enhance bacterial 
attachment to IECs. Bacterial numbers recovered after the 30 minute incubation period 
were >106 cfu for the wild-type, 105 cfu for the cadF mutant and <106 cfu for the flpA 
mutant (Monteville et al., 2003b, Konkel et al., 2010). In contrast to Konkel’s data and 
the results of this study, another group reported neither cadF, flpA or any cia mutants 
were detected in a screen for invasion-related genes in C. jejuni 81-176 (Novik et al., 
2010). However more recent reports of the role of both CadF and FlpA in host cell 
invasion has made the study of these fibronectin binding proteins an important area of 
research. 
Both cadF and flpA mutants displayed changes in the interaction with and invasion of 
Caco-2 or T84 IECs at 3 h, 6 h and 24 h time-points used in this study. However, this 
study found that although there is an initial reduction in attachment ability of both cadF 
and flpA mutants, which correlates with Konkel’s work, there are changes clearly 
occurring over the longer periods in which the assays in this study were performed in. 
One of the reasons for this could be due to the increased AAG levels observed for the 
cadF mutant, which may allow higher numbers of the cadF mutant to adhere over time, 
(although, the increase for the cadF mutant was only observed in the Caco-2 IECs). C. 
jejuni is reported to translocate across Caco-2 IECs by entering through the IECs 
(transcellular entry) (Konkel et al., 1992c, Grant et al., 1993, Bras and Ketley, 1999). In 
the T84 IECs C. jejuni translocates between cells (paracellular entry) exiting at the basal 
surface and then re-attaching to the host receptors located basolaterally (Monteville and 
Konkel, 2002, Backert et al., 2013). However, exactly how the bacteria accomplishes 
this is unknown. The adhesins CadF and FlpA which can bind to the basolaterally 
located fibronectin on T84 IECs, have been reported to cause triggering of integrin 
complex and thus invasion can occur from the bottom of epithelial cells (van Alphen et 
al., 2008). Both cadF and flpA mutants were not only reduced in invasion of T84 IECs, 
but the numbers of internalized bacteria recovered were significantly lower than those 
recovered from Caco-2 IECs. Similarly, a previous study also reported a significant 
reduction for the F38011 cadF mutant interactions with T84 IECs after 2 h and 4 h 
(Monteville and Konkel, 2002).  
The Caco-2 IEC line has been reported to lack detectable expression of fibronectin, 
EGFR and α5 and β1 receptors (Kuwada and Li, 2000) and Caco-2 IEC differentiation 
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has been shown to lead to dramatic reductions specifically in the expression of 
fibronectin and laminin due to down regulation of gene expression (Levy et al., 1994). 
This differentiation and possible lack of expression of fibronectin may affect C. jejuni 
interactions with Caco-2 IEC in both in vitro and in vivo conditions (Simo et al., 1991, 
Levy et al., 1994). Hence the variations not only observed in this study but also in 
previous reports in interactions with and invasion of IECs by C. jejuni may be due the 
presence or absence of specific receptor sites. However, in this study the interactions of 
cadF and flpA were the same for both Caco-2 and T84 IECs, but the numbers of 
internalised bacteria recovered from T84 IECs were less than those recovered from the 
Caco-2 IECs. 
The intracellular survival of the cadF mutant was significantly reduced at time 0 h and 
further decreased at the 19 h time-point compared to the wild type. The flpA mutant, 
although significantly decreased in intracellular numbers compared to the wild-type, 
actually displayed an increase in the number of viable bacteria surviving intracellularly 
at the 19 h time-point, this may be due to lower numbers of the flpA mutant at the start 
may have had an effect on the numbers of bacteria surviving intracellularly. In addition 
the, flpA mutant still possesses a functioning CadF, perhaps the presence of this adhesin 
is allowing the bacteria to activate host cell signalling pathways and enabling 
intracellular survival. 
The dynamic bacterial interactions observed for the cadF and flpA mutant in the 
interactions and invasion assays and intracellular survival studies may be due to the 
presence of one fully functioning fibronectin binding adhesin, that may still be capable 
of attaching to fibronectin triggering host cell signalling, leading to FAK activation of 
Cdc42 and internalization of the bacteria (Krause-Gruszczynska et al., 2011).  
There is still a need to use an optimum incubation time which would allow the study of 
realistic interactions of C. jejuni with IECs to be observed, but these timings have been 
found to vary for each cell line. Fauchere et al reported a 1 hour incubation time to be 
sufficient for C. jejuni to be internalised using Hela IECs (Fauchere et al., 1986). 
Infection of INT407 IECs with C. jejuni strain 81116 was reported to require a maximal 
invasion time of 2 h (Wassenaar et al., 1991, Gaynor et al., 2004). In another study 
using Caco-2 IECs, Russell and Blake found that 1 h to 2.5 h was adequate for maximal 
invasion by C. jejuni (Russell et al., 1989). Although for this cell line, incubation 
	   	   	   	  
226	  
	  
periods of around 5 h are now more commonly used (Szymanski et al., 1995). 
Incubation times exceeding 5 h is advised to be avoided as C. jejuni is reported to be 
unable to survive and or replicate for extended periods within the vacuole (De Melo et 
al., 1989, Hu and Kopecko, 1999). Contrasting data was found in this study showing 
that C. jejuni was capable of interacting with and surviving within IECs over longer 
periods and a previous study also showed that other bacterial pathogens can efficiently 
utilise the vacuole for survival, for replication and spread to other tissues (O'Callaghan 
et al., 1999). C. jejuni is able survive in the intracellular environment within CCVs 
avoiding delivery to lysozymes (Watson and Galan, 2008b). In line with extended 
survival times, C. fetus has been found to replicate for up to 24 h in INT407 IECs 
(Graham, 2002). In addition, C. jejuni 81-176 has been reported to internalise more 
efficiently into INT407 and Caco-2 IECs and that the levels of internalisation decreased 
in older monolayers (Hu and Kopecko, 1999). 
Macrophages rapidly internalise and destroy C. jejuni within 24 h due to the presence of 
reactive oxygen species (Watson and Galan, 2008b). In contrast there have been reports 
regarding the ability of C. jejuni to survive within macrophages, depending on the C. 
jejuni strain and/ or macrophage cell type (Wassenaar et al., 1997, Day et al., 2000). In 
this part of the study, both cadF and flpA mutants were significantly reduced in 
macrophage survival, with the cadF mutant decreased in survival at 4 h and no survival 
at 16 h was observed compared to the wild-type. The flpA mutant exhibited reduced 
survival at 4 h but exhibited similar survival rates at 16 h to those observed for the wild-
type. 
In order to further study the interaction with and invasion of IECs, a Vertical Diffusion 
Chamber (VDC) system was used which allowed the co-culture of bacteria and IECs 
under different medium and gas conditions (Cottet et al., 2002a, Schuller and Phillips, 
2010, Mills et al., 2012). The co-culture of the cadF and flpA mutants with Caco-2 IECs 
in the VDC resulted in severely reduced invasion levels of the cadF mutant and even 
further reduced levels for the flpA mutant compared to the wild-type strain. Equally, 
severely reduced invasion levels of T84 IECs was observed after infection with the 
cadF or flpA mutant, however the numbers of intracellular bacteria recovered were 
slightly higher than when using Caco-2 IECs. The use of the VDC system emphasises 
the importance of culture conditions, by mimicking the in vivo environment, the 
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conditions could be allowing access of the bacteria to the basolaterally-located 
fibronectin, thus allowing higher numbers of bacteria to be internalised. In addition, the 
importance of bacterial and strain differences when studying C. jejuni interactions with 
IECs are also shown to be important using the VDC. Using standard tissue culture 
assays, both the cadF and flpA mutant invaded T84 IECs at lower levels than the Caco-
2 IECs. In the VDC, both mutants invaded the T84 IECs at slightly higher levels than 
Caco-2 IECs. A rpoN mutant that is completely aflagellate and non-motile was also 
included as a control and despite a complete absence of motility, was still capable of 
being internalised into Caco-2 IECs with the numbers recovered higher than those 
observed for the cadF and flpA mutant. However, the number of cadF and flpA mutant 
bacteria internalised into T84 IECs was significantly higher compared to the rpoN 
mutant. Perhaps a combination of bacterial virulence factors including motility, the 
presence of at least one functional fibronectin binding protein, under the right in vivo 
conditions still allows C. jejuni internalisation. The interactions of CadF and FlpA 
mutants with Caco-2 or T84 IECs in the VDC showed that these proteins are involved 
in C. jejuni invasion, however there are clearly other bacterial factors involved as C. 
jejuni were still able to invade the IECs. 
The role of CadF and FlpA in induction of IL-8 and TNFα was also investigated 
following infection. Previous studies have reported that Caco-2 IECs secrete minimal 
levels of IL-8 in response to C. jejuni infection, whilst using the T84 IECs resulted in 
much higher levels of IL-8 secretion (MacCallum et al., 2006). In addition, infection of 
Caco-2 and HEp-2 IECs with the 81-176 wild-type strain was reported to induce a 
higher IL-8 response than when infected with 11168H wild-type (Zilbauer et al., 2005). 
This variation is indicative of the differences in strains producing differing levels of 
virulence and thereby triggering varying levels of cytokine release. IL-8 is a well-
characterised marker of the host immune response against pathogens and been shown to 
be involved in the host innate immune response to C. jejuni (Hu and Hickey, 2005). 
TNFα, a cytokine primarily produced macrophages in response to stimuli activating 
toll-like receptors (Old, 1988, Oppenheim et al., 1991, Hobbie et al., 1997). TNFα is 
also expressed by activated natural killer cells, B cells and T cells, playing a role in cell 
recruitment, apoptosis, cell activation and differentiation (Old, 1988, Sedgwick et al., 
2000). Therefore, to study host cell response the T84 IEC line was used to study the 
induction of IL-8 and TNFα following co-culture with C. jejuni. 
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The cadF and flpA mutants induced significantly reduced levels of IL-8 compared to the 
wild-type strain. In the induction of TNFα, the 81-176 cadF mutant displayed no 
differences compared to the wild-type, whilst the 81-176 flpA mutant was significantly 
reduced in TNFα induction. The 11168H cadF was significantly increased in TNFα 
induction, whilst the flpA mutant induced a reduced TNFα response compared to the 
wild-type strain. The supernatants from the VDC were also probed following co-culture 
with C. jejuni for the presence of IL-8 and TNFα. Both cadF and flpA mutants produced 
a significant reduction in IL-8 induction, with the flpA mutant exhibiting a severe 
reduction in comparison to both the cadF mutant and the wild-type strain, in induction 
of IL-8. Both 81-176 and 11168H flpA mutants induced reduced levels of TNFα 
compared to the wild-type strain. Equally, the induction of TNFα was also significantly 
reduced compared to the wild-type following co-culture with T84 IECs in the VDC. 
Previous data showed higher levels of IL-8 induction in T84 IECs following 24 h 
infection time-points using the VDC compared to the results obtained in this study 
(Mills et al., 2012). A possible explanation for this discrepancy could be due the fact 
that the VDC assays performed in this study were performed for a 6 h infection period. 
Both 81-176 and 11168H flpA mutants induced reduced levels of TNFα compared to the 
wild-type strain. Suggesting that these adhesins may play a role in triggering the pro-
inflammatory cytokine TNFα.   
The precise bacterial factors and host cell signalling events involved in the induction of 
the pro-inflammatory cytokines upon co-infection with C. jejuni are still unknown but it 
is thought to be caused by the attachment to and invasion of the IECs by the bacteria 
and by the production of CDT (Hickey et al., 1999, Hickey et al., 2000). The production 
of IL-8 is central in the host mucosal inflammatory response, this is an important 
response for not only inducing diarrhoea but also to clear the infection (Watson and 
Galan, 2005). 
The first evidence that C. jejuni delivered virulence factors in OMVs was the discovery 
of OMVs containing CDT toxin, highlighting the biological significance of C. jejuni 
OMVs (Lindmark et al., 2009). In this study, the effect of pre-treatment of Caco-2 IECs 
with OMVs on bacterial interactions with and invasion of Caco-2 IECs was 
investigated. Pre-incubation with OMVs 10 µg isolated from 81-176 wild-type, cadF or 
flpA mutants significantly increased bacterial interactions compared to the control IECs 
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with no pre-incubation. Pre-incubation with OMVs isolated from cadF and flpA resulted 
in a significant reduction in intracellular bacteria compared to pre-incubation of IECs 
with the OMVs isolated from the 81-176 wild-type and the control. A previous study at 
LSHTM found that proteomic analysis of OMVs isolated from 11168H wild-type found 
151 proteins and virulence-associated proteins identified included the fibronectin 
binding proteins CadF and FlpA. The study found that virulence-associated C. jejuni 
proteins are delivered via OMVs (Elmi et al., 2012). Indicating that these adhesins may 
play a role in OMV production and enable or play a part in internalisation of C. jejuni. 
Motility is essential for C. jejuni colonisation of the host and to determine the effect of 
the mutations in both cadF and flpA, motility assays were performed. The results 
showed that 81-176 and 11168H cadF were significantly reduced in motility compared 
to the wild-type strain, although the 11168H cadF seemed to exhibit some recovery of 
motility by the 72 h time-point. In contrast, the 81-176 and 11168H flpA mutants were 
severely affected in motility and displayed a non-motile phenotype compared to the 
respective wild type strain. As motility has been attributed to C. jejuni interactions with 
and invasion of IECs, the data produced in this study found that although a significant 
reduction in motility was observed for both cadF and flpA mutants which correlated 
with an initial reduction in interactions with and invasion of IECs at the 3 h time-point. 
Both cadF and flpA mutants were still capable of interaction with and invasion of IECs 
especially after extended periods of infection (6 h and 24 h). Motility studies were 
performed on F38011 cadF and flpA mutants were reported not to exhibit any 
differences in motility over a 48 h period (Flanagan et al., 2009). However, the results 
were not shown which makes the comparison with the motility impossible.  
Motility has been reported to play a role in AAG, a virulence trait of C. jejuni (Guerry 
et al., 2006). The AAG results obtained with the 81-176 wild-type, cadF and flpA 
mutants showed that increased levels of AAG were observed with the cadF mutants 
compared to the wild-type AAG in both 81-176 and 11168H, whilst the 81-176 flpA 
mutant showed no difference in AAG ability in comparison to the wild-type strain, 
whilst displaying a non-motile phenotype. The 11168H flpA mutant displayed a 
reduction in AAG compared to the wild-type AAG levels. Previous studies have 
reported that different strains of C. jejuni exhibit varying levels of AAG (Misawa and 
Blaser, 2000).  
	   	   	   	  
230	  
	  
Both the 81-176 cadF and flpA mutants exhibited reduced cytotoxicity in the G. 
mellonella model and the cytotoxicity levels were higher than those observed for the 
11168H cadF and flpA mutants. The initial lack of motility of the cadF mutant may 
have affected the cytotoxicity in the larvae as the effect was increased after 72 h 
(correlating with lower survival levels of the larvae at these time-points). The AAG was 
increased for the cadF mutant in both strains, possibly increasing the interaction of the 
bacteria with the larval cells. In contrast, the flpA mutant was severely attenuated in 
motility in both strains, yet was still cytotoxic in the larvae at levels higher than those 
observed with the 81-176 cadF mutant. The AAG levels observed for the 81-176 flpA 
mutant were not significantly different to the wild-type strain but were significantly 
lower than those observed for the cadF mutant. These results indicate that a lack of 
motility may result in reduced cytotoxicity in the larvae and although the direct 
injection of bacteria into the larvae removes the need for motility and adhesion to the 
larval cells, there was still an attenuation in cytotoxicity of the larvae. 
As both CadF and FlpA are fibronectin binding proteins (Konkel et al., 1997, Flanagan 
et al., 2009), fibronectin binding assays were performed to study the interaction of the 
cadF and flpA mutants with fibronectin. Binding to fibronectin coated wells was 
significantly reduced for the cadF and mutant and the effect was more pronounced for 
the flpA mutant compared to the wild-type. Previous studies have similarly reported a 
reduced fibronectin binding ability for both cadF and flpA mutant (Konkel et al., 2010). 
In addition, a cadF/flpA double mutant showed a similar reduction to the individual 
mutants in binding to INT407 IECs, showing that cadF and flpA are both required for 
binding to fibronectin and a flpA complement was shown to restore fibronectin binding 
ability (Konkel et al., 2010). In this study, the construction of a cadF complement was 
unsuccessful despite numerous attempts. Konkel’s group also reported difficulty in 
construction of the cadf complement (Derrick Samuelson, personal communication). 
The flpA complement was successful in construction, yet failed to grow; further work 
would involve remedying these problems. 
In summary, cadF and flpA mutants were reduced in their interaction with and invasion 
of Caco-2 and T84 IECs, yet exhibited increasing levels of interactions with and 
invasion of IECs over the infection time-points.  
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Chapter 6: Final Discussion 
6.1 Invasion  
For invasion studies, the 81-176 wild-type displayed both a microfilament and 
microtubule-dependent mechanism of entry as invasion was enchanced in the presence 
of CytD and significantly reduced in the presence of colchicine. Also caveolae-mediated 
endocytosis, clathrin-mediated endocytosis and host cell signalling pathways are also 
involved, suggesting that C. jejuni modulates a number of host cell pathways during 
invasion. The limitations of the invasion study were that due to time constraints only 
one C. jejuni strain and one cell line were utilised for inhibition of invasion studies. 
Future work should focus on the use of different cell lines, a comparison of a number of 
fully sequenced C. jejuni wild-type strains, variations in the MOI, the use of different 
inhibitors and variation of the concentration of the inhibitors employed.  
6.2 Visualisation of C. jejuni 
In an attempt to track the course of C. jejuni invasion of and survival within IECs, 
studies were conducted using eGFP or Evoglow® expressing C. jejuni strains which 
were constructed for use in confocal studies but the results were only partially 
successful. The bacteria produced high levels of fluorescent signal when grown in broth 
cultures in the VAIN. Studies were attempted at visualising C. jejuni or C. jejuni 
expressing eGFP or Evoglow® within G. mellonella larvae in an attempt to locate 
CCVs within the larvae. The aim was to formalin fix the larvae and after a few days 
embed the larvae in wax to produce thin slices for subsequent staining and visualisation. 
The larvae were extremely difficult to slice thinly, different fixing times were applied, 
with the same disappointing results. The next step was to visualise the bacteria 
expressing eGFP or Evoglow® following infection of IECs. The main problem 
encountered was that once IECs were infected with these strains, the levels of 
fluorescence depleted rapidly. As the aim was to study the course of the bacteria during 
invasion, incubation times were extended to >2 h based on the results of the interaction 
and invasion assays. However, very few bacteria were observed within the IECs, 
possibly due to the presence of a polarised monolayer, as C. jejuni has been reported to 
traverse polarised IECs or the harsh intracellular environment of the IEC (Konkel et al., 
1992c, Bras and Ketley, 1999). The lack of detectable signal could also have been due 
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to the fact that certain E. coli promoters are unable to function in C. jejuni (Taylor, 
1992, Wosten et al., 1998). The use of an anti-C. jejuni antibody for visualisation of 
both extracellular and intracellular bacteria was also only partially successful, data 
produced using the anti-C. jejuni antibody showed internalised and non internalised 
bacteria. However, the numbers visualised were very low. This could be due to non-
specific binding of the antibody utilised and the use of intact monolayers in an attempt 
to ascertain the real in vivo interactions of the bacteria with the IECs. Future work 
would require optimisation of the constructs, including the use of a stronger C. jejuni 
promoter upstream of the eGFP/Evoglow®. Modifications in the MOI used for infection 
studies and the use of different  mutants as eGFP and Evoglow® expressing cadF, flpA 
and ciaB mutants were also constructed but not tested due to the lack of fluorescence 
signal observed with the wild-type strain. In addition, this work could be modified using 
monolayers that have not reached confluency as fully confluent and intact monolayers 
are less well invaded by C. jejuni (Konkel et al., 1992c, Monteville and Konkel, 2002, 
van Alphen et al., 2008).  
6.3 ciaB mutant 
The interaction and invasion data produced in this study supports Konkel’s 
observations. The 81-176 ciaB mutant was significantly reduced in invasion compared 
to the wild-type strain. However, the levels of invasion for the ciaB mutant did increase 
over longer incubation time-points, suggesting a role for other virulence factors in 
internalisation of the bacteria. The ciaB mutant also exhibited reduced intracellular 
survival and reduced cytotoxicity in the G. mellonella model of infection. The role of 
CiaB is thus important in virulence of C. jejuni and future studies should aim to dissect 
this further, by including ciaB mutants in inhibition of invasion studies. A combination 
of inhibitor(s) alongside a ciaB mutant in interaction and invasion assays at the time-
points used in this study could reveal more detail regarding the mechanism of entry and 
the role of CiaB. This could be further extended to use in the VDC models with 
treatment of Snapwells prior to infection with wild-type or ciaB mutant bacteria which 
should provide novel data. Due to time constraints and extensive optimisation studies 
required, this was not possible in this study. 
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6.4 cadF mutant 
Studies with the 81-176 cadF mutant indicated the requirement of this adhesin for C. 
jejuni invasion. The 81-176 cadF mutant exhibited significant reductions in interactions 
with, invasion of IECs and reduced cytotoxicity in the G. mellonella model of infection. 
Although, over longer time-points the interactions of the cadF mutant increased. One 
issue with this part of the study was in the problems encountered in construction of a 
cadF complement. Following numerous attempts and the use of an alternative 
complementation vector, there were significant issues in the construction of the cadF 
complement. The availability of a cadF complement could be tested alongside the cadF 
mutant to study the effects. It should be noted that Konkel’s group also admitted to 
having significant problems with regard to complementation of the cadF mutant and are 
yet to produce this (Derrick Samuelson-personal communication). Future studies could 
involve the use of a reliable proof reading enzyme as the use pfx and pfu polymerases 
introduced numerous errors into the amplified cadF gene. Further work should aim to 
test the role of this bacterial adhesin by using a combination of inhibitor(s) alongside a 
cadF mutant and a cadF complement in interaction and invasion assays at the time-
points used in this study to reveal more detail regarding the mechanism of entry and the 
role of CadF in C. jejuni invasion of IECs.  
6.5 flpA mutant 
The 81-176 flpA mutant exhibited a severe reduction in motility in comparison to the 
wild-type strain. An initial reduction in interaction and invasion of IECs was observed 
and despite this severe lack of motility, the flpA mutant displayed increased interactions 
with and invasion of IEC over longer time-points. The numbers of intracellular flpA 
mutant recovered from Caco-2 IECs following co-culture in the VDC resulted in 
significantly lower numbers of bacteria recovered compared to the wild-type and cadF 
mutants, suggesting that this adhesin may be playing a more significant role in initial 
interactions with IECs and possibly in disrupting host cell signalling. One limitation of 
this part of the study was although a flpA complement was constructed, electroporation 
of the flpA construct into the flpA mutant resulted in no growth. Controls were set up to 
ensure the results were not due to the electroporation procedure. The problem remained 
with the flpA complement construct. In addition, attempts were made to construct a 
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cadF flpA double mutant, however following electroporation of the constructs, no 
bacterial growth was observed. Future work would involve problem solving this issue to 
ensure the availability of a viable double mutant and a complement and further 
dissecting the role of FlpA by using inhibitors that specifically disrupt the host cell 
signalling pathways. 
6.6 Final comments 
C. jejuni invasion mechanisms are still yet to be accurately elucidated as it is not exactly 
clear which routes C. jejuni utilises and various studies have reported multiple uptake 
pathways. There are differences reported in which pathways are important for C. jejuni 
invasion and the use of different C. jejuni strains, different cell lines, the fact that 
standard tissue culture assays are performed under normal atmospheric conditions are 
all contributory causes as to the differences in C. jejuni invasion which have been 
reported. The ways in which tissue culture assays are performed are highly varied as 
many variations of this method have been reported. There are no studies reporting the 
use of cadF, flpA or ciaB mutants in interaction and invasion assays with IECs over 
longer time-points, making it difficult to compare the data produced here. C. jejuni 
infection studies using the VDC system under microaerobic conditions were the first to 
be performed at LSHTM and resulted in novel data (Mills et al., 2012).  
This study provided further confirmation of the action of C. jejuni CadF, FlpA and CiaB 
virulence proteins through studying interaction and invasion, survival within IECs and 
macrophages, cytotoxic effect in the G. mellonella infection model, role in OMV 
production and roles in induction of IL-8 and TNFα. The study could be further 
improved by introducing additional studies in a number of areas. Firstly, with the use of 
Galleria mellonella as an infection model, the advantages of this model are ease of use, 
cheap to maintain, the larvae can be studied at 37°C and also the ability to screen large 
numbers of different mutants. This study found that cadF, flpA and ciaB mutants 
exhibited a reduced cytotoxic effect in the larvae compared to the wild-type strain. This 
model could have been further utilised by enumeration of bacteria from within the 
larvae at different time-points by dissecting the larvae that were inoculated with either 
the wild-type or the mutants and removing the haemolymph. This would provide 
additional data alongside the cytotoxicity data. Studies performed during this study but 
not reported in this thesis, attempted to visualise C. jejuni wild-type or mutants within 
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the G. Mellonella larvae, wax embedding was not very successful, however this could 
have been remedied by freezing the samples and then thin slicing for staining with 
hematoxylin and eosin (H&E). Also, in order to view CCVs within the G. mellonella 
larvae, the haemolymph from larvae infected with C. jejuni wild-type, cadF, flpA or 
ciaB mutants within CCVs could have been visualised by isolating the haemocytes and 
then analysing these samples by TEM for the presence of CCVs. The interaction and 
invasion studies performed in this study showed that the mutants were significantly 
reduced in interactions with and invasion of Caco-2 and T84 IECs over a 3 h, 6 h and 24 
h infection period. The extended infection times were used due to the fact that there is a 
lack of studies reporting C. jejuni interaction with and invasion of IECs over 3 h. For 
this reason, cadF, flpA and ciaB mutants were tested at 3, 6 and 24 h. The use of a 
polarised cell model provided a relevant model for studying C. jejuni interactions by 
mimicking more closely the in vivo conditions present in the human gut, where the 
mucosal epithelium is highly differentiated and provides strong structural integrity. It 
has been reported that C. jejuni can translocate across Caco-2 and other polarised cell 
monolayers without causing significant disruption to the integrity of the cell monolayer 
(Konkel et al., 1992c, Everest et al., 1992).  
However this integrity can be disrupted over time as the tight junctions can become 
leaky due to the damage of the proteins involved in the maintenance of these junctions 
such as occludin, claudins and a number of other proteins which provide important 
structural factors in the establishment of cell polarity. These proteins are necessary for 
the tight sealing of the cellular sheets, and maintain tissue homeostasis by enabling the 
control and movement of ions in the cell (Backert et al., 2013). Inoculation of high 
doses of C. jejuni (> 108-109 cfu) onto monolayers was found to reduce the TEER at the 
24 h time-point (Bras and Ketley, 1999), albeit much slower than the timings observed 
for S. typhimurium (< 6 h) (Jepson et al., 1995). The results of this study showed an 
initial decrease in interactions and invasion of IECs by cadF, flpA and ciaB mutants but 
with numbers of bacteria increasing over the infection period. Many important bacterial 
pathogens are able to cross polarised IECs using different mechanisms: paracellular and 
transcellular routes. Previous studies have shown that C. jejuni was only able to invade 
polarised IECs following disruption of the tight junctions with EDTA, thereby 
providing access to the subcellular space (Monteville and Konkel, 2002, van Alphen et 
al., 2008). However the question as to how C. jejuni reaches the subcellular space and 
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invades when a polarised monolayer is present has yet to be answered. The mechanism 
of this process may involve disruption of tight junctions or trancytosis enabling entry 
into the IECs. This has been observed in in vitro using IECs grown on Transwell 
supports (Hoy et al., 2012, MacCallum et al., 2005). Invasion may also occur due to the 
growth of C. jejuni in the intestinal crypts which would inevitably damage the epithelial 
cells, leading to a lack of a viable protective barrier thereby allowing C. jejuni access to 
the subcellular space (Bouwman et al., 2013). In addition, similar to Shigella invasion, 
C. jejuni may utilise and gain entry through M-cells, these cells function by sampling 
the intestinal lumen and delivering the contents to underlying immune cells.  
Previous studies have shown that C. jejuni can translocate across Caco-2 and other 
polarised cell monolayers without disruption to TEER. In contrast, other studies 
reported a time-dependent decrease of TEER in response to C. jejuni infection, however 
the actual bacterial factors involved in triggering a reduction in TEER were not reported 
on (Chen et al., 2006). Thus, there is once again conflicting data in the literature and a 
consensus is yet to be reached among investigators as to the invasion mechanism of C. 
jejuni. Whether the results observed in this study were directly due to the specific 
mutation would require further studies as cadF, flpA and ciaB mutants exhibited slight 
increases in interaction and invasion of Caco-2 and T84 IECs over the 24 h infection 
period, possibly suggesting that C. jejuni is able to translocate more easily once cell 
junctions have been disrupted, especially over a prolonged period of infection. Another 
reason could be due to the accumulation of bacterial toxins or other bacterial products.  
Therefore the cadF, flpA and ciaB mutants were still able to enter between cells due to 
the disruption of the tight junctions/adherens and the presence of a viable adhesin 
present on each mutant (eg: The cadF mutant - possesess a viable FlpA adhesin and 
vice versa) and was therefore still capable of reaching the basolateral surface of the 
IECs and attach to fibronectin. Complementation of cadF and flpA mutants would also 
have provided further insights into the data collected in this study. 
With regards to the intracellular survival assays and macrophage survival assays, firstly 
C. jejuni is able to penetrate the mucus layer in humans, interact with the IECs inducing 
IL-8 production. Induction of IL-8 leads to the recruitment of DC, macrophages and 
neutrophils, which interact with C. jejuni. These interactions result in a massive pro-
inflammatory response (Young et al., 2007). Future studies should involve the use of 
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neutrophils rather than Caco-2 IECs as a mechanism of studying host cell-bacterial 
interactions and therefore provide a more relevant model to answer the questions posed. 
This work is currently underway with our collaborators, Mona Bajaj-Elliott’s group at 
the Institute of Child health (ICH).  The macrophage cell line used in this study was 
J774A.1 (a murine macrophage line) as previous studies have reported that C. jejuni is 
killed rapidly by macrophages dervived from human monocytes (Kiehlbauch et al., 
1985). Human macrophages would be a more appropriate model to study the survival of 
C. jejuni wild-type and the cadF, flpA and ciaB mutants. 
The main drawbacks of the VDC system were the time-consuming preparation of the 
chambers prior to infection studies. The VDC had to be placed in the VAIN to provide 
microaerobic conditions for the bacteria and also attached via a gas manifold to a 
separate oxygen supply providing the IECs with oxygen. The regular use of the VAIN 
by other researchers inevitably resulted in gas and pressure alterations, affecting the 
chambers and the results. Another major drawback was the risk of contamination was 
high using the VDC, despite a 3 h soaking and washing step in Haz-tab the chambers 
were extremely difficult to sterilise. Future work could involve using the VDC system 
used to study the interactions of the cadF, flpA and ciaB mutants over longer time-
points and compare the results with those observed in the standard tissue culture. The 
bacterial supernatants could be used to analyse gene expression of the wild-type and the 
mutants under the microaerobic conditions of the experiment. In addition, other C. 
jejuni mutants could be also be tested in the VDC system, different cell lines could be 
utilised. Pre-treatment of the Snapwells with inhibitors prior to infection with wild-type 
bacteria and the mutants could provide interesting results and the data could be 
compared to the results of the inhibition of invasion assays performed under standard 
tissue culture conditions. Staining of the Snapwell following infection with C. jejuni 
expressing eGFP or Evoglow® constructs to locate the bacteria once inside the IEC 
could provide further information on the behaviour of the wild-type strain, cadF, flpA 
and ciaB mutants.  
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7 Appendices 
7.1 Appendix 1 
Columbia blood agar plates  
16 g of Columbia agar base was dissolved in 400 ml of Milli-RO water. The solution 
was mixed and autoclaved and allowed to cool. 24 ml of horse blood (7%) was also 
added to the agar. Skirrow was added and antibiotics. 
Brucella broth 
Brucella broth was prepared by dissolving 20 g of broth to 465 ml of Milli-RO water, 
the solution was mixed by shaking then autoclaved. When antibiotics were required, 
Brucella broth was cooled and supplemented with either individual or a combination of 
antibiotics; chloramphenicol (10 µg/ml), ampicillin (100 µg/ml), kanamycin (30 µg/ml). 
Luria-Bertani LB agar plates 
LB agar plates were prepared by dissolving 15 g of LB agar in 400 ml of Mill-RO 
water, the solution was mixed by shaking then autoclaved. For preparation of antibiotic 
plates, the medium was allowed to cool and supplemented with either individual or a 
combination of antibiotics; chloramphenicol (10 µg/ml), ampicillin (100 µg/ml), 
kanamycin (30 µg/ml). Plates were stored for at 4 ºC for 3 weeks. 
LB broth 
LB broth was prepared by dissolving 18.4 g of LB broth in 400 ml of Milli-RO water, 
the solution was mixed by shaking then autoclaved. For preparation of overnight 
cultures, LB broth was supplemented with either individual or a combination of 
antibiotics; chloramphenicol (10 µg/ml), ampicillin (100 µg/ml), kanamycin (30 µg/ml). 
LB broth was stored at room temperature for up to 1 month. 
Preparation of Motility Plates 
C. jejuni motility media was prepared by dissolving 6 g of Brucella broth (Oxoid) and 
1g of bacto agar (Oxoid) in 250 ml of DH20 and autoclaved at 121°C for 15 min. For 
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motility plates, agar melted in microwave, cooled and poured into sterile petri dishes 
and stored at 4°C until required (appendices). 
Inactivation of Fetal calf serum  
FCS was heat inactivated at 56ºC for 30 minutes in a water bath and then filter sterilised 
using 0.2 µM syringe prior to use in tissue culture experiments. The FCS was aliquoted 
into 50 ml sterile falcon tubes (Corning) and stored at -20ºC. 
Dulbeccos Modified Eagle Medium 
For tissue culture studies Dulbeccos Modified Eagle Medium (DMEM) was prepared by 
adding 5 ml of penicillin and streptomycin (100x) and 50 ml of heat inactivated FCS. 
The solution was mixed and then filter sterilised using a 0.2 µM syringe filter and 
aliquoted into 50 ml sterile falcon tubes and stored at -20ºC for up to 1 month. 
Cell freezing medium 
Cell freezing medium was prepared prior to freezing cells by mixing 10 % DMSO with 
DMEM (prepared as above). 
Preparation of antibiotic concentrations. 
Stock concentrations of ampicillin (20 mg/ml) were prepared by dissolving 1 g of 
ampicillin in 20 ml of sterilised water and filtered with a 0.22 µm filter. Aliquots of 1 
ml were prepared and stored at -20ºC for up to 1 year. 
Stock concentrations of chloramphenicol (20 mg/ml) were prepared by dissolving 1 g of 
chloramphenicol in 50 ml of ethanol. Aliquots of 1 ml were prepared and stored at -
20ºC for up to 3 months. 
Stock concentrations of kanamycin (25 mg/ml) were prepared by dissolving 500 mg of 
kanamycin sulphate powder in 10 ml sterile water and filtered with a 0.22 µm filter. 
Aliquots of 1 ml were prepared and stored at -20ºC until required. 
0.2 % Triton X-100 solution 
200 µl of Triton X-100 was added to 100 ml of PBS 
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Preparation of oligonucleotide primers 
100 µM stock solutions of primers were prepared using sterile DNase free water as 
described below: 
Eg: 5.6 OD260 = 37.18 nmol (37.18 x 10 = 371.8) 
371.8 µl of water was added to the appropriate primer giving a 100 µM stock. 10 µM of 
working solutions prepared by diluting 1 in 10 and storing aliquots at -20ºC. 
Preparation of 10 mM dNTPS 
25 µl of each dATP, dCTP, dGTP and dTTP (at stock concentrations of 100 mM) were 
added to 900 µl of sterile water, briefly vortexed. Final mixture contained 10 mM 
dNTPs (2.5 mM of each dNTP) and stored at -20ºC. 
Preparation of running buffer for agarose gel electrophoresis  
50 x TAE  
242 g of Tris base, 57.1 ml of Acetic acid and 18.6 g of EDTA (0.5M pH 8.0). The 
solution was mixed and the volume adjusted to 1 litre with Milli-RO water  
Ethidium Bromide working solution 
Ethidium bromide Stock (10 mg ml-1) was diluted with 20 mM MOPS-NaOH (pH 7) 
and used at 0.5 µg ml-1 
Agarose gel 
1.5 g of agarose was added to an Erlenmeyer flask for a 1 % agarose gel. 150 ml of 1X 
TAE was added. Solution was mixed and heated in a microwave on a medium setting 
for 3 minutes or until the agarose completely melted. With safety glove the flask was 
inspected and swirled to ensure mixing and allowed to cool. 4 µl of ethidium bromide 
was added, mixed again by swirling and poured into a pre-prepared clean casting plate 
with an appropriate comb in place. The gel was then left to set for 30 minutes before 
use. 
 
	   	   	   	  
241	  
	  
Ethanol 
70% ethanol was prepared by adding 350 ml of 95% ethanol to 150 ml sterilised water 
and stored in Duran bottles until required (Duran, Mainz, Germany) 
Primary culture 
15 ml of Brucella Broth was pre- incubated in T75 flask, 37 °C under micoaerobic 
conditions for 24hrs, with shaking. At the same time a 24 hour plate of C. jejuni was set 
up. From this a bacterial suspension was made and the OD600 was adjusted to OD600 0.1. 
This was made using previously pre-incubated BB to produce an OD600 of 0.1. This was 
then added to the pre-incubated flask and incubated at 37°C, microaerobic conditions 
with shaking. This method was used for taking measurements for GK, motility and 
autoaggregation studies. 
Mini- prep purification 
Mini preps were set up in 10 ml LB broth with the required antibiotic and a single 
colony of the restreaked transformants was added to the universal containing the LB 
broth and antibiotic. This was incubated at 37°C for 12-16 h in a shaking incubator at 
150 rpm. The overnight bacterial suspensions were then centrifuged at 4,000k rpm for 
10 min and supernatant discarded. The overnight were purified using QIAgen plasmid 
mini prep kit according to manufacturer’s instructions, briefly. Bacterial cells were 
resuspended in 250 µl of Buffer P1 and transferred to clean 1.6 ml eppendorf tube. 250 
µl of buffer P2 was added and the tube was inverted 4-6 times, followed by the addition 
of 350 µl buffer N3 and mixed immediately by inverting 4-6 times. The tube was then 
centrifuged at 13,000k rpm for 10 min. Supernatant was transferred to a QIAquick 
column and then centrifuged for 1 minute at 13,000k rpm. Flow through was discarded 
and 0.5 ml buffer PB was added to the column and centrifuged for 1 min. Flow through 
was discarded and 750 µl of buffer PE added to the column. Column was centrifuged at 
13,000k rpm for 1 minute. Flow through was discarded and tube was centrifuged again 
to remove residual wash buffer. The QIAprep column was transferred to clean 1.5 ml 
tube and 30 µl of MQ sterilised water was applied to the column, allowed to stand for 1 
minute and then centrifuged for 1 minute at 13k rpm. The purified plasmid DNA 
concentrations were quantified using Nano drop ND-1000 spectrophotometer, and 
samples were stored at -20C until required (appendices) 
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7.2 Appendix 2 
dATP -               Promega, Southampton, UK 
dGTP -                Promega, Southampton, UK 
dCTP -               Promega, Southampton, UK 
dTTP -                Promega, Southampton, UK 
MgCl2-               Promega, Southampton, UK 
 
10X buffer, Taq DNA polymerase M166F (2,500 U)        Promega, Southampton, UK 
 
ABI prism terminator ready reaction mix           Applied Biosystems, Warrington, 
UK 
 
Agarose       Sigma-Aldrich, Poole, UK 
Ampicillin       Sigma-Aldrich, Poole, UK 
Bacto agar       BD, Oxford, UK 
Bovine Serum Albumin (BSA)    Sigma-Aldrich, Poole, UK 
Brucella broth       Fluka, Gillingham, UK 
Campylobacter selective supplement (Skirrow)  Oxoid Basingstoke, UK 
Columbia agar       Fluka, Gillingham, UK 
Dulbeccos Modified Eagles Medium (DMEM)   Sigma-Aldrich, Poole, UK 
DH5- Alpha cells      Invitrogen, Paisley UK 
Ethidium Bromide      Promega, Southampton, UK 
Foetal Bovine serum      Sigma-Aldrich, Poole, UK 
Genelute gel extraction kit     Sigma-Aldrich, Poole, UK 
Glycerol       VWR, Lutterworth, UK 
Horse blood in Alsevers TCS Biosciences, Botolph, 
Claydon, UK 
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1kb ladder      Invitrogen, Paisley, UK 
Kanamycin      Gibco/Invitrogen, Paisley, UK 
Luria Bertani agar       Merck, Hoddesdon, UK 
Luria Bertani broth     Difco, Northampton, UK 
Lysozyme      Sigma-Aldrich, Poole, UK 
β2 Mercaptoethanol Stratagene, Agilent Technologies, 
Santa Clara, CA, USA 
 
Minelute PCR purification kit   Qiagen, Crawley, UK 
Non-essential amino acids    Sigma-Aldrich, Poole, UK 
Oligonucleotide primers    Sigma-Aldrich, Poole, UK 
Pen-strep solution     Sigma-Aldrich, Poole, UK 
Phosphate buffered saline    Sigma-Aldrich, Poole, UK 
pGEM-T easy vector      Promega, Southampton, UK 
Restriction endonucleases    Promega, Southampton, UK 
Soc broth      Fluka, Gillingham, UK 
SCS110 competent cells Stratagene, Agilent Technologies, 
Santa Clara, CA, USA 
 
T4 DNA ligase     Promega, Southampton, UK 
T4 DNA ligase buffer     Promega, Southampton, UK  
Triton x-100      Sigma-Aldrich, Poole, UK 
0.25% Trypsin-EDTA    Sigma-Aldrich, Poole, UK 
Qiaquick PCR purification kit   Qiagen, Crawley, UK 
Qiaquick gel extraction kit    Qiagen, Crawley, UK 
Qiaprep spin miniprep kit    Qiagen, Crawley, UK 
Puregene DNA purification system  Gentra systems Inc. Flowgene, 
Lichfield, UK 
XL2-Blue MRF cells Stratagene, Agilent Technologies, 
Santa Clara, CA, USA 
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Gel loading buffer 
100% (v/v) glycerol         10 ml 
20% (v/v) SDS        500 µl 
5% 9w/v) Bromothenol blue       100 µl 
EDTA (0.5M)         100 µl 
Sterilised Milli Q water               to 20 ml 
dNTP 1.25mM stock (1ml total volume) 
dATP (100mM)        12.5 µl 
dTTP (100mM)        12.5 µl 
dGTP (100mM)        12.5 µl 
dCTP (100mM)        12.5 µl 
Sterilised Milli-Q water               to 950 µl 
PCR pre-mix (1ml total volume) 
10X buffer         100 µl 
dNTPS (1.25mM)        168 µl 
MgCl2 (25mM)          60 µl 
Taq polymerase (5 U/µl)            6 µl 
Sterilised Milli Q water                 to 1 ml 
Ice cold wash buffer 100ml 
100% (v/v) Glycerol               15 ml 
10% (w/v) Sucrose                    10 ml 
Sterilised Milli Q water             to 100 ml 
 
 
 
 
Soc broth 
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Tryptone (20g/l) 
Sodium chloride (10nM) 
Potassium chloride (2.5mM) 
Yeast extract (5g/l) 
Magnesium chloride (10mM) 
Magnesium sulphate (10mM) 
Glucose (20mM) 
To a final pH 7 
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